Genetic variation in the non-canonical Wnt signalling pathway and predisposition to tetralogy of Fallot by Palomino Doza, Addison Julian
 Genetic variation in the non-
canonical Wnt signalling pathway 
and predisposition to Tetralogy of 
Fallot 
ADDISON JULIAN PALOMINO DOZA 
 
A thesis submitted to Newcastle University for the degree of doctor of Philosophy 
08/12/2010 
 
 
 
  
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
To my grandfather who learnt English by mail and taught me the value of work, the weight 
of dignity, the color of honesty 
 
To my grandmother who endured all the mail courses and loved me more than anyone 
else  
3 
 
ABSTRACT 
Introduction 
Congenital cardiovascular malformation (CCM) is a prevalent group of conditions in 
humans. Tetralogy of Fallot (TOF) is the commonest cyanotic heart defect affecting 
0.24/1000 newborns worldwide. Human CCM etiology has a genetic component with 17% 
of CCM attributable to particular genetic syndromes.  The remaining 80% of "sporadic" 
cases nevertheless show a high heritability, suggesting complex polygenic inheritance 
modulated by environmental factors. Multiple previous studies have explored the 
involvement of the non-canonical Wnt signaling pathway, also known as the planar cell 
polarity pathway, in cardiogenesis but none has explored the relationship between genetic 
variation within the pathway and predisposition to TOF in humans.   
Methods 
Exonic sequences of 7 key genes within the pathway (ROCK1, ROCK2, Wnt11, Wnt5a, 
Dvl3, Dvl1l1 and ANKRD6) were obtained in 93 TOF probands as an initial mutational 
screen. All novel variants were genotyped in at least 465 TOF probands and 1465 controls 
and analyzed using in silico methods to determine impact in structure and splicing. Three 
variants were functionally assessed. Genotypes for tag SNPs in ROCK1 were also 
obtained. 
Results   
Twelve uncommon previously unreported variants were found within the seven genes: four 
non synonymous, 3 synonymous, 3 intronic (near exon/intron boundaries) and 2 located at 
untranslated regions.  Two novel common variants were also found: one synonymous and 
one intronic. None of the variants was proven to be de novo. None of the probands carried 
more than one novel variant. Statistically significant differences in allele frequencies were 
found for ROCK1 C807T and WNT11 207 +47 G>T. WNT5A Asp119Ser was found as a 
singleton in one proband and not in controls. Functional experiments did not show splicing 
changes associated with ROCK1 C807T and WNT11 207 +47 G>T. Rs288979, an intronic 
common variant (mAF=0.051) was significantly associated with TOF (p=0.000015 OR: 
0.61). 
Conclusions 
Results of this work suggest that genetic variation in the non canonical Wnt signaling 
genes is involved in the etiology of TOF in humans. The genetic predisposition to TOF 
seems to be given by a combination of rare variants (ROCK1 C807T, WNT11 207 +47 
G>T and WNT5A Asp119Ser) associated with high ORs and common variants (rs288979) 
associated with low ORs. Further deep sequencing work in larger samples should unravel 
the remaining rare variants associated with TOF, while genome-wide association study 
(GWAS) may reveal the role for additional common variants.  
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1. INTRODUCTION 
1.1. Genetics of complex diseases - background 
 
A complex disease or trait corresponds to a condition in which risk cannot be ascribed to a 
single genetic or environmental factor (1). Inheritance in this type of conditions does not 
correspond to Mendelian models and multiple genes act to increase or reduce the risk of 
developing them (2). In complex diseases individual risk is determined by an unknown 
combination of genetic, environmental and stochastic factors (3).  Typically, no single 
factor, genetic or environmental, is either sufficient or necessary to develop the disease. 
 
In contrast to the relative success finding the genetic aetiology of Mendelian diseases, 
research on genetic predisposition to complex diseases had proven difficult until very 
recently (4). Initially, only a few genes were consistently linked to conditions and many of 
the associations were characterized by non reproducibility. However, since the completion 
of ground breaking genome wide associations (GWA) studies, a large number of 
consistent associations have been described and reproduced (5). 
 
The evolution of research into complex diseases departed from the point where success 
was achieved in mapping Mendelian diseases. The first approach to unravel genetic 
susceptibility was linkage analysis. The strategy was extremely successful in Mendelian 
diseases, with approximately 2200 disorders linked to a gene today (6). When applied to 
common diseases, linkage mapping proved a valuable tool to discover rare Mendelian 
forms of common diseases like hypertension, breast cancer or diabetes, but the proportion 
of heritability linked to the loci identified was minimal. In terms of discovering variants 
causing the non-Mendelian forms of these and other complex diseases, linkage analysis 
either in extended pedigrees or in affected sibling-pairs was an almost complete failure.  
Failure of linkage analysis in common disease was primarily due to the fact that the 
method is dependent on the size of the risk associated with the variant being large, and as 
a consequence that there is a close correlation between allele transmission and the 
presence of the phenotype in affected families. In 1996, Risch and Merikangas published 
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in Science perhaps the most influential article in genetics of the past twenty years.  This 
was a theoretical explanation of the failure of linkage studies of common diseases.  It was 
shown mathematically that for variants conferring a relative risk of less than 2 for disease, 
the probability of being detected by linkage mapping was minimal, and that an association 
approach using single nucleotide polymorphisms, the commonest form of variation in the 
human genome, would be required. (7).    
 
The next step was association studies of candidate genes. In this case the constraints of 
family studies and transmission imbalance were solved but the method faced other 
problems. There was only a small prior probability of any one of 20,000 candidate genes 
being associated with the conditions, and the studies needed a high methodological rigor 
to avoid false positives due to population stratification and multiple test analysis (4, 6). 
Some encouraging results were obtained, often with genes where the prior probability of 
involvement could be inferred to be large (for example, the ApoE E2/E3/E4 polymorphism, 
which affects plasma lipid levels, and myocardial infarction) but still there was an 
overwhelmingly large portion of heritability not being explained by the loci found, and most 
of the positive results failed to be reproduced. 
 
Two main factors influenced development of the next tool to investigate complex disease 
genetics in the “post genomic era” following the publication of the human reference 
genome:  description and build of comprehensive genomewide human genetic variation 
databases; and development of commercial massively high througput genotyping 
methods, chiefly “SNP chips”. Using these databases and genotyping methods, studies in 
where more than a hundred thousand to a million SNPs across the genome are genotyped 
at thousands of individuals were made possible. These studies were called genome wide 
association studies (GWAs) (5, 8). 
 
GWAs were believed for some years to be the tool to take forward genetics of complex 
diseases, but it was only in 2007 with the publication in Nature of the Welcome Trust 
Case-Control Consortium (WTCCC) study that their full potential became apparent. The 
WTCCC was a joint GWA research project conducted in a British population examining 7 
diseases in 2000 probands and 3000 shared controls. This work identified 24 independent 
association signals in case control comparisons for rheumatoid arthritis, type 1 and 2 
diabetes, bipolar disorder, Crohn’s disease and coronary artery disease (9).  Today, 
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hundreds of consistently associated loci with a number of different diseases have been 
identified using this approach.  
 
GWAs were designed to capture most, if not all, common genetic variation in the genome.  
However, despite encouraging results most of the heritability is still not explained by the 
associated loci found (8).  A number of explanations have been suggested to explain the 
“missing heritability” in GWAs, including the possibility of larger numbers of variants of 
smaller effect not found yet, the larger effect of uncommon variants that are poorly 
detected by available genotyping arrays, rare structural variants poorly captured on 
existing chips (like copy number variants (CNVs)) and low power of studies to detect 
gene/gene, and gene/environment interaction.  
 
In general it remains unclear how associated variants explain genetic susceptibility to 
complex diseases. One of the striking results of GWAs for all conditions is that the 
overwhelming proportion of identified loci do not correspond to missense or nonsense 
variants, and are not even located in known protein reading frames. Research into the 
functional implications of these non coding variants is related to the understanding of 
genetics of gene expression and the effects of these variants on transcription and 
translation (10).   
 
1.2. Genetic architecture of complex diseases 
 
Allelic or genetic architecture of complex diseases refers to the number of alleles and their 
frequencies affecting susceptibility to a given condition at a given disease locus (11). The 
importance of this allelic architecture is based on the marginal risk increase associated 
with each allele at a disease gene, and therefore the size of the statistical signal 
associated with it (7). If this architecture is understood, study design can be adapted, 
increasing the probability of success. 
 
The structure and implications of “genetic architecture” have been one of the most debated 
topics in complex disease genetics. Two main hypotheses: the common disease-common 
variant (CDCV) and common disease-rare variant (CDRV) theories have been advanced 
to explain genetic contribution to individual diseases susceptibility. 
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The CDCV hypothesis supports the idea that genetic variation or susceptibility in complex 
traits is due to a common variant or a small number of them with small effects on 
quantitative phenotypes related to disease risk, or with very low penetrance (odds ratios 
generally less than 1.5) in the population. In this case allelic heterogeneity at any locus 
would be low, and susceptibility alleles should be found using linkage disequilibrium 
strategies (11, 12).  
 
These alleles are ancient variants that due to different genetic effects have become 
common among the populations. As ancient variants they would be segregated in “blocks” 
and would be linked to other variants that can be used as markers. The reasons explaining 
a deleterious variant reaching high frequencies at a population include random genetic drift 
and fluctuating selection pressures if at some time the allele has granted selective 
advantage. This might be the case for the principal allele causing cystic fibrosis (∆F508). 
Some theories have linked the high prevalence of this clearly deleterious variant to 
resistance to secretory diarrhoea transmitted by cattle in the early stages of civilization in 
Europe (13, 14).   The CDCV hypothesis is certainly to some extent true, having been 
borne out by the recent results of GWA studies; however, as noted above, variants 
detected so far account for only a small proportion of the calculated heritability of any 
disease studied. Two well known examples, from before the GWAs era, that support the 
CDCV theory are the APOE and the PPARγ loci. In the first one a common allele, known 
as ε4, with frequencies ranging between 0.05 and 0.4 predisposes to Alzheimer disease 
(15). In the second one, a single frequent variant (ProAla12), seems to decrease risk of 
type 2 Diabetes (16). 
 
Due to the success of GWAs and the number of alleles being discovered with the 
approach, a catalogue to group the findings has been built (17). The last available 
catalogue (09/07/2010) lists 631 papers and 3073 significantly associated SNPs. The 
description of these findings is beyond the scope of this thesis. See Table 1 for a list of a 
few conditions with the number of loci found to be associated at GWAs and heritability 
explained by the variants. For a graphical example of the number of loci associated with 
148 traits see Figure 2. 
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Figure 1. Graphical representation of feasibility of identifying susceptibility variants 
depending on their effect (RR) and their minor allele frequency. The area between the red 
lines represents the variants commonly detected on genetic research in complex diseases. 
Yellow circle represents those very rare variants with high effects, typically associated with 
Mendelian forms of disease, detectable historically by linkage mapping, and more recently 
by whole-exome sequencing. Blue circle represents those rare variants that confer 
intermediate risk and can be detected on mutational screenings or association studies. Red 
circle represents those common variants often associated with low risk and that are 
detected by GWAs or association studies. The area under the red lines with parallel blue 
lines represent those rare variants with that confer low risks and probably lie below the 
threshold for detection. The grey circle represent the very few common variants that confer 
high RRs. Adapted from Manolio et al. Nature 2009; 461(7265):747-753 
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On the other hand, the CDRV hypothesis supports that genetic susceptibility to complex 
traits is principally due to numerous uncommon variants associated with high risk of 
suffering the condition. Allelic heterogeneity in this case would be high, and the probability 
of finding susceptibility alleles using LD would be low. These uncommon variants are 
therefore a consequence of mutational events, and they correspond to recently acquired 
mutations subjected to evolutionary pressures with frequencies that depend on the 
deviation of fitness associated with them.  
 
There is evidence to support both, CDCV and CDRV hypotheses, and the genetic 
architecture of disease susceptibility may, in general, be a mixture between common and 
uncommon variants. The genetic architecture of particular diseases might be determined 
by conditions like mutation rate and evolutionary pressures (11).  
 
The achievements of GWAs have completed a broader picture of genetic susceptibility to 
complex diseases. However, the GWA studies are designed to fit the CDCV theory and as 
a consequence findings correspond to common genetic variants and the risk associated to 
uncommon ones is still under investigation.  
 
 
 
Table 1. List of 8 traits, the number of loci associated with them at GWAs and the portion of 
heritability explained by the variants. Note that there are traits, like height, where a high 
number of associated variants have been found but the percentage of heritability explained 
is low. On the list there are also traits with a small number of variants associated explaining 
a big portion of heritability (eg. Age related macular degeneration)  
  
Trait Heritability explained Number of loci 
Fasting glucose 1.50% 4
Early myocardial infarction 2.80% 9
Height 5% 40
HDL cholesterol 5.20% 7
Type 2 diabetes 6% 18
Systemic lupus erythematosus 15% 6
Crohn's disease 20% 32
Age related macular degeneration 50% 5
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To illustrate evidence for CDRV we can take the example of research on NOD2, a gene 
implicated in the susceptibility to Crohn´s disease (CD).  The Caspase-Activation 
Recruitment Domain containing protein 15 , also known as NOD2, was the first 
susceptibility gene identified to be associated to the risk of developing CD (18). Despite 
around 30 loci having been associated to the condition, the highest risk is still linked to 
variants at NOD2 (19). Three relatively common (mAF around 5%) variants in NOD2 have 
been associated with CD: R702W, G908R and 1007fsinsC (20). However, mutational 
screening experiments and a metanalysis have shown numerous uncommon variants 
being associated with the trait and explaining a portion of heritability (21) .  
 
As clearly explained in a model by Pritchard et al (11), it would be expected that genetic 
susceptibility alleles would be subject to purifying selection and, at expected human 
mutation rates, genetic susceptibility loci would have high genetic heterogeneity and a high 
number of uncommon and relatively new variants responsible for phenotypic variation. It 
seems, nonetheless, that in certain diseases allele frequencies can be subjected to 
unexpected effects due to random drifts or selective advantages (11, 22).  
 
Knowing the genetic architecture of each disease locus would be the first task for an 
optimal research design in complex diseases. Still, most of the factors involved are 
unknown and the debate is open. 
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Figure 2. Scheme representing by colours association signals on the 24 chromosomes for 
148 traits. Taken with permission from www.genome.gov/gwastudies. Accessed 
[3/09/2010]. 
 
1.3. Epidemiology of Congenital Cardiovascular Malformations 
 
The prevalence and incidence of CCM varies from cohort to cohort. This variation depends 
not only in the proband’s genetic background but also in the ascertainment criteria and 
diagnostic methodology used.  
 
Hoffmann in 2002 (23) analysed the available data from research works after 1955 in 
incidence and prevalence of CCM, concluding that the incidence of CCM is approximately 
8 per 1000 newborns. This incidence increases to 20 if the Bicuspid aortic valve (BAV) and 
silent patent ductus arteriosus (PDA) are taken into account. According to Hoffman, 
variation between different estimates was related to the relative frequency of VSDs, and 
this in turn was related to how early diagnosis was made. His conclusion was that given 
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the source of variation, incidence of CCM is homogeneous between geographical regions 
and time points.  
 
Findings in Hoffmann’s study were higher than estimates from two of the biggest previous 
studies: the Baltimore-Washington Infant Study, which reported a 6 year incidence of 
4.34/1000 live births (24), and the Pradat et al. study which reported an incidence of 
2.85/1000 live births including data from three large registries from France, Sweden and 
California (25). The difference was mainly due the detection and inclusion of small VSDs 
and BAV.   
 
A good approximation for many western countries is that the incidence of CCM is 
approximately 7/1000 live births or 1 in 145 newborns, with variations depending in the 
methodology used (26).   Adult CCM prevalence is more difficult to determine. It is thought 
that in the UK at least 150,000 adults carry a form of CCM. This would give an 
approximate prevalence of 250 cases per 100,000 (26). In 2009 Oyen et al. published a 
paper in Circulation exploring CCM epidemiology in a large population-based study in 
Denmark. Births between 1977 and 2005 were analysed. From 1,793,591 persons born in 
the period, 18,708 showed at least one form of CCM with a calculated prevalence of 103 
per 100,000 live births (27).  
 
Being the most common form of congenital malformation(28), and the leading cause of 
mortality in the paediatric population (29), CCM constitutes not only a challenging group of 
diseases for researchers but also for clinicians. Despite the fact that 50 years ago only 
25% of the patients survived beyond childhood (30), the mortality for this group of 
diseases in the paediatric population calculated by Wren in 2001 was 18%, and in the 
adult population it was 13.9%(31). A linear increase is therefore expected in the number of 
patients reaching maturity. CCM mortality is associated with acute surgical complications, 
arrhythmias, endothelial dysfunction, secondary structural damage and heart failure (30). 
In conclusion, CCM is a group of highly prevalent conditions, with great impact in terms of 
morbidity and mortality in the community. 
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1.4 Aetiology of Congenital Cardiovascular Malformation 
 
Congenital Cardiovascular Malformations (CCM) are defined as a group of defects present 
at birth within the cardio-circulatory structure and that are actually or potentially of 
functional relevance (27, 32). However, a percentage of these anomalies are not detected 
at birth and some experts include in this group diseases not present but with a latent 
predisposition at birth, like cardiomyopathies. Approximately 60% of CCM are diagnosed 
in babies less than 1 year old, 30% in infants and 10% in adult life (26)  
 
These defects are caused by aberrant patterns of development or failure to progress from 
an early stage in normal cardiogenesis (32). In the next pages I will review the process of 
normal cardiogenesis, the genetic factors involved and how the normal process is either 
truncated or distorted to produce CCM.  
 
The crucial time of cardiac development occurs between gestation week 6 and 12 and 
therefore most of the factors involved in CCM exert their influence at this stage. 
Additionally, some other anomalies can be developed later in pregnancy, like valve 
diseases (26) . A broad spectrum of factors, acting at crucial stages of cardiogenesis has 
been implicated as contributors to CCM. These contributors could be grouped into 
“genetic” and “environmental”. Nonetheless, the majority of cardiac malformations are 
neither purely genetic nor environmental, with most of CCM being classified as 
multifactorial or “complex diseases”. As an example, Ferencz et al concluded in 1989, that 
cardiac malformations associated with non cardiac abnormalities are caused by 
chromosome abnormalities in 12.9%, single mutations in 4.6%, and teratogenic factors in 
8.3% (33). However, in the remaining group without non cardiac abnormalities the causes 
remained unknown in 73.2%. Most of the subsequent studies have concluded similarly, 
with approximately 17% of CCM being “purely genetic” or as I will call them thereafter 
“syndromic” and the remaining cases called “sporadic” behaving as complex traits. 
 
It is important to remember that families in this large group of “sporadic cases” present 
higher familiar recurrence rates than general population, pointing to genetic factors being 
involved (34). In 1998 Burn et al. (35) published  the results of a cohort of patients  
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affected by CCM, where the recurrence rate was 2.1% and the overall risk for first degree 
relatives was 4%. Most previous and subsequent cohorts have found higher recurrence 
rates among relatives of CCM patients when compared to general population, with rates 
varying depending on patient selection and ascertainment methods. A meta-analysis 
published in 1994 showed an overall 5.8% risk of transmission if the mother suffers CCM, 
and 3.1% if the father is affected (36).  
 
In the Oyen et al. population based study calculated relative risks for monozygotic and 
dizygotic twins were 15.17 and 3.33 respectively. Recurrence risk for singletons with an 
affected first degree CCM affected family member was 3.21. Interestingly, “same heart 
defect” recurrence risk was calculated in 8.15 for first degree relatives overall. When 
probands with known chromosomal aberrations and extracardiac malformations were 
excluded the risk only slightly changed (8.15-8.61), indicating that the increased risk 
corresponded to non syndromic CCM. When data for dissimilar defects were analysed 
recurrence risk among first degree relatives was calculated as 2.68. However, in this 
cohort the population attributable risk for CCM family history was only 2.2%. The low PAR 
can be attributed to the preponderance of environmental factors or low penetrance genetic 
variants requiring either a combination of them or an additional environmental trigger (27).  
 
Numerous environmental exposures are suspected to be responsible for approximately 
8% of CCM cases. Among these we count: Infections like rubella; maternal diseases like 
diabetes, lupus, epilepsy or phenylketonuria; drugs like alcohol, hydantoin, thalidomide, 
retinoids, cocaine, and solvents; or environmental pollutants like nitrofen (37, 38). In 
summary, CCM is a heterogeneous group of diseases, in which the contributing factors 
have been elucidated for a fifth of the cases, including Mendelian and environmental 
causes. Research results in the remaining 80% of the cases of unknown aetiology suggest 
a complex interaction between genetic and environmental factors. 
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1.4.1. Syndromic CCM 
 
Numerous syndromic forms of CCM have been described. Many of them are rarely seen 
and some are relatively common. Among the commoner syndromic CCMs is the 
association of Down’s syndrome and atrio-ventricular septal defects (AVSD). Down’s 
syndrome coexists with AVSDs in 35% of cases and 75% of AVSDs encountered clinically 
are present in Down’s syndrome sufferers (26). Other chromosome number anomalies like 
trisomy 18, trisomy 13, Klinefelter Syndrome and Turner Syndrome (38, 39) are 
consistently associated to CCM. 
 
Nonetheless, not only gross genetic anomalies at the chromosome level have been 
associated to CCM. Despite a deep review of the previously described forms of syndromic 
CCM being beyond the scope of this introduction, I will describe some of the commoner 
forms with a special section for the 22q11.2 deletion. Some of the commoner and best 
described syndromic forms of CCM are:  
 
- Holt Oram Syndrome: Characterized by limb and cardiac anomalies like atrial 
septal defects (ASD), TOF and atrioventricular conduction defects. The syndrome 
is caused by mutations at TBX5 (40). 
- Char syndrome: Characterized by limb and cardiac anomalies, predominantly 
patent ductus arteriosus (PDA). The defects are associated to genetic defects at 
the so called Char locus, leading to a deficiency in the activity of the TFAPβ protein 
(40). 
- Noonan syndrome: Comprising characteristic facial features, chest deformities and 
pulmonary valve stenosis. It has been linked to mutations at the PTPN11 and K-
RAS genes. 
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Table 2. Commonest syndromic CCM and their genetic aetiologies. PS: Pulmonic valve 
stenosis, SVAS: supravalvular aortic stenosis, ASD: atrial septal defect, VSD: ventricular 
septal defect, TOF: tetralogy of Fallot, TGA: transposition of great arteries, PDA: patent 
ductus arteriosus, PDA: patent ductus arteriosus, IAA: interrupted aortic arch.  
 
Genetic aetiologies have also been found for multiple syndromes associated with CCM as 
a secondary feature like: Marfan (Fibrilin 1/ 2, TGFBR2), neurofibromatosis (NF1), 
Williams” (elastin), Alagille (JAG1, NOTCH2), Ellis Van Creveld (EVC) and CHARGE 
association (CHD7).   
 
1.4.1.1. 22q11.2 deletion 
Another well known form of syndromic CCM is the Di George syndrome, also called 
CATCH22, 22q11 deletion syndrome, and conotruncal anomaly face syndrome. The 
nomenclature of the syndrome is sometimes confusing, because although the clinical 
diagnosis of velocardiofacial syndrome (pharyngeal dysfunction, cardiac anomalies, and 
dismorphic facies) or Di George syndrome (cardiac anomalies, hypoparathyroidism, and 
immunodeficiency) is straightforward, only 35-90% of Di George patients and 80-100% of 
the velocardiofacial patients carry the 22q11.2 hemyzygous deficiency (41). 
 
Estimates of the prevalence of the 22q11.2 deletion syndrome are around 1 in 4000 live 
births. The group of Goodship reported a prevalence of one in 3900 live births in the UK 
Syndrome Gene Cardiac malformation
CHARGE Sema3E/CHD7 ASD, VSD, mitral valve defects
Noonan K-Ras/PTPN11/Shp2 PS
Cardio-Fascio-Cutaneous K-Ras PS
Costello H-Ras PDA, PS
Cardio-Fascio-Cutaneous MEK1/MEK2/B-Raf PS
DiGeorge modifier VEGF promoter VSD, PTA, IAA, TOF
DiGeorge TBX1 VSD, PTA, IAA, TOF
Char TFAP2β PDA
Ellis-Van-Creveld EVC/EVC2 ASD
Heterotaxy syndrome CFC1/ZIC3 d-TGA with Heterotaxy
Alagille NOTCH2/JAG1 PS, TOF
Holt-Oram TBX5 ASD, VSD, conduction
William Elastin SVAS
Neurofibromatosis-Noonan NF1 PS
Neurofibromatosis NF1 PS
Marfan TGFBR2 and Fibrilin 1/2 Aortic aneurysm
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(42). In the biggest population based study in Atlanta metropolitan area, USA, Botto et al. 
reported an overall prevalence of 1 in 5900 live births (43).  
 
Of the recognized 22q11.2 deletion syndrome patients 49-83% present a form of CCM of 
which 17-22% is TOF, 14-15% interrupted aortic arch, 13-14% ventricular septal defect 
(VSD) and 7-9% truncus arteriosus (41). Most of the defects, not only the cardiovascular 
manifestations,  are related to impaired development of fourth branchial arch (41). 
Pathophysiologically most of the defects seem to be related to haploinsufficiency of the 
TBX1 gene, despite the commonly deleted region containing 35 genes. This hypothesis is 
strongly supported by the phenotype exhibited by the TBX1 knockout mouse. In 2001 
Lindsay et al published a letter to Nature describing a series of experiments comprising a 
nested deletion strategy at the mouse homologous region to 22q11.2. The conclusion was 
that TBX1 deletion was responsible for the phenotype observed at the mouse carrying 
deletion of the whole region. Phenotype was fully penetrant at E10.5 and consisted in 
defective development of fourth branchial arch arteries (44).   
 
Also in 2001 Jerome and Papaioannou published a paper describing the phenotype of the 
TBX1 -/- mouse. At E11.5 17% of TBX KO heterozygotes showed either absent or reduced 
fourth branchial arch. No living homozygotes were found among the offspring of 
heterozygote mice. Nevertheless, cesarean sections found homozygotes in Mendelian 
ratios. TBX -/- were edematous indicating heart failure and showed abnormal facial 
structure, shortened necks and low set ears. All homozygotes showed single outlet outflow 
tract (PTA) and in some cases right or double aortic arch (45).    
  
TBX1 is expressed in the secondary heart field which, as described below, is involved in 
the development of structures like the outflow tract (OFT) and the right ventricle. TBX1 
seems also to be expressed at some cell populations at the anterior heart field fated to be 
cardiomyocytes in the OFT (46). These fated cells seem to be involved at the neural crest 
cell migration in OFT formation. The pathophysiology of the parathyroid and thymic defects 
associated with TBX haploinsufficiency has been extensively researched. TBX1 deficiency 
leads to decrease of proliferation of endodermal cells at branchial arches and therefore to 
defects at the structures derived from them. Endodermal proliferation depends on the 
activation of a transcription factor cascade that involves TBX1. TBX1 directly activates 
FGF8 and 10, factors involved in proliferation of surrounding cells; MYO1 and MYF5, 
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factors involved in the development of branchiomeric muscles; and other factors including 
PAX9, GCM2, GBX2, EYA1 or HOXA3 involved in cardiac, thymic and parathyroid 
development (47). 
 
On the other hand, cardiac defect development in 22q11 deletion is not as well understood 
as the branchial defects are. It is, however, recognized that a similar proliferation factor 
cascade is truncated with TBX1 deficiency: Islet 1 (ISL1) regulates sonic hedgehog (SHH). 
SHH in turn enhances the expression of forkhead family members (FOX). FOX family 
members bind to TBX tissue specific enhancers. TBX activates FGF8 and 10 as previously 
described (48).  
 
Perhaps the most striking feature of 22q11.2 deletion syndrome is the phenotypic 
variability.  Despite the syndrome being located at the “genetic end” of the CCM spectrum, 
its phenotype is not uniform and it may be related to background- environmental-stochastic 
factors (41). This is the case argued by experiments showing that despite TBX1 knockout 
mice showing little or no thymic defects initially, when they were bred into different strains 
these defects became obvious and highly prevalent. Also, despite the fourth branchial arch 
defect being fully penetrant at early stages in heterozygotes only a few present the 
phenotype at birth (49). This background-environment- genetic interactions might explain 
the case of 22q11.2 deletion syndrome phenotypic differences between human 
populations (50). 
 
1.4.2. Non-syndromic genetic forms of CCM 
 
Despite most of the genetic causes of CCM remaining unsolved, a few predisposing allele 
have been consistently identified in syndromic forms of CCM. As considered before, it 
might be that these genes posses a simpler architecture with less allelic heterogeneity and 
fewer common associated alleles. These facts make these genes good candidates to start 
the search in non syndromic forms of the disease using linkage tools and family studies. 
 
Among the commonest forms of non syndromic CCM is the bicuspid aortic valve. In 2005 
Garg et al. described that premature stop codons at NOTCH1 segregated with bicuspid 
aortic valve and early onset valve calcification in two families (51).  
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Associations between genetic variants at Nkx2.5, atrial septal defects (ASD) and 
atrioventricular conduction block have also been described. Between 8-19% of familial 
ASDs and 1-4% of sporadic ASDs are related to mutations at NKx2.5 (52). Multiple groups 
have described associations between sequence variants at NKx2.5 and the phenotype 
(40). However, it remains impossible to predict the phenotype associated with the variants. 
Moreover, nonsense mutations at NKX2.5 have been also linked to other phenotypes in 
small samples, like hypoplastic left heart, VSDs or conotruncal defects. The phenotypic 
heterogeneity of the NKX 2,5 variants is not yet fully understood leaving open questions 
about the protein role and the interactions at cardiogenesis. 
 
Other gene previously associated with heart septation defects is GATA4. Variants at 
GATA4 have been linked to ASDs, VSDs and AVSDs in families. Research at the variants, 
starting with the phenotypic similarity to the defects apparently caused by NKX2.5 and 
TBX5, has revealed that the variants seem to disrupt the interaction between these three 
proteins. The complex formed by NKX2.5, GATA4 and TBX5 is apparently a cornerstone 
for human heart septation (40). 
 
A search done at the catalogue of published genome wide association studies 
(www.genome.gov/gwastudies) revealed that up to August 2010 there have not been 
publications showing results on GWAs exploring CCM. 
 
In summary, predisposition to non- syndromic CCM have been extensively researched 
giving some insights, not only into CCM pathogenesis, but also at the embryological 
process of cardiogenesis. Nonetheless it is important to clarify that most of genetic 
predisposition to CCM is still unsolved and most of the genetic architecture, embryological 
implications and interactions are still unanswered questions. 
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1.5. Tetralogy of Fallot 
 
1.5.1. Introduction 
 
The defect now known as Tetralogy of Fallot was first described in 1671 by Stenson, but it 
first precise anatomical description was illustrated by William Hunter at St George’s 
Medical School in 1784: “…the passage from the right ventricle into the pulmonary artery, 
which should have admitted a finger, was not so wide as a goose quill; and there was a 
hole in the partition of the two ventricles, large enough to pass the thumb from one to the 
other. The greatest part of the blood in the right ventricle was driven with that of the left 
ventricle into the aorta, or great artery, and so lost all the advantage which it ought to have 
had from breathing” (53). The modern definition of TOF was refined by Etienne Louis 
Fallot, but the term is attributed to the Canadian Maude Abbott in 1924 (54).   
 
Tetralogy of Fallot is a congenital heart defect of the outflow tract characterized by right 
ventricular outflow tract obstruction, ventricular septal defect between the anterior and 
posterior limbs of the trabecular septal band, dextroposition (over-riding) of the aorta and 
right ventricular hypertrophy(55) Figure 3.  The condition is associated often with a number 
of other cardiocirculatory anomalies like coronary malformations or pulmonary atresia(38). 
That is the reason why now we regard the condition as a family of diseases characterised 
by intracardiac anatomy but variable in terms of associated abnormalities, pulmonary 
anatomy and outcomes (54). 
 
About 3.5% of all infants suffering CCM have TOF (54). TOF is the commonest cyanotic 
heart defect affecting nearly 0.24/1000 newborns worldwide, with both sexes being 
affected equally [2]. The calculated prevalence in the United Kingdom is nearly 0.31/1000 
newborns(56).  
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Figure 3. Tetralogy of Fallot Anatomy. Taken from the heart centre encyclopaedia (Public 
domain), www.cincinnatichildrens.org (57). Oxygenated blood is depicted red and de 
deoxygenated in blue. Note the shunt/mixture of deoxynated/oxygenated blood in the aorta 
consequence of the overriding position and the VSD. Pulmonary stenosis is also 
represented and is the determining factor for the right-left shunt.  
 
1.5.2. Clinical features and management 
 
The VSD in TOF is almost always non restrictive, with the pressure in both ventricles being 
equal. As a consequence the direction and magnitude of flow between ventricles depends 
on the degree of right ventricular outflow tract obstruction (54).  
 
Diagnosis of TOF, as in many complex CCM, is frequently made during foetal life using 
ultrasonography.  The diagnosis is only made when outflow tract images are obtained (58). 
However suspicion can be raised with abnormal views of the vessels at the upper 
mediastinum or a smaller diameter of the pulmonary artery. Nevertheless, most of patients 
are diagnosed during early life. The clinical presentation, as the degree of flow through the 
VSD, depends on the right sided outflow tract obstruction (58). The condition is suspected 
due to its clinical presentation characterised by: a variable degree of cyanosis, palpable 
right ventricular impulse and thrill; an early systolic aortic ejection sound; an usually single 
second heart sound; a systolic murmur which intensity and duration depends inversely on 
the severity of right ventricular outflow tract obstruction: with extreme degrees of 
obstruction the murmur is almost inaudible (32).  
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Before the development of surgical intervention, 50% of TOF patients died during early 
years of life with almost none reaching maturity (54). From 1955 the treatment for the 
condition was surgical, with the age of patients receiving primary surgical correction 
gradually decreasing (54).  
 
Most centres offer primary surgical correction between 3-6 months with a transatrial, 
transpulmonary approach sparingly using RVOT patches. However, in some centres a 
staged approach consisting in first constructing a right to left shunt, and afterwards 
complete repair, is also offered (38). Detractors of the two staged approach argue about 
the consequences of the long lasting right ventricle pressure overload and the effects of 
sustained cyanosis.  
 
However, it seems that depending on the expertise of the surgeons at the Blalock-Taussig 
shunt operation technique, the construction of these left to right shunts can favour growth 
of pulmonary arteries facilitating delayed repair (58). Irrespective of timing, ideal surgical 
repair should consist in closure of VSD, preservation of right ventricle structure without 
outflow tract obstruction and preservation of a functional pulmonary valve (54). 
Unfortunately, the nature of the RVOT obstruction usually makes this impossible.  
 
Modern surgical repair techniques have shifted from a “complete obstruction relief” policy 
to sparing techniques where the pulmonary valve is preserved even at the cost of some 
residual stenosis (54). This trend has reduced the adverse late effects of pulmonary 
incompetence and aneurysmal dilation. Despite the great advances in surgical technique, 
intensive care and diagnosis, TOF patients survival rate is approximately 86% at 32 years 
(59). The 3 leading causes of late death are: heart failure, arrhythmia and complications of 
re-operation (60). 
 
In the early postoperative period most children have an uneventful recovery. The most 
common complication is “restrictive right ventricle physiology”. This type of physiology is 
apparently related to the amount of right ventricle manipulation and transannular patch 
usage. The complication is characterized by a low cardiac output state and longer duration 
of intensive care stay and inotropic support (54). 
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Perhaps the most serious post surgical complication is pulmonary regurgitation. Until 
recently pulmonary incompetence was regarded as an unimportant consequence of 
surgical repair. Nevertheless, it has been shown that the amount of incompetence is 
directly related to exercise intolerance, ventricular arrhythmia, sudden death and right 
ventricular failure (54). The amount of pulmonary regurgitation can nowadays be 
measured by the gold standard cardiac magnetic resonance.  
 
There is now a consensus that the timing of pulmonary valve replacement after TOF repair 
has been too late most of the time (58). Prevention of the late consequences of pulmonary 
regurgitation has shifted the opinion to accept earlier indication for replacement, either 
surgical or percutaneous, in the presence of significant pulmonary regurgitation (>30%) 
and: subjective or objective deterioration of exercise tolerance, right ventricle dilation, 
ventricular tachycardia, pregnancy contemplated, QRS duration >180 msec or if cardiac 
surgery is indicated for other reason (58). 
 
There is also a trend to contemplate the effects of right ventricle dilation failure and dilation 
over the left ventricle. It seems that the poor left ventricular performance is related to 
biventricular dys-synchrony. Functional improvement has been reported with biventricular 
pacing and resynchronisation (61). It has been reported that 6% of surgically repaired TOF 
patients suffer sudden death in the long term (59). The risk of sudden cardiac death seems 
to be related to QRS duration but not to non sustained VT episodes during 24h ECG 
monitoring. Some groups have advocated to the use of implantable cardiac defibrillators  
in high risk patients (58). 
 
1.5.3. Introduction to TOF genetics 
 
Most cases of TOF seem to be sporadic. However, almost 20% of TOF patients show a 
syndromic form of the disease (39). In this group, the 22q11 microdeletion and 
velocardiofacial syndromes have been described several times. Johnson et al. described 
the presence of the 22q11 deletion in 14% of the probands in a cohort of Tetralogy of 
Fallot patients (62).  
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TOF can arise in the context of maternal infections, illness or exposure to teratogens, 
Boon (1972) calculated the heritability of the condition as 54%, with a recurrence risk in 
siblings of 2% for TOF and 1% for any cardiac defect (63). Digilio encountered a similar 
rate (64). Burn et al studied patients undergoing cardiac surgery at 12 centres in the UK 
(35). His group encountered 395 TOF patients who had 223 children with a recurrence 
rate of CCM (not only TOF) of 3.1%, which is around six times the general population risk. 
Risk was greater for mothers compared to fathers. 
 
TOF have been linked to dominant mutations causing decrease of gene product dosage. 
These associated genes correspond to cardiac transcription factors (NKX2.5, TBX1, TBX5 
and GATA4), transmembrane receptors NOTCH1 and NOTCH2, and their ligand JAG1. 
Cytogenetic anomalies like 22q11.1 deletion and trisomy 21 account for approximately 
15% and 7% of TOF respectively.  
 
In non syndromic cases of TOF, a number of genes have been linked with TOF in small 
number of patients. For example: Eldadah encountered 9 TOF patients carrying a mutation 
in the JAG1 gene, and Goldmuntz in 2001 described 4 TOF patients with mutations in the 
NKX 2.5 homeo-box. Other genes previously linked to the condition are: CSX, ZPFM2 and 
VEGF (64). However, in the majority of patients the causing factor is unknown, with some 
authors suggesting that TOF is a “complex” disease with a probable oligogenic origin (35). 
 
In 2009 Greenway et al. published a paper describing the results of a genome copy 
number variant (CNV) survey on 121 TOF trios (proband and two unaffected parents) 
using an Affymetrix assay. De novo CNVs of more than 20Kb found were compared to 
those found in a 2265 controls cohort. CNVs present in more than 0.1% of the controls 
were discarded, the rest were validated using MLPA. At the end, 11 rare de novo CNVs 
were found in the TOF cohort and 4 were found among controls, the difference was not 
statistically significant. Analysis of inherited CNVs showed 3 rare CNVs, not present 
among controls, inherited from unaffected parents. Further analysis explored CNVs in 9 
loci in 398 non syndromic TOF probands. A total of 17 rare CNVs not present in controls 
were identified. In summary 1% of non syndromic TOF sufferers presented a CNV on 
1q21.1; additional CNVs were identified at 3p25.1, 7p21.3 and 22q11.2; in a single 
individual 6 CNVs were identified, two of them on genes previously reported to be 
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associated with TOF (NOTCH1 and JAG1). Accordingly to this research results 10% of 
sporadic TOF can be explained by rare CNVs. 
 
According to the published research thus far, TOF genetic architecture might correspond 
to an entity with most of its predisposition being based on uncommon variants conferring a 
high risk to carriers. This would be the case if the lack of publications associating common 
variants to the condition, especially GWAs, corresponds to a biological fact and is not a 
consequence of methodology and sample collection.  
 
1.6. Cardiogenesis 
1.6.1. Morphological aspects of cardiogenesis 
 
The heart is the first organ to form during development, and begins to pump at 3 weeks of 
gestation (40, 65).Cardiogenesis is a extremely delicate process and involves different cell 
types and the interaction of genetic and epigenetic factors (40). One interesting fact about 
cardiac development is its evolutionary conservation in terms of morphological and 
molecular keystones (66). Human cardiogenesis resembles phylogenetic heart evolution, 
and its molecular similarities and differences with other organisms establish a parallel 
between acquisition of new structures and functional specialization (66).  
 
The process of heart development follows a conserved line of morphological changes 
among vertebrates. The cardiac progenitor cells have been identified in the anterior region 
of the embryo primitive streak. These cells of mesodermal origin migrate to each side of 
the midline, fusing and forming the structure known as the cardiac crescent (28, 65). At 
human embryonic day 21-23, the cardiac progenitors fuse forming a tube, start expressing 
cardiac markers and develop contractile function. Subsequently, the cardiac tube loops to 
the right and rotates in the anterior-posterior axis allowing the convergence between the 
outflow and inflow tracts. Cardiac cells undergo expansion, and the septation process 
begins forming mature chambers and the outflow tract. Finally, valves, coronary arteries, 
and conduction tissue are formed (65). Figure 4 shows a graphic summary of 
cardiogenesis. 
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Figure 4. Graphic summary of the major stages in cardiogenesis. Taken with permission 
from Buckingham et al (65). 
 
Scientific opinions about cardiogenesis have changed with time. Initially, heart 
development was believed to follow a tight spatial patterning of cell fate. Indeed, early 
experiments established correspondence between crescent regions and mature structures 
(65, 67). That was followed by the discovery of two group of cells named primary or first 
heart field (FHF) and secondary heart field (SHF), and the new goal was to build maps of 
cell fates based on those groups (28).  
 
The finding of cardiac neural crest cells contribution, and new animal models have 
radically changed scientific opinion about cardiogenesis, showing overlapping of regions 
and difficulties defining zones (28) . Both heart fields express different markers which will 
be explored in following chapters (67). These differences allowed mapping the cells and 
identification of regional relevance. It is now believed that the primary heart field 
constitutes a general scaffold, and contributes essentially to the left ventricle (28). The 
secondary heart field which is formed by a group of cells in the anterior pharyngeal 
mesoderm, contributes almost ubiquitously to the chambers but is highly important to OFT 
and right ventricle (RV) development (28).  The contribution from the NCC is mainly to the 
formation of the OFT and will be explored in the OFT section. 
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Figure 5.  Heart development and contribution of Primary Heart field (FHF), Secondary Heart 
Field (SHF), and Cardiac neural crest cells (CNC). Taken with permission from Srivastava 
(2006) (28). 
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1.6.2. Molecular aspects of cardiogenesis 
 
1.6.2.1. Introduction 
Cardiogenesis refers to the cellular and molecular mechanisms that lead to the 
commitment of undifferentiated mesodermal progenitors into the cardiac lineage (68) and 
the formation of the complex structure we call the heart. This differentiation process 
responds to the influence of molecular signals within the mesodermal cells and from non 
mesodermal adjacent tissues. 
 
Previous works in heart development and comparative genetics have shown a conserved 
gene regulatory network from simple heart like structures in invertebrates to complex 
chambered hearts in vertebrates. It has been therefore hypothesised that the addition of 
structures and increasing complexity of the heart are due to the expansion and 
modification of that genetic network.   
 
The first heart structure is believed to have been developed by a billaterian approximately 
500 million years ago. This heart structure was apparently a monolayer structure with 
peristaltic contraction similar to the ones encountered in tunicates. From that monolayered 
structure the heart evolved to be able to separate oxygenated from deoxygenated blood in 
a multichambered complex structure exhibiting synchronous contraction like the human 
heart (66). All this structure addition (valves, chambers, conduction system) corresponds 
not only to an increasing complexity of the genetic network controlling the process but also 
the acquisition of additional cell lineages within the process (such as the neural crest 
cells). Genetic evolution of cardiogenesis is thought to have been driven by three key 
processes: gene duplication, changes in cis regulatory sequences and mutation in the 
genes involved resulting in new function.  
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Figure 6. Scheme representing the basic transcriptional circuit for cardiogenesis in 
vertebrates. Taken with permission from Munoz-Chapuli R et al. Cardiogenesis: an 
embryological perspective. Journal of Cardiovascular Translational Research; 3(1):37-48 
 
Heart development in vertebrates seems to be controlled by two groups of genes. The first 
is a core of evolutionary conserved transcription factors, including NK2, MEF2, GATA, 
TBX and Hand. These proteins regulate cell fate, expression of contractile machinery and 
morphogenesis, also regulating expression of each other and reinforcing the cardiac gene  
development program (66). Other accessory transcriptional factors also contribute to 
cardiogenesis.  Disruption of each one of these core cardiac inductors does not completely 
suppress cardiac differentiation but rather alters the fusion in the midline of the heart fields, 
or impairs cell diversification, chamber formation and maturation (68). The second group of 
genes is an accessory group related to the function of the regulatory core and to the 
acquisition of new structures. As an example we can cite Isl2 which is a protein related to 
the secondary heart field and the expression of Mef2c (66). 
 
The pattern of expression of the previously mentioned genes in the heart fields follows this 
line: cardiac induction; expression of specific activators and regulatory transcription 
factors; construction of contractile machinery; and finally growth and patterning  control 
(66). It is also known that cis regulatory elements control the expression of different genes 
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in a spatially specific fashion creating specialized groups of cells among the cardiac 
progenitors contributing to the complexity of the developed heart.  
 
As it is understood at the moment, the first step is the induction of the mesoderm to 
cardiac fate during gastrulation. This induction seems to be exerted by the endoderm 
through the expression of Bone Morphogenetic Proteins (BMPs) and Fibroblast Growth 
Factors (FGFs) (67). The activation of the cardiac progenitors by BMPs through the SMAD 
pathway induces the expression of Nkx 2.5, a domain homeobox ortholog to the 
Drosophila Tinman, expressed in cardiac mesoderm and the adjacent endoderm that 
serves as the signal to initiate cardiogenesis. Forced expression of Nkx2.5 in zebrafish 
was shown to induce size increase of the heart field and cardiac profile protein expression 
in fibroblasts (69). Dominant negative Nkx2.5 constructs can block cardiogenesis in 
Xenopus (66). However, targeted disruption in mice of Nkx2.5 disrupted cardiogenesis at a 
much later stage, with failure of looping at the linear stage but without compromise of 
contractile machinery expression (70). 
 
Mef2 is a protein that belongs to the MADs- box family and is perhaps the most ancient 
myogenic transcription factor.  Mef2 participates in the differentiation of muscle cell types 
with the subtype MEf2c being implicated in the expression of specific cardiac proteins and 
with the regulation of gene transcription in the secondary heart field. The GATA family of 
genes regulate the expression of contractile protein genes and upstream genes including 
Nkx2.5 and Hand (66).  Three of the six GATA genes in vertebrates are expressed in the 
developing heart. Forced expression of GATA4 in Xenopus results in premature induction 
of cardiogenesis and more importantly have been implicated in non syndromic forms of 
CCM in humans (See section 1.4.1). 
 
Seven genes of the Tbx family are so far known to be expressed in the mammalian 
developing heart. Mice lacking Tbx5 present defects in the posterior region of the heart 
tube. Tbx5 disruption using dominant negative constructs cause failure to develop early 
cardiac heart fields in Xenopus. Additionally, defects in TBX5 are the cause of Holt Oram 
syndrome in humans (40).  The transcription factor’s action leads to the expression of 
muscle genes and genes controlling growth and patterning (like our pathway of interest: 
the Wnt family of proteins).  
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Table 3 shows some of the key genes with their expression pattern and mutant phenotype 
in animal models. 
 
When the cardiac precursors initiate differentiation, specific activators of the heart fields 
induce the expression of the core transcription factors. In the primary heart field the 
activators are genes NKx2.5 and GATA4, whereas in the secondary heart field they are 
Isl1 and Foxh (28, 65-67). At this stage, the anterolateral population of cardiac progenitors 
expressing Nkx2.5/ BMP are called the primary heart field, and the posteromedial region of 
progenitors expressing Isl2/ FGF8 are known as the secondary heart field. Not only 
activators but also inhibitors like the Wnt canonical proteins family are essential to this 
stage of development (71). 
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Gene Mutant 
phenotype 
Cardiac Tube Secondary 
field 
Crescent 
expression 
Nkx2.5 Single atria and 
ventricle. No Hand1 
Yes Yes Yes 
Tbx5 Hypoplastic LV, 
Sinoatrial defects 
Left Ventricle, 
Atrium, 
Infundibulum 
No Yes 
Hand1 LV disrupted Left ventricle No Yes 
Fgf10 No No Yes No 
Fgf8 Outflow tract 
defects 
No Yes No 
Tbx1 Outflow tract 
defects 
No Yes Yes 
Isl1 Single atria and 
ventricle. Atrial 
venous pole 
abnormal 
All Yes No 
Foxh1 Outflow tract defect 
absent, Right 
ventricle does not 
develop 
No Yes No 
Hand2 RV abnormalities Right ventricle Yes Yes 
Tbx20 Chambers don’t 
develop, Outflow 
tract disrupted 
Outflow tract, 
ventricles 
Yes Yes 
 
Table 3. Relevant genes in cardiac embryogenesis, expression and mutant phenotype. 
Adapted from Buckingham et al (65). 
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1.6.2.2. The heart fields and the outflow tract 
The first experiment describing a second population of cells that were added late in 
cardiogenesis, after the formation of the heart tube, and contributed to the outflow tract 
formation, was made as early as 1977 by de la Cruz et al. (72). In this classic experiment 
an iron oxide marking technique was done to the most cranial part of the chick embryo. If 
the labelling was made at HH12 the region was incorporated into the right ventricle 
trabeculae. Labelling at stage HH22 identified the marked region in the myocardium below 
the semilunar valves. Nevertheless, it was only in this century that the molecular bases of 
OFT development were discovered.  
 
The development of the OFT is, like cardiogenesis as a whole, a complex process 
involving the interplay of genetic and environmental factors in which different groups of 
cells have a key role. The OFT is the final result of remodelling a tubular structure called 
the conotruncus (73). This process includes the formation of cardiac cushions, migration of 
endothelial cells, myocardialization of the endothelial cells, fusion of the cushions, 
septation and remodelling (73).  
 
In 2001 three different groups identified, using different experimental approaches, a novel 
cell population to the FHF that contributed to the OFT formation that was named the 
anterior heart field. Kelly et al made an experiment with a FGF 10- nlacZ reporter mouse 
determining that the right ventricle and the OFT are derived from the splanchnic 
mesoderm and the pharyngeal arch core in stages E8.25-E10.5 (74). Mjaatvedt labelled 
cells anterior to the heart tube using mitotracker or an adenovirus and later found them in 
the OFT. This same group ablated the bilateral heart fields anterior to the heart tube 
resulting in development of a rudimentary heart (75). Wal et al., after indentifying 
expression of GATA4 and Nkx2.5 in the mesoderm anterior to the heart tube, labelled the 
region, finding the cells in the proximal OFT (76). Kirby et al.  also had shown in 1983 that 
removal of mesodermal cells anterior to the heart tube produce a failure in outflow tract 
septation (77).  
 
Another key discovery in the understanding of cardiac embryogenesis and particularly the 
embryogenesis of the OFT was the description of the pattern of Isl1 expression. Isl1 is 
expressed in the rostrolateral mesoderm of the chick embryo and its expression is lost in 
the fusing differentiating myocardium remaining at the undifferentiated regions (78). 
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Reporter experiments of Isl1 show expression of the gene in the OFT, the atria and the 
right ventricle. Cai et al reported in 2003 the cardiac phenotype for the Isl1 KO mouse, 
which roughly is characterized by absence of OFT, part of the right ventricle and atria (79), 
regions that correspond to the previously labelled expression domain. This group of 
experiments showed that there are two progenitor cell lineages separated by time; the first 
and the second lineages. The primitive left ventricle seemed to be exclusively derived from 
the first lineage whereas the right ventricle was from the second one. In the rest of the 
cardiac chambers the two lineages intermixed. These cell lines were not spatially 
identifiable in the heart fields but the first seemed to undergo early differentiation while the 
second remained undifferentiated and contributed late to the arterial and venous pole of 
the developing heart (78).   
 
It seems that the heart fields are not different group of cells but a unique region separated 
by spatial and temporal patterns of expression, the terms of first, second, anterior and 
secondary heart field are useful. Summarizing, the first heart field refers to the first group 
of cells that differentiate and express muscle specific proteins. These cells are the first to 
down-regulate Isl1 expression. The second heart field are the cells added to the cardiac 
poles when the heart tube is formed. The anterior heart field corresponds to the cells 
labelled with a Fgf10-lac reported and which exclusively contribute to the OFT and right 
ventricle. Finally, the secondary heart fields refers to the splanchnic mesoderm caudal to 
the OFT that gives rise to the most distal part of the OFT and the media of the great 
arteries (78). 
 
Importantly, addition of myocardium to the OFT derived from the secondary heart field 
adds length to the structure. This added length allows OFT to rotate in order to anneal with 
the respective ventricles. Failure in this key process, as illustrated by the results of ablation 
of the secondary heart fields, produces mis-alignment of the aorta and pulmonary atresia-
stenosis, a phenotype that closely resembles TOF (80).  
 
1.6.2.3. The cardiac neural crest cells 
 
An important element in the OFT formation is the population of cardiac neural crest cells 
(CNC). The first article describing the contribution of this cell group to cardiogenesis was 
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published in 1983 (81). Early experiments were performed using ablation and quail-chick 
chimeras. The role of this group of cells was revealed when ablation of premigrating CNC 
showed outflow tract defects and hypoplastic or aplastic parathyroid, thymus and thyroid 
glands (81). Strikingly the phenotype derived from CNC ablation closely resembles 
DiGeorge syndrome in humans.  
 
From the seminal ablation works, experiments using fate mapping of the CNC determined 
their contribution to cardiogenesis in mammals. Waldo et al. used a Cx43 (gene expressed 
at CNC)- β galactosidase expressing transgenic mouse showing CNC presence within the 
pharyngeal arches, the OFT and  ventricular myocardium (82). Subsequent revision of the 
matter showed that Cx43 can be also expressed in myocardial cells. Several works have 
performed fate mapping of CNC using Cre- Lox models. MacMahon et al. produced a 
transgenic mice using the Wnt1 promoter regulating expression of Cre in CNC cells (83). 
The model was used by the group of Sucov et al to fate map CNC. Labelled CNC were 
identified invading the aortic arch and the pharyngeal arches at E10. CNC were found 
invading the OFT by embryonic day 10.5 and contributing to the aorto-pulmonary 
septation(83). 
 
During the last decade multiple CCM mouse models have been described, with many of 
them showing defects in CNC development. Most of our knowledge of the embryological 
involvement of these cells in cardiogenesis and the genetic pathways involved are derived 
from these models. (78). For a summary of the pathways implicated in CNC development 
see Table 4.  Bone morphogenetic proteins are members of the transforming growth factor 
beta superfamily known to be important in CNC development. BMPs have been shown to 
be key regulators during morphogenesis in general and cardiogenesis in particular. 
Kaartinen reported in 2004 a Cre/Loxp experiment specifically disrupting Alk2, a BMP 
receptor, in CNCs. Disruption of the receptor resulted in failure of OFT septation and 
differentiation of CNC derived muscle (84). Disruption of type II and 1A BMP receptors 
also result in outflow tract defects (83).  
 
Notch receptors are transmembrane proteins involved in a wide number of cell 
specification and differentiation processes. The activation of the pathway leads to a 
proteolytic cascade resulting in liberation of the Notch intracellular domain that 
translocates into the nucleus activating the expression of downstream targets as the basic 
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helix-loop-helix transcription factors (83). As previously mentioned in the section on 
syndromic CCM, mutations in Jagged1 are the cause for the Alagille syndrome. In mouse 
inactivation of Jagged1 causes severe vascular defects, and double heterozygotes for 
Jagged1/Notch2 show severe cardiac abnormalities including pulmonary stenosis. 
However, despite the high likelihood of these defects being linked to the CNC migration, 
there is still lack of evidence in the matter. 
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Table 4. Summary of genes and pathways implicated in neural crest development. Adapted 
from Stoller J, Epstein J. Cardiac neural crest. Seminars in cell and developmental biology 
2005; 16:704-715 
  
Family Genes
Bone morphogenetic proteins Alk2, Bmpr1a, Bmpr2, Msx2
Transforming growth factor beta TGFβ2, perlecan
Fibroblast growth factors Fgf8
Notch, Jagged Jagged1, Notch2, Presenilin1, Ht2
Wingless/Wnt Dvl2, Wnt1, Wnt3a, APC
Endothelins EdnrA, ECE-2, ET-1
Semaphorins, neuropillins, plexins Npn1, PlexinA2, Sema3C, PlexinD1
Neurotrophins Trk-C, Neurotrophin 3
Vascular endothelial growth factos VEGF165, Hif1-alpha
Transcriptional regulators Ap2α, Cited2, Foxc1, Foxc2, FoxD3, Nkx2.6, Pax3, Sox9, Tbx1
Adhesion molecules NCAM, N- cadherin, Connexin-43
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1.7. The WNT pathway 
 
1.7.1 Introduction to the Wnt pathway 
 
The wnt family of genes is a highly evolutionary conserved group of proteins characterized 
by their homology with the wingless gene in Drosophila, the first described member of the 
family (85). This family of secreted lipid modified glycoproteins comprises 19 genes in the 
mammalian genome (71), controlling numerous processes like cell migration, cell fate and 
cell proliferation or apoptosis (71, 86).  
 
Initially, it was thought that this group of proteins exerted their function via a unique 
pathway. However, nowadays we recognize at least 2 functionally distinct groups of 
interacting proteins: the canonical or β catenin dependent and the non canonical or β 
catenin independent pathway (85). As a consequence, we can divide the wnt proteins into 
two functional groups: the first one comprising Wnt1, 3a and 8 which trigger just the 
canonical pathway, and the second one comprising Wnt4, 5a and 11 which in turn activate 
the non-canonical pathway and seem to have inhibitory properties over the canonical one 
(71). However, due to the high degree of interaction between the pathways some models 
are attempting to unify the wnt signalling as a whole interacting signalling pathway (71, 87) 
 
Equally, the importance of the wnt inhibitors during development has been recognized. 
Two big groups of these molecules are distinguished: the secreted frizzled related proteins 
(sFRP) and the Dickkopf proteins (Dkk) (71). 
 
1.7.2. The canonical pathway 
 
Within the canonical pathway, the signal is started by the coupling of the Wnt protein to a 
Frizzled receptor (Fz). The activation of the Fz receptor and its Lipoprotein related protein 
co receptor (LRP) activates one of the proteins that will be explored during this research, 
Dishevelled, inducing disassembly of the complex between Glycogen synthase kinase 3 
(GSK3), Axin and Adenomatosis Polyposis Coli (APC). This process blocks the 
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phosphorylation of β -catenin, decreasing its degradation. The accumulation of β catenin 
allows its interaction with the LEF/TCF family of transcription factors. The complex 
translocates to the nucleus and regulates gene transcription trough interaction with 
TCF/LEF transcription factors (71, 85). Certain target genes such as c-myc and cyclinD1 
allow the canonical pathway to regulate cell proliferation. Latest experimental results have 
linked protein Gβq and Gβo subunits in canonical function (88). See Figure 7 
 
1.7.3. The non- canonical pathway 
 
Research in the non-canonical Wnt signalling, or Planar Cell Polarity Pathway (PCP), 
started in 1983 when Gubb et al described a small set of genes controlling polarity of hairs 
and bristles in Drosophila (89). Studies of PCP have included multiple model organisms 
and a summary of the most relevant findings will be summarized in this section. 
 
PCP research in Drosophila has been based in the orientation of eye and wing structures. 
Interestingly mutations in the PCP genes do not cause random distribution of the hairs in 
the wing but rather patterns, for example one resembling impressionist brushstrokes and 
motivating the mutant name Van Gogh. There are approximately 10 core PCP genes in 
Drosophila. The accepted sequence of activation of the noncanonical Wnt pathway follows 
this line: Wnt proteins activate Frizzled receptors which in turns recruits the adaptor protein 
Dishvelled (Dvl) as in the canonical pathway (71). Dvl activates, in a way still poorly 
understood, a Jun-Rac-Rho kinase pathway controlling cytoskeleton dynamics (89). The 
mechanism explaining how neighbouring cells communicate PCP signals and how global 
organism polarity is determined is still under research. The most widely accepted theory is 
that two Cadherin proteins (Dachsous and Fat), together with a Golgi protein called Fj, set 
up a global polarity signal that is translated by the asymmetric assembly of a protein 
complex including Fz receptors, Vang, Dvl, Stan and intracellular adaptor protein Diego.  
Interestingly Wnt protein loss of function and overexpression experiments have failed to 
produce PCP phenotypes in Drosophila, a fact that might be explained by functional 
overlapping between the Wnt proteins. 
 
There are 5 processes known to be PCP controlled in vertebrates: convergent extension, 
neural tube closure, eyelid closure, hair bundle orientation and follicle orientation in the 
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inner ear cells. Additional to the previously mentioned PCP gene core, derived from the 
research in Drosophila, there are also a number of associated proteins that are essential 
to the PCP pathway involving for example transporters and chaperones. All genes that 
play a role in PCP signalling are homologs to one of the core Drosophila PCP genes (89). 
 
Convergent extension (CE) movements correspond to medial migration and intercalation 
of mesodermal cells, movements that are controlled by lamellipodia formation. These CE 
movements can be disrupted in Zebrafish by mutation of Vangl2 (trilobite), prickle, or 
wnt11 (siberblick) and in Xenopus by disruption of any of the core PCP genes. For 
example disruption of Dvl in Xenopus produces a failure in CE movements (89). In mice 
loss of Vangl2, Celsr1, Ptk7 and simultaneous loss of two of the Dvl genes leads to neural 
closure defects, shortened embryo and CCM (90, 91).  
 
The accumulation of the non canonical effector proteins in certain subcellular regions lead 
to the activation of the small G proteins Rho and Rhac, Phospholipase C, Protein Kinase 
C, and intracellular calcium release (87, 92). This complex interaction of processes control 
cell polarity, adhesion and motility through the action of the Rho induced kinases (85, 92) 
that results in control of cell elongation, cell body orientation and protrusive processes 
(93).  Expression of dominant negative forms of Rok2 decreases dorsal cell migration in 
Zebrafish (93). Also Rok2 overexpression in siberblick Wnt11 zebrafish mutants 
suppresses the defects shown by the mutation, suggesting a regulatory role in the 
pathway downstream of Wnt11.  
 
Finally, transcriptional changes also take place due to the modulation of the JNK 
transcription factor (71, 85, 92, 94). Rac binds the domain of Dvl and directly activates Jnk. 
In Xenopus morpholino knockdown of Jnk impairs CE movements, and produces cell 
adhesion defects (93). 
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Figure 7. The canonical Wnt pathway. Colour filled figures represent the genes involved in 
this research. In yellow dishevelled. 
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Figure 8. The non-canonical wnt pathway. Colour filled figures represent the genes involved 
in this research. In green the Wnt protein; In yellow dishevelled; In red ANKRD6 or its mouse 
ortholog Diversin; And in blue Rho associated kinases. 
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1.7.4. Wnt signalling and body axis patterning 
 
One of the main processes in development is the regionalization of embryo sections in two 
axes, dorsoventral and anteroposterior, providing an orthogonal system for regional 
patterning.  Wnt signalling, canonical and non canonical, is key for axes development. 
Research into body axes development has shown some conserved features among 
species, like the Hox gene expression, but also has revealed that this process has unique 
features between species (95). 
 
Early processes in axis configuration can vary widely among species due to selective 
conditions like internal or external development. The basic body plan and axis of 
vertebrates is established during gastrulation by coordinated movements that originate the 
three germ layers (96). Among these movements, convergent extension is key to the 
correct configuration of the axes. One of the most important pieces of evidence of Wnt 
signalling being involved in axis configuration are the phenotypes of known mutants as 
silberblick (slb), pipetail (ppt) and trilobite (tri). All of these previously mentioned mutants 
show shortened bodies with evidence of defects in axis development due to defective 
convergent extension movements. The mutated genes responsible for these three 
mutants, Slb, ppt and tri are part of the non canonical Wnt signalling in Zebrafish. 
 
In developmental terms, polarization of embryos can occur as early as egg fertilization. 
Nowadays is recognized that polarized expression of genes in the visceral endoderm 
directs the orientation of antero-posterior axis in vertebrates (97). Formation of the 
primitive streak due to mesenchymal transformation of endodermal cells in the epiblast 
define, perhaps for the first time, the anterior and posterior poles of amniote vertebrate 
embryos. Asymmetric expression of Wnt3/Cer1-Lefty1 is involved in the migration of 
visceral endoderm and organization of the axis. Wnt3 expression marks the posterior 
embryonic region with the anterior visceral endodermal cells migrating towards regions 
that express Cer1-Lefty1 (97). Wnt3 and β catenin KO mice fail to form the primitive streak 
(98, 99). Dorso-ventral axis determination, in a simplistic view, apparently depends on a 
gradient of Bmp proteins expression that takes different forms depending on the organism 
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(95). For example in frogs, Wnts expression results in the formation of the Spearman’s 
organizer at the dorsal region. The organizer express BMP inhibitory proteins.   
 
Despite that in mammals the left and right sides of the embryo are determined when the 
primary A-P and D-V axes are developed, the first event showing left right asymmetry in 
the embryo is the leftward fluid flow at a cavity called the node (99). More evident 
asymmetry starts to be shown at 6-8 somite stage when the embryo begins to rotate along 
its rostro-caudal axis. Axial rotation is accompanied by ventral closure. During this rotation 
organ situs start to become apparent and left right differences between paired organs 
emerge. Differences in paired organs are intrinsic to the organ itself with explanted organs 
maintaining their developing pattern (100).   
 
Numerous human situs defects have been reported ranging from single organ to complex 
conditions like the immotile cilia syndrome. In mouse the inversus viscerum mutation 
causes randomization of heart looping and body situs whereas the inversion of embryonic 
turning (inv) mutation show complete inversion of body situs and turning (100). It seems 
that early disruptions cause randomization or complete inversion of situs. The insertion 
that causes the inv phenotype disrupts the coding sequence of the inversin gene, an 
ortholog of ANKRD6 and a key signalling protein of the non canonical Wnt signalling.  
  
To account for the directionality of the left right axis development Brown and Wolpert 
proposed a theoretical model based on a chiral molecule (101). Lately, research has 
focused on cilia, which contain a chiral motor structure. Evidence of ciliar involvement in 
laterality came from a human disease model, Kartagener syndrome, characterized by 
inmotile cilia and high incidence of left right inverted organs (101). The first laterality sign, 
the leftward fluid in the node, due to coordinated ciliar movement, must be transmitted to 
subsequent stages of development. In that sense, differential expression of genes at each 
side of the midline directs the asymmetric development of the left-right axis.  
 
A conserved characteristic among vertebrate embryos is the left-sided expression of Nodal 
at the left side of the midline as a consequence of repression of Shh expression at the 
right side and therefore up regulation at he left one. There are several proteins 
downstream of nodal that are differentially expressed, making possible left-right 
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asymmetry development, like LEFTY1 and LEFTY2 or Pitx2. A deep review of this pattern 
of protein expression is over the scope of this introduction. 
 
1.7.5. Wnt signalling and early cardiogenesis 
 
Cardiogenesis is a complex process that can be subdivided in overlapping phases such as 
linear heart tube formation, cardiac looping, chamber formation, septation and maturation. 
In all these phases Wnt proteins, Fz receptors and Wnt inhibitors have been shown to be 
expressed in a consistent fashion in different model organisms (102) (85, 102). Eleven 
WNT orthologs have been encountered in the heart forming fields and early cardiac tube 
of mouse, chicken, quail and xenopus (85, 103, 104). Also Wnt 3a, 5a, 5b, and 8c are 
expressed in the primitive streak of avian and mouse embryos (71). Wnt 8, 2b, 5a, 7a and 
14 have been shown to be expressed on the tubular heart of chicken embryos (71, 85). 
Also the mouse receptors Fz-2, 4, 9, the Xenopus receptors Fz 7, 8, 10a, 10b, and the 
human Fz receptors 1, 2, 7, 8 and 9 have been found within the heart fields mesoderm, 
cardiac neural crest cells and adult heart (85). 
 
Works in the function of the canonical Wnt pathway in early cardiogenesis were initially 
confusing. A positive involvement of the pathway had been described in Drosophila  
whereas inhibition of the pathway in Xenopus using Crescent or Dkk seemed to induce 
cardiogenesis (105). The endothelial specific disruption in mouse of β catenin resulted in 
the formation of multiple heart forming fields (102). This particular conflict seems to have 
been answered by later experiments showing that canonical Wnt signalling can exert 
different effects depending on the time and location of action. In 2007 Ueno et al. 
published an experiment showing that shock inducible Zebrafish transgenic embryos 
expressing Wnt8 before gastrulation resulted in more cardiomyocyte formation while 
expression of Wnt8 after gastrulation resulted in the complete opposite (106). Some late 
experiments suggest that even this temporal biphasic model is too simple with different 
progenitor cell populations showing different responses to canonical Wnt signalling 
depending on their differentiation status and their molecular make up (102).  
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It is important to notice the relationship between mesodermal specification and β catenin 
signalling. Huelsken published in 2000 the phenotype of the β catenin KO mouse showing 
an early defect of anterior-posterior axis formation with complete absence of subsequent 
mesodermal tissue formation (99). In the same direction Wnt3 -/- mouse shows no 
primitive streak, failure of mesoderm formation, and failure to develop a posterior-anterior 
axis (98). 
 
Mesp1 is the earliest cardiovascular lineage marker. The gene is upstream of Isl1 among 
other genes. Another important marker is Flk1, a tyrosine kinase receptor that can, in a 
time dependent fashion, induce the differentiation of cardiac progenitors formation. 
Consistent with the early mesodermal positive influence of Wnt/β catenin signalling 
influence on early mesodermal commitment, depletion of this pathway results in absence 
of Mesp1 expression and downregulation of Flk1 (102). 
 
A number of observations also link canonical Wnt signalling to roles in the differentiation of 
cardiac progenitors in the SHF. Tissue specific down regulation of β catenin leads to a 
reduction in Isl1 cells in this field and the loss of SHF derived structures (102). Moreover, 
chromatin immunoprecipitation experiments have shown that β catenin binds directly and 
positively regulates the promoter of Isl1 (102).   
 
With respect to the non canonical Wnt pathway, the best investigated factor is Wnt11. In 
Xenopus, loss of function experiments have shown that Wnt11 is essential for 
cardiogenesis and that its overexpression can cause contractile tissue formation (107). 
Loss of function experiments in Xenopus, artificially blocking non canonical ligands such 
as Wnt 11 or proteins like Dishevelled lead to defects in heart tube formation including 
cardia bifida (103, 107). Also important is the antagonistic effect at this early stage 
between Notch signalling and canonical Wnt signalling. It has been described that Notch4 
activation can redirect Flk1 + cells fated to become blood progenitors into the cardiac 
lineage, an effect that is dependent on the expression of secreted Wnt inhibitors as Sfrp1 
and Sfrp5. This effect was abolished with the addition of Wnt3 but not with Wnt5a (102).  
 
Experiments in embryonic stem (ES) cells have also shown the relevance of non canonical 
Wnts in cardiogenesis. In ES cells, as in endothelial progenitor cells (EPCs), a cardiogenic 
program can be triggered trough the induction of Notch signalling. In turn, Notch signalling 
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upregulates Wnt ligands, specially Wnt5a (102). Also Wnt5a seems to be upregulated in 
response to Mesp1. It is however interesting that the Wnt5a KO mouse reported by Tai et 
al and Yamaguchi et al. do not exhibit a cardiac phenotype (108, 109). Downstream 
identity of the proteins involved in the cardiac induction exerted by the non canonical 
ligands Wnt11 and Wnt5a has also been researched. The activation exerted by Wnt11 can 
be inhibited trough the inhibition of PKC and JNK in Xenopus (102).  
 
 
In summary, during early cardiac differentiation Wnt involvement can be elegantly 
described in 4 phases as in the paper of Gessert et al.: 1. Wnt β catenin signalling is 
needed for mesoderm/endoderm formation; 2. For cardiac specification, canonical 
signalling must be low. Canonical inhibitors as Srpfs and non-canonical Wnt pathway 
ligands as Wnt11 and Wnt5a might be involved in the process; 3. Canonical signalling is 
needed for the proliferation of certain cardiac progenitors, especially in the SHF; 4. Finally, 
for cardiomyocyte final maturation canonical signalling should be low. Non canonical 
signalling is involved in the process (102). 
  
1.7.6. Wnt signalling and the formation of the four chambered mature 
heart. 
 
The wnt signalling pathway has been shown to be involved in later stages of cardiogenesis 
in the formation of OFT, cardiac valves and the conduction system(85). Cardiac 
morphogenesis is a complex process involving tube formation, looping, chamber formation 
and heart maturation, all these processes require regulation of cell adhesion. Mediating 
this cell to cell interaction a key protein is N-cadherin, a calcium dependent adhesion 
molecule. It is widely accepted that non canonical Wnt signalling regulates N-cadherin 
mediated cell adhesion. Wnt11 KO mice show OFT defects and thinner ventricular walls, 
and exhibit defects in the localization, organization and intercellular contacts mediated by 
N-cadherin (110).  Loss of function experiments in Xenopus, artificially blocking non 
canonical ligands such as Wnt 11 or downstream proteins such as Dishevelled lead to 
defects in heart tube formation like cardia bifida illustrating the relevance of the non 
canonical Wnt signalling for cell adhesion, heart tube formation and looping (103, 107). 
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As previously described cardiac looping is followed by the process of formation of the 4 
heart chambers, process that includes: ballooning of the atria and ventricles, trabeculation 
of the ventricles, septation and valve formation. Expression analysis in cardiac cushions 
have identified active canonical signalling gene expression (102). Loss of APC function in 
zebrafish leads not only to defects in heart looping but also to excessive endocardial 
cushions due to increased proliferation and endocardial-mesenchymal transition. In 
contrast, overexpression of APC or inhibition of Dkk, inhibits cardiac cushion formation 
(111). Also Wnt9a and the inhibitor Frzb1 are expressed in chick cardiac cushions. Wnt9a 
is found in endocardial cells while Frzb1 is in cells undergoing EMT, showing the 
proliferative effect of Wnt9a canonical signalling and the inhibitory, pro non canonical 
influence of Frzb1 (102).   
  
As described before, CNCs are implicated in OFT development. Wnt1 and Wnt3a are 
expressed in CNCs. The CNC cell type specific proliferation has been linked with β catenin 
dependent expression of regulators like Pitx2 (85).  Cell proliferation seems to be 
upregulated by this signal. Loss of Wnt1 in an experiment with Wnt1-Cre in mice showed 
reduced proliferation of CNCs (102). In 2001, the group of Brault demonstrated that mice 
lacking beta-catenin, even in the presence of activating signals, show defective NCC 
proliferation (112). Experiments by Kioussi et al. showed that inhibition of β-catenin 
produces OFT malformations due to reduced CNC proliferation.  Also, Dvl loss of function 
lead to OFT tract malformations related to NCC proliferation defects (113). 
 
In terms of the non canonical pathway Wbt5a and Wnt 11 are expressed in the OFT 
myocardium. Disruption of the non canonical wnt pathway in the Vangl2 -/- mice known as 
loop tail (Lp), produces profound OFT malformations (114). The Vangl2 protein is co-
expressed with Wnt-11 and Dvl2. Coexpression of ROCKs and Vangl2 and the 
polarization of migrating cardiomyocytes is  disrupted in the Lp mouse (114). In the same 
way, Wnt5a loss of function results in OFT septation defects. Schleiffarth et al. showed 
PTA associated to a mutation in Wnt5a in mice. Also this group described the expression 
of Wnt5a in the pharyngeal mesoderm adjacent to CNC cells and in the myocardial cell 
layer of the conotruncus at the time when CNC cells begin to form the aortopulmonary 
septum (115).  
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The relevance and functional implications of wnt pathways in human development is still 
under research. Part of the objective of this work is to link the available information to 
human cardiac phenotypes.  
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Table 5. Animal models of Wnt pathway disruption. (103, 111, 113, 114, 116-122). 
Gene Ortholog Organism Model Phenotype
Diversin ANKRD6 Zebrafish Dominant Negative Cardia Bifida
Apc APC Mice Knockdown GI tumors
Knockdown Homozygous Lethal
Zebrafish Knockdown Looping failure, valve abnormalities
Vangl2 VANGL2 Mice Knockdown Outflow tract
RhoA RHOA Chick RNAi Cardia Bifida
Mice RhoA Inhibition Defects in looping, septation and maturation
Fzd3 FZD3 Mice Knockout Neural defects, no mention to heart
Fzd4 FZD4 Mice Knockout Cerebelar and esophageal defects
Fzd5 FZD5 Mice Knockout Vasculogenesis defects
Rock2 ROCK2 Mice Knockout Placental malformations. Note: Cardiac expression
Rock1 ROCK1 Mice Inhibition Looping and chamber formation defects
Wnt11 WNT11 Xenopus RNAi Fusion, cardia bifida, duplication, thickening of Myocardium
Wnt1 WNT1 Mice RNAi Pericardial edema, ventricle enlargment, narrowing outflow tract
Wnt3 WNT3 Mice RNAi Pericardial edema, ventricle enlargment, narrowing outflow tract
Dvl2 DVL2 Mice Knockout Lethal:Double outlet, transposition, peristent truncus. Neural tube defects
Dvl1 DVL1 Mice Knockout Social disturbances. Cardiac phenotype when disrupted with Dvl2
64 
 
1.8. The genes 
 
The genes investigated in this thesis are Rock1, Rock2, Wnt5a, Wnt11, Dvl2, Dvl3, Dvl1l1 
and ANKRD6.  
 
1.8.1. ROCKs 
 
The proteins of the Rho family of small GTPases are key cell behaviour regulators and 
have been shown to be involved in several processes as smooth muscle contraction, cell 
migration and division, apoptosis, cytoskeleton organization, focal adhesions and myocyte 
hypertrophy (121, 123). Rocks, also known as Rho kinases, are the main and first 
described effectors of the small Rho GTPases (123). 
 
Two isoforms of Rocks have been characterised in the mammalian genome: Rock I also 
known as Rockβ, and Rock II  or Rockα (123).  Rock 1 is a gene located on chromosome 
18 of the human genome, comprising 32 exons and translating into a protein of 1354 
aminoacids. Rock2 is a gene located on chromosome 2 of the human genome, which has 
32 exons and translates into a 1388 aminoacid long protein (39, 124) . 
 
Rocks are a family of serine/threonine kinases of approximately 160 kDa similar to 
myotonic dystrophy kinase, Cdc42 binding kinases and citron kinases. Structurally, Rocks 
have an amino-terminal kinase domain, followed by a coiled-coiled region with a Rho 
binding motif and functional motif at C terminus. These motifs comprise a pleckstrin 
homology domain (PH) involved in subcellular location (123). See Figure 9. 
 
 
Figure 9. Scheme of Rock protein domains and regions. 
 
Kinase domain 
Coiled-coil 
Rho binding Pleckstrin Cysteine rich 
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The kinase activity of the proteins is triggered by the binding of Rho GTPases, and some 
lipids like arachidonic acid. When activated, the protein changes its configuration 
decreasing the autoinhibitory activity of the C-terminus leading to the phosphorylation of 
downstream proteins. Their physiological function is exerted via phosphorylation of 
proteins like myosin light chain kinase, myosin light chain phosphatase, LIM kinases and 
Adducin among others. The overall effect is an increase in contractility and organization of 
the cytoskeleton (123).  
 
The mRNA of Rock1 and Rock2 have been ubiquitously identified in rat and mouse tissues 
(125). However, Rock2 is most strongly expressed in brain and muscle tissues (123). In 
the same way, Rock1 and 2 expression has been detected in early  (121) and late 
cardiogenesis (126), in mice and chick embryos. 
 
These proteins which are the primary effectors of the non canonical Wnt pathway (127) 
have been linked in several ways to development and especially to cardiac 
morphogenesis. They have been identified as key factors to organogenesis in vertebrates 
like mouse and chick (126), and to regulate movements of convergent extension and 
gastrulation in Xenopus, Drosophila and C. Elegans (128, 129). Interestingly knockdown of 
Rock 2 in mice causes lethality due to vascular malformations mainly in the placenta (120). 
 
In early cardiogenesis, Zhao in 2003 showed that inhibition of Rocks in mouse embryos 
produces failure of heart looping and chamber formation, his group argued as the main 
explanation a decrease in cardiomyocyte proliferation (121). In the same year, the group of 
Kaarbo demonstrated that the inhibition with RNAi of RhoA in chick embryos causes 
cardia bifida (130).   
 
Zhao also showed that Rocks are expressed in mouse endocardial cushions and that the 
inhibition of Rho kinases causes developmental arrest of these structures (131). In the 
same experiment, in vitro inhibition of ROCKs produced decrease in endocardial cell 
migration (131), finding which is similar to the one of Sakabe’s group using chick embryos 
(132).  
 
It is interesting that disruption of Rho kinases (ROCKs) seems to not produce cardiac 
malformations in mice. The ROCK1 KO mouse phenotype is characterized by eyelid 
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defects with 50% showing fully open eyes and the rest varying degrees of eyelid fusion 
and omphalocele. No obvious heart defects have been described in the ROCK1 -/- mouse 
(133).  The ROCK2 KO mouse phenotype is characterized by intrauterine growth 
retardation and lethality associated with abnormalities and thrombus formation at the 
labyrinth layer of the placenta. As in the case of the ROCK1 -/- mouse, no heart 
abnormalities have been described (120) 
 
It is also relevant to mention the numerous works relating the expression and activities of 
Rho kinases in cancer cells and their relationship with metastasis generation. Despite not 
being directly related with the cardiogenesis subject, research into the cytoskeleton 
changes due to ROCK effects is relevant to the physiology of cell migration and adhesion 
giving insights into some functional aspects of these proteins (134).  ROCKs primary 
action due to the activation exerted by Rho GTPases is to induce specific types of 
cytoskeleton rearrangements in the cell and to modulate local dynamics of microtubules. 
The typical cytoskeleton rearrangement induced by these proteins are stress fibers and 
the contractile ring in the mitotic cell, both actomyosin bundles of anti-parallel actin fibers 
cross-linked by myosin fibers (134).  
 
To migrate, cells polarize protrusions towards the stimuli and make adhesions to the 
extracellular matrix pulling the cellular body forward. At the rear cell tail should be 
detached and recoiled. Cytoskeleton and particularly actin, myosin and micro-tubules are 
key to this process. Two Rho GTPases, Cdc42 and Rac, seem to control cell polarity and 
membrane protrusions respectively (134). The first experiments like the ones by 
Worthylake et al. or Yoshinaga showed in cell migration models that ROCK was necessary 
to the retraction of the rear tail but that its inhibition did not decrease cell polarity and 
protrusions (134). Further research into the mechanism of tail detachment showed that it 
was dependent on cell adhesion attenuation. Despite the vision of that ROCK is not 
indispensable for forward protrusion formation in cell migration, some experiments like the 
one by Grosse et al. have found that Rho colocalizes with mDia (a coeffector) at the front 
of the migrating cell and that siRNA mDia inhibition interferes with cell migration and 
microtubules stabilization (134).  
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The previous experimental data in addition to evidence of Rho proteins expression in 
migrating neural crest cells (135), make Rho kinases ideal aetiological candidate genes for 
CCM.  
 
1.8.2. ANKRD6 
 
Ankirin repeat domain containing protein 6 (ANKRD6) is a human ortholog for the protein 
Diversin in vertebrates (136).  Diversin is in turn a protein related to Diego in Drosophila, 
which has a recognized role in the non canonical Wnt signalling pathway (116, 137). 
Recent findings have also linked Diversin as a regulator of  the canonical wnt pathway in 
mouse (138).  
 
The ANKRD6 gene is located on chromosome 6, comprising 16 exons and coding for a 
protein of 727 amino acids (124).  ANKRD6, like Diversin, is a modular protein, mainly 
encountered in the cytoplasm, has an amino terminal Ankirin repeat domain, a central 
casein kinase binding domain and  a conductin binding domain at C terminus (116) . The 
casein kinase binding domain and the conductin binding domain seem to be involved in 
canonical Wnt signalling whereas the region involved in non canonical signalling has not 
yet been identified. 
 
In 2002 the group of Scharwz-Romond described the effect of Diversin in cell culture and 
Xenopus embryos, showing that the protein increases the degradation of B-catenin and 
blocks the formation of the secondary body axis (138) . The same group also found that 
the expression inhibition of this gene produces convergent extension defects in Zebrafish 
embryos. In summary, the data points to an inhibitory function in the canonical pathway 
and a regulatory function in the non-canonical one. In terms of interaction, Diversin and 
Diego seem to cooperate with proteins like Dishevelled, Strabismus or Van Gogh in the 
localization of the complex responsible for the action of the non canonical wnt signalling 
pathway (116, 137). 
 
Moeller in 2006 showed that the injection of Diversin mRNA lacking the ankirin repeat 
domain produces cardia bifida in a dominant negative fashion, demonstrating also that the 
protein directly interacts with Dishevelled in PCP movement control during development 
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(116). Due to its involvement in the non canonical wnt pathway, interaction with Dvl and 
phenotypes in animal models ANKRD6 is a strong aetiological candidate gene for CCM.  
 
1.8.3. Dvls 
 
Three Dvl genes have been described in mammals: Dvl1, Dvl2 and Dvl3 (139). 
Additionally, in 1996 the group of Pizzuti reported a homologue gene to Dvl, located within 
the DiGeorge syndrome region: DVL1L1(140). This is one of the candidate genes explored 
in this work. 
 
The genes, which code for 500-600 amino acid long proteins, show a high degree of 
structural and functional conservation among vertebrates and invertebrates. Structurally, 
the proteins are characterised by three domains: The DIX, functionally related to the 
canonical wnt pathway, the PDZ involved in both canonical and non-canonical pathways, 
and the DEP which is mainly non-canonical related (141).  See Figure 10. 
 
 
 
Figure 10. Dvl proteins structure scheme. Adapted from Wallingford et al. (141) 
 
The DVL genes chosen as candidate genes in this research are: DVL2, DVL3 and 
DVL1L1. DVL2 is a gene located on chromosome 17, containing 15 exons and coding for 
a 737 aa long protein. DVL3 is a 15 exon long gene located in chromosome 3, coding for a 
716 amino acid long protein. Finally, DVL1L1 is a single exon gene located on the short 
arm of chromosome 22, without characterised product in the proteome yet (39, 124). 
 
Initially, it was thought that Dvl was mainly involved in the canonical pathway signal 
transduction, but now its involvement in both canonical and non-canonical pathways has 
been recognized (141).  Despite that the nature of the changes leading to Dvl activation 
and the processes behind its selectivity for one of the pathways in a given context are 
under research, some of the molecular interactions have been described (141). 
N CDIX PDZ DEP
Ser/Thr rich Proline rich
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In terms of the canonical pathway, Dishevelled seem to bind and inhibit Axin in a Wnt 
dependent fashion blocking the phosphorylation of β catenin and thus activating the 
pathway (141). On the other hand, non canonical involvement seems to be related to two 
parallel pathways. As mentioned before, the signal in the PCP pathway is triggered by the 
accumulation of an incompletely understood group of proteins in an asymmetrical fashion 
within the cell(142). In this context Dvl activates DAAM1 (Dishevelled associated activator 
of the morphogenesis 1 and  Rhac leading to ROCKs and JNK signalling respectively 
(143). 
 
Experiments in animal models have shown that in Drosophila Dsh (Dvl) is involved in the 
PCP pathway controlling hair and bristle polarity (141). Park in 1996 showed that the gene 
is able to rescue cardiac development in Drosophila wingless mutants demonstrating that 
the protein is downstream in the pathway (144). 
 
In terms of vertebrate development, Dvl involvement in convergent extension and the 
canonical wnt pathways has been largely recognized (141). The gene has been proven  
asymmetrically expressed in xenopus gastrulation, controlling anterior-posterior body axis 
patterning (145). In 2004, Ewald and coworkers demonstrated that Dvl inhibition in 
Xenopus embryos cause gastrulation defects like blastospore closure failure(146). 
Furthermore, cell studies trying to elucidate this fact have shown that disruption of 
dishevelled genes block the formation of lamellipodia in migrating cells  (147). 
 
In 2002, Hamblet and coworkers showed that knockout mice lacking Dvl2 had 50% 
perinatal lethality, Dvl2 -/- often failed to thrive and were cyanotic, showed reduced 
mobility and did not feed. Pups that survived beyond 24h developed into adulthood but 
25% of them showed kinked tails and also exhibited scoliosis and rarely vestigial tail. 
Strikingly, most of the Dvl -/- pups that survived were females. Embryo analysis showed 
that also a minority of Dvl2 -/- embryos showed incomplete thoracic neural tube defects 
and exencephaly (113).  
 
Lethality was due to cardiac defects, especially double outlet right ventricle and persistent 
truncus arteriosus. The same group also demonstrated that the cardiac defects were due 
to failures in migrating NCC. Dvl2 KO mice developed neural tube closure defects and 
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somite segmentation defects, reinforcing the theory of Dvl involvement in vertebrate 
convergent extension movements (113). Interestingly mice lacking only Dvl1 do not show 
cardiac abnormalities. The phenotype is characterised rather by poor social interaction and 
gating defects (148). 
 
Due to the animal model findings, biology and relevance as a central branch point of wnt 
pathways, I believe that dishevelled genes are strong candidates as causal factors for 
CCM.  
 
1.8.4. Wnts 
 
The Wnts are a family of cysteine rich glycoproteins comprising 19 genes in the 
mammalian genome (71). Two of the non canonical pathway wnt activator proteins are 
part of this research: wnt5a and wnt11. Wnt 5a is a gene located on chromosome 3 of the 
human genome, comprising 4 exons and coding for a 380 aminoacids long protein (124). 
Wnt 11 is a gene located on chromosome 11 of the human genome, comprising 4 exons 
and translating into a 253 aminoacids long protein (124). 
 
Expression of these two genes throughout cardiac development has been reported in the 
literature: Wnt 5a has been detected in the primitive streak, precardiac mesoderm, outflow 
tract and primitive ventricle of chick and mouse embryos (71).  Expression of wnt11 has 
been shown in the primitive streak, precardiac mesoderm, primitive heart tube, outflow 
tract myocardium and conduction system of mice, chick and frog embryos (71).  
 
In 2007 Schleiffarth et al (115) analysed the cardiac phenotype Wnt5a -/- mouse. Wnt5a -/- 
mice were grossly abnormal and died shortly after birth. OFT defects were present in all 
Wnt5a mice, including PTA (Majority of cases), TGA and double outlet right ventricle. 
Large ventricular septal defects were present in all specimens. These findings are similar 
to the previous results from the Oishi group who encountered VSDs at Wnt5a -/- mice 
(149). Angiographic analysis of Wnt5a embryos showed other aortic arch associated 
abnormalities like interrupted aortic arch, right sided aortic arch and coarctation of the 
aorta. The observed phenotype combining persistent truncus arteriosus and ventricular 
septal defects not only constitutes an OFT malformation but grossly resembles TOF. 
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Schleiffarth et al also showed that Wnt5a is expressed in the mouse secondary heart field 
mesoderm. Wnt5a was not found to be expressed at migrating neural crest cells. Wnt5a 
knockout mice did normally express primary and secondary heart field markers. In 
contrast, neural crest cell markers as Sox10 and Crabp1 expression were decreased in 
Wnt5a -/- mice. The hypothesis the authors advanced to explain the phenotype was that 
Wnt5a plays a regulatory role in neural crest cell migration and is expressed primarily in 
the secondary heart field. 
 
In 2007 Zhou et al. published a work describing several experiments related to the 
regulation of morphogenesis exerted by the PCP pathway, including the description of the 
cardiac phenotype of WNT11 -/- mice (150). They found that Wnt11 KO mice, similar to 
Pitx -/- mice, present cardiac conotruncal defects. Pitx is a downstream effector of the 
canonical Wnt signaling pathway, and Wnt11 expression seems to be also regulated by 
Pitx.  At 9.5 Wnt11 -/- mice OFT were shorter than in wild type controls and at 11.5 Wnt11 
-/- OFT were still shorter and lacked the rightward curve present in wild type controls. 
Wnt11 -/- mice exhibited OFT defects with a penetrance of 100%. OFT defects were 
accompanied by VSDs.  
 
 
 
  
72 
 
1.9. Hypothesis and Aims  
 
The hypothesis of this project is: 
 Common and/or uncommon variants within the Wnt non-canonical pathway genes 
ROCK1, ROCK2, DVL2, DVL3, DVL1L1, WNT5a, WNT11 and ANKRD6 are 
aetiologically responsible for a fraction of non-syndromic TOF heritability in a 
human population of British origin. 
 
With the hypothesis in mind, the aims of this project are: 
 
 To identify and quantify the contribution of rare genetic variants within the Wnt non-
canonical pathway genes ROCK1, ROCK2, DVL2, DVL3, DVL1L1, WNT5a, 
WNT11 and ANKRD6, to the risk of suffering TOF. 
 To identify and quantify the contribution of common genetic variants within the Wnt 
non-canonical pathway genes ROCK1, ROCK2, DVL2, DVL3, DVL1L1, WNT5a, 
WNT11 and ANKRD6, to the risk of suffering TOF. 
 To explore the contribution of gene-gene interaction within the Wnt signalling 
pathway to the risk of developing TOF. 
 To perform functional studies based on the genetic findings in order to explain the 
mechanisms of associated candidate gene variants.  
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2. MATERIALS AND METHODS 
2.1. POPULATIONS 
2.1.1. CHANGE 
 
The majority of the TOF probands included in this study were ascertained within the frame 
of the CHANGE study (Congenital Hearts: A National Gene/Environment study), a 
research effort led by my host laboratory with the aim of collecting a substantial number of 
trio families composed by a Tetralogy of Fallot proband and his/her parents (151). The 
sample was recruited during the experimental stage of this thesis and as a consequence 
the number of samples available was not completely uniform depending on the availability 
of samples. 
 
The ascertainment strategy was as follows: Caucasian patients with Tetralogy of Fallot or 
pulmonary atresia with ventricular septal defect were recruited through the practice of 
Cardiology Consultants in 5 centres: Bristol Royal Hospital for Children, Royal Liverpool 
Children’s Hospital NHS Trust, Alder Hey Hospital in Liverpool, Leeds General Infirmary 
and Newcastle Freeman Hospital.  
 
The cardiologists identified the patients and informed them about the study. If the patients 
and the family were interested, a nurse met them to explain in detail the research protocol. 
Informed consent was obtained, a blood or saliva sample or mouth swab was taken from 
the proband and the parents when available. Finally, a form including key questions (See 
Appendix A) and a pedigree was filled for each family (151). Patients classified as TOF 
associated with known syndromes, 22q11 microdeletion, known maternal teratogen 
exposure, learning difficulties or with a high probability of being associated with a 
mendelian transmitted condition were excluded. Ethical approval was granted by the 
Northern and Yorkshire MREC. 
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2.1.2. CONCOR  
 
The CONCOR project is a initiative in the Netherlands for the development of a National 
registry and a DNA bank of patients with congenital heart disease(152). 
 
The Netherlands Heart foundation and the Interuniversity Cardiology Institute of the 
Netherlands (ICIN) with the collaboration of all 8 University Medical Centers in the 
Netherlands initiated the CONCOR project and now more than 20 non-university hospitals 
have also joined(152). Ethical approval was granted.  
 
Patients with congenital structural heart defects or Marfan syndrome are eligible for the 
CONCOR cohort. Patients are asked to enter the study by their cardiologist or nurse 
during their outpatient visit. Probands are informed about the aims and characteristics of 
the study and informed consent is signed. Twenty cm3 of peripheral blood is taken and 
DNA extracted and stored. Clinical data is entered by trained research nurses in a 
centralized database(152). 
 
The DNA of 468 Tetralogy of Fallot patients were kindly facilitated by the CONCOR 
Steering committee to our laboratory. Tests in our laboratory identified probands carrying 
22q11 deletion who were excluded from the analysis. 
 
2.1.3. Oxford TOF Cohort 
 
Samples from Caucasian patients with Tetralogy of Fallot ascertained as part of the GO-
CHD (Genetic Origins of Congenital Heart Disease) study were used during this research, 
through collaboration with Professor Shoumo Bhattacharya, Oxford University. 
Ascertainment strategy consisted of recruitment of European Caucasian cases with non-
Mendelian, non-chromosomal congenital heart disease sufficiently serious to require 
cardiac catheterisation and/or surgical correction.  Probands were collected from five 
paediatric cardiology units when attending outpatient clinics, catheterisation or surgery. 
Informed consent was obtained and a blood sample taken. Family history of congenital 
75 
 
heart disease and consanguinity was obtained.  Diagnostic data were mapped to 
European Paediatric Cardiac Codes (EPCC).  Permission to collect parental blood 
samples and parental attendance for transthoracic echocardiography was sought where 
possible. Ethical approval was granted. 
 
2.1.4. Nottingham TOF Cohort 
 
Samples from Caucasian patients with Tetralogy of Fallot, for the Nottingham Family Study 
of Congenital Heart Disease were made available for this research through collaboration 
with Dr. Frances Bu’Lock (Leicester University) and Professor David Brook (Nottingham 
University). The ascertainment strategy consisted of recruitment of European Caucasian 
cases with non-mendelian, non-chromosomal congenital heart disease sufficiently serious 
to require cardiac catheterisation and/or surgical correction. Trio families consisting of TOF 
patients and their parents when available were recruited at Glenfield Hospital, Leicester. 
Informed consent was taken and a blood sample was obtained. Ethical approval was 
granted. 
 
2.1.5. HTO 
 
One of the control populations used in this research was a large cohort comprising 1428 
patients from 248 nuclear families (that is, over 1000 control chromosomes). The 
recruitment process of the HTO population has been described in the literature(153). 
Briefly, families were recruited through a proband diagnosed with essential hypertension. 
Families were required to consist of at least three siblings clinically assessable for blood 
pressure if at least one parent of the sibship was available to give blood for DNA analysis, 
and to consist of at least four assessable siblings if no parent was available for DNA 
analysis. The majority of the individuals in the family collection therefore have blood 
pressures within the conventionally accepted “normal range”. The families were subjected 
to a cardiological evaluation and echocardiography, and Congenital Cardiovascular 
Malformation was excluded. Ethical approval was granted. 
 
76 
 
 
2.1.6. ECACC 
 
The commercially available Human Random controls population (HRC) from ECACC was 
kindly facilitated by Dr Tim Goodship. The HRC is a DNA collection from a control 
population of 480 randomly selected, non-related UK Caucasian blood donors (154). 
 
DNA is obtained from lymphoblastoid cell lines derived by EBV transformation of 
peripheral blood lymphocytes from the blood samples and is organized in five panels. 
Each panel contains samples from 96 separate individuals (154). 
 
 
Table 6. Number of total subjects in each one of the populations used. Cases and controls 
were genotyped as specified in each one of the chapters.  
 
2.2. MUTATIONAL SCREENING 
 
2.2.1. Sequencing 
 
2.2.1.1. PCR 
The published reference genomic sequence of  ROCK1, ROCK2, DVL3, DVL1L1, WNT5A 
and WNT11 was downloaded from the Ensembl webpage release number 38 (39). 
Primers aimed to amplify exonic sequences and 100 bp at each side were designed using 
the web based resource Primer 3 (155). The configuration was set up to obtain primers 
with an optimum Tm of 60, minimum length of 18bp and minimum complementarity. Each 
primer was reviewed manually and blasted to rule out unspecific annealing. Redesigning 
Population Subjects
HTO 1428
ECACC 480
CHANGE 465
CONCOR 468
Oxford+Nottingham 140
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of primers with poor PCR performance was done using the Primer Blast tool on the NCBI 
web page (155). PCR amplification of 2 Dvl2 exonic regions, completing a previous 
screening performed in our laboratory, in 93 TOF patients was performed during this 
research work. The method used was the same as for the other PCR reactions. See 
primers in Table 12. 
 
Primers were purchased from Metabion TM; the dNTPs were ordered from Metabion TM, 
the Taq polymerase, the Buffer, Magnesium Chloride and Q solution were purchased with 
the Hotstar Taq polymerase kit from Qiagen TM. The machines used during the PCR 
protocols were DNA engine TETRAD TM. 
 
Standardized PCR reactions were performed using the following concentrations: 1mM of 
buffer, 2.5 mM Magnesium chloride, 0.2 µm dNTPs, 0.2 µm of each primer and 0.2 units of 
Taq polymerase per well. Optimization was achieved performing a PCR reaction with a 
gradient of annealing temperatures for each exon and checking it in agarose gel 
electrophoresis.  
Table 7 shows the generic temperature program used. 
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Table 7. Generic PCR program used 
 
 
 
Figure 11. Agarose gel to check PCR reactions. 
No of cycles Temperature and time
1 95C for 15 min
95C for 20 sec
40 T depending on exon  for 30 s
72C for 1 min
1 72C for 3 min
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Table 8. Rock1 primers, optimal annealing temperature and PCR product length. 
Region Forward Primer Reverse Primer Opt annealing T Product lenght
1 CGGAGGAAGTTGGTTGAAAT TGCAGCGAACCAGACTAATG 64.5 243
2 CACAAGATGTGTTAGGGGAAA AAAAATAAGGGCTTGAATGACA 61.5 275
3 CATGAAGTTTGTTGTTTTTCATTG AAATAATATGTTAAACACACAAGTGGA 61.5 288
4 TGGAATAATTTGGCAGAAGAGAA AAACACAAACTAAGCTTCTCAGACA 61.5 370
5 TTGCAACTTCTGTAATTTGATTATTT ACGGAAGAAGAATGGGTGAA 61.5 399
6 CCTAGATTGAGGATGCTTGACC TCCAGCTATGGTTAGTAAATTCTTACA 61.5 299
7 CAAAGATTTGGAGTCCCATAGGT ACGAAGCAGGTTTGGATCAT 62.5 385
8 CGGGTAACTTTGACTCTTCCTT TTACATCAGGTTTCACTGTCATTT 64.5 352
9 TGGGCTGATACTATGCTGACA CCCATATAGTATTTGTGGCTTCTG 64.5 369
10 ACCATCAGTAGTTGGTATGGAA ATGAAATACTGGAAATATCATGC 55.5 394
11 AGGCGTGTAGTATTTATTATTGGTT CAGCTAACCACAGCTTCACA 61.5 257
12 TTGTATTTCTAATGGCCTAACG TCAATTCTAGCCGAGACACA 58.5 445
13 GGCCATAGGCTTCACTTGAC TCAGGAAACGAAACAATTTGAA 58.5 272
14 GCGTTTGAAACAGAACATTCA CCTGAGACCTGGGTTATTTAGC 61.5 409
15 GGCTTTGGGAGTGGACCTA GCTGTGTCCGATTCTGTCCT 64.5 367
16 AGTGTTTCAAATGAGGTTCCTT TGATGATGGTTGCATACATTG 58.5 469
17 TCGGATCAGGAAACTTAATACA CCACATACAACCAATCAAACA 54.5 370
18 AAGGCATCATATCTCTTCCAGA GATGGGATTACAGGCATGAG 54.5 399
19 GAAACCAGTTTACAGCCCATA GTGAACACAGACCCATGTCA 54.5 379
20 AAACACGTGGAACAATGAAGA CCTGAAAACCTTTGCAAGTAA 58.5 499
21 TGTGGCCTGACCAAGTTAAT ATGCCAAGAAACAAATGGAC 54.5 405
22 TTTGCATTTGTCATGGGTAA CCATAAAGGCAAATTTCAGC 58.5 393
23 TTTTATAGAAAGTTTGCAATGGA ACTTGCACACACACTTACCC 61.5 410
24 CTGGAAACCAGACATTTGCT TCTTAGAAACCTAACACAACATAGG 61.5 309
25 TCATCATGTTAAATCAAATTCAGTG GCCTGGCCTTGAAATTCTAT 58.5 496
26 GTCCTGCTTCCTGATTTTGA ACAGCCATATCCCAATTTCA 58.5 431
27 AATCTGTGGTAGCAAACATTCA GGAATCCATGGACAAAATGA 58.5 400
28 TTTGTGTGATTGAAGCATGG CAAGAGCAACATTAACTTGGTT 58.5 402
29 AGTGGCAAATATTATGCTTATCA GGTAACAGTGCTGAAGTAACACA 60.5 275
30 TCACCCATATGTCCTCTTTAGTG CATTCAGGAATGGTGAAAGG 58.5 279
31 AGAATCTAAGTCCTAAGCGTTTT CCCCACCAGTGTCAAAATA 61.5 491
32 TGCATTTGATAGGTTGGATTT AAATGATGCCCTCTGTGGT 61.5 384
ion Forward Pri r Reverse Primer Opt annealing T Product l th
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Table 9. Dvl3 primers, optimal annealing temperature and PCR product length. 
Region Forward Primer Reverse Primer Opt annealing T Product length
Exon 1 CCAGTCCAGTCGGGAGAGT GTAGCGAGGCAAGTCGAAAC 62 469
Exon 2 tcccagtttaggatggagga ccagctacaatctcagtgatgc 62 249
Exon 3, 4 atgccttgctggaagtgaac ggtagctgggtggaaagtga 67 480
Exon 5 acccaccttcttgccctact cccaacacaaagcccataag 62 369
Exon 6,7 gcttatgggctttgtgttgg gggcagggaacatattctacg 61.5 571
Exon 8 tcagttcctgtccctttcca gcctctgaaggagcagggta 62 310
Exon 9,10 ggaagactccctgacctacca gggttctgggtgagagaaga 66.5 395
Exon 11 tggatgggagactcagtccta gtctccacatggaccctcat 65 373
Exon 12 cccagcattgatcccataat cagatcaaaggaagggtcca 61.5 338
Exon 13 tggacccttcctttgatctg cagagtctgctgccacttcc 61.5 354
Exon 14 ctctcatccagagcccacct gactgcctgtaggaggcaaa 64.5 400
Exon 15A GAGGAAGGCTATAGGTGGGC CCTGCTCACATCACATCCAC 62.5 520
Exon 15B ATCGGAGGAAGGAGAAGGAC CTGGTCCCAGAGACAAAAGG 61.5 675
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Table 10. Rock2 primers, optimal annealing temperature and PCR product length. 
Region Forward Primer Reverse Primer Opt annealing T Product length
1A GAAGGGAAAGAAAGGGAGGA CCTCCAGCTTCCTCTGGC 53 736
1B CGCGAATCTGACTGAGGG ACAGAATCGTTTGGTCTCCG 53 565
2 ggaaaccagttaaagctgttgg ttgaataaatcaaatggtaagcaaa 61.5 393
3 aaaccatagagagttttggttctt catgggtgggcatagaaatta 61.5 388
4 aaatgttctcctttgtttctttca tgaagcataagacttggcaca 61.5 400
5 tccattacatacgcctgagtct tggttatatcttgtttgggtgct 62.5 567
6 tcagcagtgaagttctgttgg ttccctacgacaaaggcaat 65 379
7 tttgttcttccctgcatgtg gggtaatgagaggcagactga 58.5 355
8 tcacatactgtaacttgggattgc ccacagaacaaatttgaaatgaa 58.5 411
9 gtgaatcgataaaatggcaaa tgagtctcaaaataacacatcatct 61.5 374
11 tgcaaagctaaatcatacatgg ttgggaacttctctcttggg 53 324
12 cattgttttctttaagcctctca attacaggtgtgagccacca 61.5 249
13 ggcaacagagcaagacttcg aaggtaggtttcaaggcacg 64 296
14_15 tttttatctgtttggaatagcaagt gccttttgcaacactgtca 62 495
16 aattgacagtgttgcaaaagg tccagcacactatccatcatct 66 500
17 gctcacaaacaacagctcca gaatccatgagcatgtggaa 64.5 334
18 ggctgcaatgagccataatc ttttccctccaattcccaat 61.5 433
19 acaaagagctgagattgcgt agttaaaccaacaggttgcaga 53 518
20 catcaccatattttataccaacttca tgctcaaaagaaaatccacaga 53 356
21 cccagaccatactttgagagc tttgcccagctgctcttt 62 246
22 tcatttgctcggggacttag tcattttaatggttcagttttcac 58.5 384
23 gctcctagaacaatgcctggta caacattgagaaggtggcagt 68 461
24_25 aagactcacctgggtgacaga cattcgatgactactgctaccaa 64 548
26 gccctgtatgtagggaagga ttggatgcaacataactcaaca 58.5 452
27 tttcatgtctgtgttttactggtt tccttcagagcagtcagtcg 62 376
28 tgatgtatagtgataaattctaaagga tcctacaactacaaaagccaaa 58.5 282
29 aatttattgttattttaaggaagactg tgaagcaaatcacaggaaaa 62 386
30 tctgagttcctaacatgggtca cctgaagagggtcaaagaatg 58.5 315
31 gattaagtttgcgtaatcaagagc CAGATTCTTTGCCGTTGAAA 64 545
32 GCACCTTGCAAAGgtaaatga catgcacattaagacagttccaa 58.5 471
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Table 11. Ankrd6 primers, optimal annealing temperature and PCR product length 
Region Forward Primer Reverse Primer Opt anealling Temp Product length
Exon 1 gcggtgccacctctctctc cgtcctccccgacctgag Pending 415
Exon 2A caacatgcaagcagcagaat GAGAAGGCGCTCTGAAAGTG 62 290
Exon 2B CTTGTCTACCGCTTCCCTGA gctgtgaaccaaacacagca 61,5 251
Exon 3 gagggagtgatcatccgaaa cctcagagcaggtcttccag 66,5 386
Exon 4 gggtccttgtgtccaagtgt tcgaggactcaaaagtttcca 62 285
Exon 5 caattgagaaaggccgtctg ccactctgggctctcactct 65 320
Exon 6 agaatgtgagcgttgccttt ctcacatgcctgaatgatcc 62 389
Exon 7 ttggggtggagcatctatgt cccgtttgcactaacagacc 62 330
Exon 8 cacacctaggccaggtaatga gctgtggttccagcagagat 62 313
Exon 9 tgtgactgggtgtggaactg ccccatgcatgcctatacct 58,5 331
Exon 11 ctcgtgggtcccttaccata cagccaagtgagtggctttt 55,5 348
Exon 12 tggtgtcagtcttgcagagg ccaggaatgccgttaaacaa 55,5 318
Exon 13 ccatcatctctatcccctggt ggaagggtgtgctaaagtcg 62 348
Exon 14 caggggctcctacttggttc gggagtctcagcctctgagtt 62 318
Exon 15 tgaaaagtccatccttgatgc ttcccacagccctagcatac 62 327
Exon 16A aaatactgacccgcagccata GGCACGATGCCTTGTTGG 62 360
Exon 16B GCCCTCAACTCCACTGCTAC GGCTTCGTGCTTCTTCAATC 62 385
Exon 16C GGAAGAGTGGGCCAACAAG GTTGACTCCTTGGGCATAGC 62 396
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Table 12. Dvl2 primers, optimal annealing temperature and PCR product length 
 
 
 
Table 13. Wnt5A primers, optimal annealing temperature and PCR product length 
 
 
Table 14. Wnt 11 primers, optimal annealing temperature and PCR product length 
 
 
Table 15. DVL1L1 primers, optimal annealing temperature and PCR product length. 
 
After the optimization process, each exon was amplified in 93 TOF patients. The reaction 
was checked in 3% Agarose Gel Electrophoresis. See Figure 11. PCR products were 
cleaned using ExoSap ® purchased from USB Corporation.  5 ul of each PCR products 
were mixed with ExoSap ® and incubated at 37°C for 45 minutes. 
 
2.2.1.2. Sequencing reaction 
Sequencing was performed using MegaBACE DNA Analysis. The DYEnamic ET Dye 
Terminator Cycle Sequencing Kit for MegaBACE DNA Analysis Systems ® was purchased 
from Amersham Biosciences TM. The DYEnamic ET terminator reagent premix containing 
the Thermo Sequenase II DNA polymerase, dNTPs and labeled ddNTPs was used for the 
Region Forward Primer Reverse Primer Opt anealling Temp Product lenght
Exon 11 gctgagtcagggagggac ggtaaccagagtcagggatcg 61,5 303
Exon 15A ggatctgagggtggatgaga ccaccatcatggggttgta 61,5 362
Exon 15B agcaagtgggactagcga gagcccaggcactgtaagag 61,5 394
Region Forward Primer Reverse Primer Opt anealling Temp Product length
Exon 1 AAGGTCTTTTGCACAATCACG GGGAAATGGAGGGATAGGAA 58.5 523
Exon 2 ttaagagaccccggatgctt attgccgcatcatacaaaca 61,5 300
Exon 3 tgaggacaagcaggagagaaa aaggcatcctccttcatgc 61,5 480
Exon 4 GCCAGTGATCCCTTGTCCT TAGCAAAGGAGTGGCAGAGG 58.5 432
Exon 5A catggagaaggtcgaggaga GTCTGCACGGTCTTGAACTG 59 461
Exon 5B GTGATGCCCTGAAGGAGAAG gttgcaattcttggggaaaa 62 471
Region Forward Primer Reverse Primer Opt anealling Temp Product lenght
Exon 1 cgacccctcctttgtaatttg gaaacagaggctgagggatg 58,5 410
Exon 2 gcaaagtccattgagggaaa cctgtatccacccgtcattc 61,5 486
Exon 3 cgtcaccttggttacagcag gaagggctgaggatgaggat 67 540
Exon 4 ACTCCAGCAGGCAGTGACTC CTCAACTGAGCAGGGTCTCC 61.5 538
Exon 5 TCCCCAAAGATCAAGACAGC GCTTCCAAGTGAAGGCAAAG 61.5 471
Region Forward Primer Reverse Primer Opt anealling Temp Product length
Exon 1A ccttcaggttactgatgttcattg AAGCAGCATTTACACAGAAGCA 61,5 419
Exon 1B CTAGACATCCTGCCCACTGC tccagcttgggtgacagagt 61.5 473
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amplification PCR reaction. A mixture containing, 2.56 ul of premix, 2ul of PCR product, 
0,25pM of primer and water up to a volume of 10ul, was loaded for each sample and run 
on the thermocycler at the following conditions: 35 cycles of 95ºC for 20 seconds, 50ºC for 
15 seconds and 60ºC for 1 minute. The products were precipitated using isopropanol. 
 
The ABD files produced by the MegaBACE machine were analyzed using Staden Package 
v1.0 TM software(156). Databases were constructed with groups of 12 sequences. These 
files were assembled in the minimum number of contigs possible for analysis. Sequences 
not aligned were reviewed manually to verify the quality of trace and basecall. When the 
quality of the sequence was poor, defined as background or low confidence values, the 
files were discarded and the process repeated.  
 
Contigs assembled with GAP4 software were edited manually. The files for the forward 
and reverse strand were compared with the consensus sequence from the Human 
Genome Project. Differences were reviewed, and deleted or confirmed when necessary. 
 
2.2.1.3. Statistical analysis of variation found on Sequencing 
Allele and genotype frequencies of the previously known SNPs and the newly discovered 
ones were manually calculated using Microsoft Office Excel 2003. The degree of Fitness 
with Hardy-Weinberg equilibrium was measured for each SNP using Chi Square tests 
performed in Minitab 14 ™ software. 
 
The allele and genotype frequencies for the previously described genetic variants were 
downloaded from the NCBI SNP database builds 125-128 and Hapmap database phase 3 
(39, 124, 157). Frequencies obtained from the sample were compared to the published 
ones using Chi square tests performed in Minitab 14 ™ software. 
 
 
2.2.1.4. In silico analysis of impact of variants 
Location of the variants within the protein was performed by manual analysis of the 
Ensembl database (124). Sequence of uncommon variants and previously undescribed 
common variants was analyzed using three web based resources:  Polyphen (158) which 
evaluates the probability of structural damage based on known structural data about the 
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protein; ESEfinder (159) which determine the presence of known motifs for Intronic and 
Exonic splicing enhancers; and finally Spliceview (160) which checks the relative strength 
of splicing donor and acceptor sites within a given sequence. 
 
 
2.2.2. MALDI TOF mutational screening 
 
In an attempt to speed up the analysis and amplification steps of the mutational screening, 
Rock2 exons 10,11,13 and 28 were screened using a combination of Meta-PCR and 
MALDI TOF strategy. 48 TOF samples were screened using this method. 
 
Meta PCR is a technique of constructing a DNA artificial molecule with a combination of 
PCR fragments in any order. There are two main steps to this: the first one is a multiplex 
PCR using primers with 5’ complementary linkers at limited concentrations. At the 
beginning of the reaction the linkers are incorporated to the fragments, and at the end 
primers exhaustion produces overlapping amplification and full length product. The second 
step is a round of PCR using internally nested primers to amplify the full region (161). The 
nested primers were designed to contain 5’-3’ oriented T7 RNA polymerase promoters for 
the forward and reverse strand, splitting the second step into two reactions: one for the 
forward and one for the reverse strand. 
 
The products were amplified using T7 RNA polymerase and a mixture of nucleotides 
containing either CTP or TTP. Subsequently the products were digested with RNAase A 
producing a group of distinctive fragments with different masses (162). The reactions were 
fixed in a special resin, transferred to a SpectroChip™, and run in a Bruker Autoflex 
MALDI TOF spectrometer. The mass spectra patterns were analysed with the 
Sequenom™ SNP detection software. Manual review of the spectra was performed. See 
Figure 12 for spectra examples. 
 
The sequences were downloaded from the Ensembl web page (124).Primers aimed to 
amplify coding sequences and 100 bp at each side were designed using the web based 
resource Primer 3 (155).  The configuration was set up to obtain primers with an optimum 
Tm of 57, minimum length of 18bp and minimum complementarity. Linkers previously 
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tested by the National Genetics Reference Laboratory in Manchester were added to the 
designed primers (161). 
 
 
Table 16. Primers for Meta PCRs and Nested PCRs. Linkers in blue, spacers in red and T7 
promoter in green. 
 
Primers were purchased from Metabion®. Taq polymerase, PCR buffer and magnesium 
were obtained with the Hotstar Taq kit purchased from Qiagen. 
 
PCR reactions were performed using the following concentrations: 1mM of buffer, 2.5 mM 
Magnesium chloride, 0.2 µm dNTPs, 0.4 µm of each primer (2mM) and 0.2 units of Taq 
polymerase per well. Optimization was achieved performing a PCR reaction with a 
gradient of annealing temperatures for each exon and checking it in agarose gel 
electrophoresis. Optimal temperature for multiplexing was 54 C°. The PCR program used 
in both PCR rounds was as follows: 95 C° for 10 min.; 40 cycles of 95 C° for 20 sec., 54 C° 
for 30 sec and 72 C° for 1 min; finally 72 C° for 3 min.  
 
RNA amplification and MALDI TOF reactions were performed by specialized technicians. 
  
Type Exon Primer1 Primer2
Meta-PCR 1 10 cagcacatagattaaaatgaaatg gacgcggcggcaattaaaaacatggggattactaaaa
Meta-PCR 2 11 tgccgccgcgtcaaagtcacattaaggaggtacaaat cgggcgcgcagaatgagaggcttaaagaaaacaatg
Meta-PCR 3 13 tctgcgcgcccgaaaggagagctaccaagtaattatg ggccgggcgcttatccttaggtaagtcagacatcaaa
Meta-PCR 4 28 aagcgcccggccaagcctcacatgttgtgctta tcctacaactacaaaagccaaa
Nested 1 ALL cagtaatacgactcactatagggagaaggctcagcacatagattaaaatgaaatg aggaagagagtcctacaactacaaaagccaaa
Nested 2 ALL aggaagagagcagcacatagattaaaatgaaatg cagtaatacgactcactatagggagaaggcttcctacaactacaaaagccaaa
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Figure 12.Example of Mass spectra differences between samples. White arrows denote the 
key difference.  
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2.3. CONTROL GENOTYPING 
 
All previously undescribed variants and the previously described SNPs that showed 
significant allele frequency differences when compared to previously published data were 
genotyped in at least 1 control population.  
 
2.3.1. Sample calculation 
 
The number of controls needed to be genotyped for any variant to find a significant 
difference if the variant is common, or to probe that is absent in controls if it is uncommon, 
was calculated a priori. Traditional probability algorithms were used as an initial approach, 
see Equation 1. Power calculation was also performed using Shaun Purcell’s online 
Genetic Power Calculator and the software Quanto (163) 
 
)1log(
)log(
mAF
n



 
Equation 1. N is the number of samples needed to obtain a β error to detect a variant with a 
given minor Allele frequency mAF for any variant. 
 
The number of controls was calculated using the variant’s minor alleles frequencies, an 
hypothetical OR of 2 and the published incidence in Caucasian British population of TOF 
(0.31/1000 newborns)(56) . Power calculated for each of the variants is specified in the 
results section 
 
2.3.2 Sequenom 
A total of 16 variants consisting of: 10 non previously described uncommon variants, 3 
previously described SNPs and 2 non previously described common variants were 
genotyped using the iPlex™ method on the HTO cohort which comprises 1428 subjects 
distributed in 248 families and the complete set of CHA probands. 13 variants (W1 
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experiment) were also genotyped on 279 CHA parents, the ECACC cohort (n=465), the 
Oxford and Nottingham Fallot subjects (n= 209) and the CONCOR Fallot subjects (n=465). 
 
The iPlex™ is a MassExtend based genotyping method which uses the Sequenom® 
platform. Summarizing, it consists of three steps: a multiplex PCR amplification of 
fragments containing the variant; an extension reaction which specifically extends a 
predesigned extension primer for each variant; and a mass spectrometry to analyse the 
mass spectra of the assay to determine the basecall for each one of the variants 
depending on their mass (164). 
 
The sequence for each one of the variants and 200bp upstream and downstream was 
obtained from either the Ensembl web page (124) or our previous sequencing work. The 
sequences were uploaded to the Real SNP web based resource in order to design the 
assays (165). This software groups the variants depending on how suitable are they to be 
amplified as a multiplex and how their masses relate to each other for the mass 
spectrometry. The result was an assay with 13 variants (13 plex) and other one containing 
3 variants (3 plex), the assays were called W1 and W2 respectively. PCR primer 
sequence, extension primer sequence and mass for each variant are listed on Table 17 
and 18.   
 
Multiplex PCRs were performed following the standardized process for iPLEX® 
experiments. The taq polymerase, buffer, and magnesium chloride were purchased as the 
Hotstar Taq polymerase kit from Qiagen. Desalted primers were purchased from 
Metabion. A total volume of 10ul was mixed for each reaction containing 1ul of 10X buffer, 
1.63mM of Magnesium chloride, 0.5mM of dNTPs, 0.1uM of each primer and 1 unit of Taq 
polymerase. Cycling conditions are specified in Table 19. 
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Table 17. PCR primers, extension primers, masses and base call for the W1 sequenom experiment.  
Assay Gene SNP_ID Forward Primer Reverse Primer UEP_MASS Extension Primer Call 1 EXT1_MASS Call 2 EXT2_MASS
W1 ANKRD6 Pro636Leu ACGTTGGATGCTCAAACTAAGAAGTCTGGG ACGTTGGATGTGCCCACAGGTGCTGCTG 5140.4 GCATCGTGCCCAGCAAC C 5387.5 T 5467.4
W1 ANKRD6 rs2273238 ACGTTGGATGAGGTGGCCAAAATCTTACTG ACGTTGGATGAGAAAGCAATGTTGCAACTC 5293.5 GGAAGCCGGAGCAGATA C 5540.6 T 5620.6
W1 WNT11 720 +6 C>T ACGTTGGATGAACTGATGCGTCTACACAAC ACGTTGGATGCACAAGCACAACTATCTGGG 5324.5 GTGGGGAGACAGGTAAC C 5571.7 T 5651.6
W1 WNT5A Asp119Ser ACGTTGGATGCAATTCCGACATCGAAGGTG ACGTTGGATGTCCTACCTATCTGCATCACC 5868.8 ggCTGCAGCACTGTGGATA A 6140.0 G 6156.0
W1 WNT11 207 +47 G>T ACGTTGGATGATCCAGGGGACCCCAAAAC ACGTTGGATGTGTGAGTAGGGACCCCGCGT 5951.9 tACCCCAAAACGCCCTCCGC G 6199.1 T 6223.1
W1 ANKRD6 Leu192Phe ACGTTGGATGGCACTGACCTGGTTCTTTTC ACGTTGGATGGCGCGCTATAATCACTTGTC 5983.9 aAGAAAGCAGTGAGGAGGA T 6255.1 C 6271.1
W1 DVL3 1339 +17 A>G ACGTTGGATGACACAGAGCGTGAGTGTCC ACGTTGGATGATGGACCCTCATCAGTCCC 6053.9 cAGCGTGAGTGTCCCACCCT A 6325.1 G 6341.1
W1 ROCK1 807 C>T ACGTTGGATGCTTCCTTACTCACCTACAAG ACGTTGGATGGGAAGAGAATGTGACTGGTG 6590.3 ctgcCTCACCTACAAGCATTTC T 6861.5 C 6877.5
W1 ROCK1 1785 T>G ACGTTGGATGGCTTGCAGCTGGTAATAATC ACGTTGGATGAACAGAGAGTTGCAAGAGAG 6688.3 acTCTTTGTCTGTTTGTGACTT G 6935.5 T 6959.6
W1 ROCK1 Thr773Ser ACGTTGGATGGATCCCAATTATTTTTCTC ACGTTGGATGACAGCCGCTTATTTGATTCC 7045.6 TCATTCATAGGTTAAGAATCTAA C 7292.8 G 7332.8
W1 ANKRD6 rs9344950 ACGTTGGATGGGGTGCAGAAGGAAAATTAG ACGTTGGATGTTATGCAGTTGCAAAACTGG 7122.7 ggAGGAAAATTAGCACCAATAAA A 7393.9 G 7409.9
W1 ANKRD6 rs9353687 ACGTTGGATGTCTCCAGAAAGCTTCTGCTC ACGTTGGATGTAAGATATCCTTGGTGGATG 7261.7 CTCCAGATTCTGAATCTTTAACAT T 7533.0 C 7549.0
W1 ROCK2 672 -25 A>T ACGTTGGATGAGGACCAAGGAATTTAAGCC ACGTTGGATGAATGAATGCTTGGAAATTG 7474.9 CTGTTAAGAAATAAAAAGAGGAAA T 7746.1 A 7802.0
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Table 18. PCR primers, extension primers, masses and base call for the W2 sequenom experiment. 
Assay Gene SNP_ID Forward Primer Reverse Primer UEP_MASS Extension Primer Call 1 EXT1_MASS Call 2 EXT2_MASS
W1 DVL3 446 T>A ACGTTGGATGATAACCCATCGGAGCTGCC ACGTTGGATGACTCACTGGAAGGATGGGG 5429.5 ATCGGAGCTGCCACCACC A 5700.7 T 5756.6
W2 ANKRD6 ANK_7_T176N ACGTTGGATGGGAGCCTAATGATGGACAAG ACGTTGGATGTGATTTTTGTCCGCAGGCAG 5197.4 CAGCAACGTGCAAACAG C 5484.6 A 5524.5
W2 ROCK2 rs2271621 ACGTTGGATGTCTGTCTGTGTAACTGGTCG ACGTTGGATGCCTTGGGTGATATTTTATTCC 7674.1 ACATGAAATAACTTGCTATAAAAAA G 7961.3 T 8001.2
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Table 19. PCR program used for the iPLEX multiplex amplification PCR 
 
PCR products were cleaned with shrimp alkaline phosphatase (SAP) from Sequenom Inc. 
This step cleaves one phosphate on the unincorporated dNTPs converting them into 
dNDPs. Manufacturer instructions were followed: 5ul of the PCR product were transferred 
to a 384 well format plate and mixed with 0.17 ul of SAP buffer and 0.3 ul of SAP enzyme. 
The reaction was incubated for 45 min at 37°C. Due to the volume format used for the 
reactions a Multimek liquid handler was programmed and used to mix the components. 
 
Subsequently, a volume of 2ul containing 0.22X of iPLEX buffer, 1X iPLEX termination 
mix, a mixture of the extension primers depending on their mass (0,625 uM- 1,25uM), and 
0.041 ul of iPLEX enzyme was added to each one of the reactions. Extension cycling 
conditions were performed following manufacturer conditions. See Figure 13. 
 
 
 Figure 13. Cycling conditions for iPLEX extension reactions (164).   
 
A spectroCLEAN enzyme was used to remove salt particles from the samples. The resin 
and 10 ul of water were added to each sample and the plates were agitated for 30 min. A 
Samsung TM nanodispenser was used to transfer 15 nl of sample to an SpectroChip 
N of cycles Temperature and time
1 95°C for 15 minute
97°C for 20 seconds
34 59°C for 30 seconds
72°C for 1 minute
1 72°C for 3 minutes
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(166). The SpectroChip was introduced and analysed into a Bruker Autoflex MALDI TOF 
spectrometer, producing the spectra and reporting the alleles for each sample and SNP. 
 
2.3.3. RFLPs 
 
A total of 175 TOF patients and 1304 probands were screened for the mutation described 
by our group in 2006 in exon 14 of Dvl2 gene, 536(T/I), mRNA 1886 (C/T).   
 
The sequence of Dvl2 exon 14 was uploaded to the web based resource Web Cutter 
(167). Enzymes able to distinguish between the possible alleles were analyzed manually. 
The ECO RV enzyme was chosen. The enzyme cuts in the consensus sequence 
GAT/ATC which corresponds to the non-wild type allele. Three bands are produced, one 
of 386 bp for the wild type allele and two of 148 and 248 for the non wild type allele. See 
Figure 14. Exon 14 was amplified using previously optimized primers.  Table 20  shows 
the oligos. 
 
 
Table 20. Dvl2 exon 14 primers 
 
 
Figure 14. Agarose gel showing RFLPs designed for the mutation at position 1886 in the 
Dvl2 gene. The arrows denote heterozygous subjects. 
  
The primers were purchased from Invitrogen TM. ECO RV enzyme was ordered from 
Fermentas TM. Taq polymerase and PCR buffer were obtained with the GoTaq 
polymerase kit purchased from Promega. 
Region Forward Primer Reverse Primer Product lenght Opt anealling Temp
Exon 14 AACTGTTCCCAGTTCCTCTCC GGGCAACTGAGTCCTCACC 396 64.5
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PCRs were run at optimal temperature in Peltier Thermal Cyclers, DNA engine DYAD TM. 
Products were checked through agarose gel electrophoresis. Subsequently, enzyme 
digestion assays were performed following manufacturers recommendations. The reaction 
contained 1.5 ul of Buffer 10X, 0.15 ul of BSA 100X, 1 enzyme unit, 3 ul of DNA and water 
up to a volume of 15 ul. Assays were incubated for 12 hours at 37 C°, and heated at 80 C° 
for 20 minutes. Digestion products were run in 3% agarose gels, and genotypes obtained 
manually and stored as Microsoft Excel TM files. 
 
2.3.4. Taqman assays 
 
The rs2074216 marker and the variant Pro136Arg, previously reported in DVl2, (168) were 
genotyped in the HTO population using the Taqman platform. The technique used was the 
fast real time 7900HT, Taqman, by Applied Biosystems. Briefly, the allelic discrimination 
assays using this technique consists in two steps, the first one of amplification or preread-
run and the second one of analysis or post-read run (169). 
 
The polymorphic region is amplified using PCR primers previously designed and optimized 
by the company and a polymerase enzyme with exonuclease activity. Each reaction has, 
in addition, two probes which specifically hybridises with one of the alleles. At each end of 
the probe there is a reporting fluorescent dye molecule, either VIC® or FAM®, and a 
quencher molecule respectively. When the probe is attached to the DNA template, the 
polymerase excises the quencher and the dye from the probe in the amplification step, 
making possible the fluorescence emission when faced to light stimulation. In the analysis 
step, the samples are grouped in four clusters depending on the fluorescence spectra: 
failing, homozygous wild type, heterozygous and homozygous non-wild type (169). See 
Figure 15. 
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Figure 15. Taqman graphic result. Homozygous wild type sample are shown as blue dots, 
heterozygous as green dots, and homozygous non wild type as red dots. 
 
Universal master mix DNA taq polymerase UNG® no Amperase was purchased from 
Applied biosystems®. Probes and primers for rs2074216 were ordered from Applied 
Biosystems®, as pre-designed genotyping assays. Sequences for the primers and probes 
for this assay are not known. The variant in DVL2 residue 136 was genotyped using a 
custom made assay ordered from Applied Biosystems ®. See Table 21 
 
 
Table 21. Taqman probes and primers for Pro136Arg in Dvl2 
 
Reactions were prepared following instructions from the manufacturer. Each well 
contained: 2.5ul of Universal master mix, 0.061 of 40X primers and probes mixture, 1.37 ul 
of water, and 20 ng of DNA. The amplification run was performed in a 384 well plate using 
thermal cyclers DNA engine Tetrad TM. The standard program used consists of an 
activation step of 10 minutes at 95 C°, followed by 40 cycles of 15 seconds at 95°C and 1 
minute at 60°C. 
 
Post-read run analysis was performed using the 7900HT Applied Biosystems® machine. 
Frequencies obtained were stored as Microsoft Excel™ files. 
Assay Forward Primer Reverse Primer Reporter 1 Reporter 2
M136 AGAAACCGAGTCAGTAGTGTCACT CCATGCTCACTGCTGTCTCT CTGCGAGGCCGCT CTGCGAGGCCACT
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2.3.5. Kaspar assays 
 
Due to optimization difficulties 2 variants: ANKRD6 1 -304 A>G and WNT5A 1461 +38 
C>T, were genotyped out of our laboratory by Kbiosciences laboratory services (170). The 
sequences were obtained from our sequencing work and sent to the company to design 
the probes and genotype 465 CHA TOF proband and 1248 HTO controls. 
 
The technique used by Kbiosciences is similar to the Taqman®: the polymorphic region is 
amplified using PCR primers specifically designed and optimized by the company, and a 
polymerase enzyme with exonuclease activity. Two probes which specifically hybridises 
with one of the alleles are added to the reaction. At each end of the probe there is a 
reporting fluorescent dye molecule and a quencher molecule respectively. When the probe 
is amplified, the polymerase excises the quencher and the dye from the probe in the 
amplification and the fluorescence emission is detected when stimulated with a specific 
wavelength light. The samples are grouped in four clusters depending on the fluorescence 
spectra: failing, homozygous wild type, heterozygous and homozygous non-wild type 
(169). Results were electronically sent from K biosciences as Excel files. 
 
2.3.6. Statistical analysis of case and control genotypes 
 
The data with the genotypes and the pedigree were stored as Microsoft Office Excel 2003 
files. The files containing family-proband data and genotypes were merged together using 
Microsoft Office Access 2003. The genotypes were checked for Mendelian errors using 
Pedstats ® (171), the resulting errors were reviewed and deleted when necessary. 
Additional checks based on unlikely recombination patterns within families were carried 
out using the error-checking option in MERLIN version 1.1.1 (172). Errors were corrected 
when possible by reference to the raw genotyping data, and when this was not possible, 
genotypes were excluded from analysis. The degree of fitness with Hardy Weinberg 
equilibrium was measured for each marker using the Pedstats ® software. 
 
Population variable frequencies were calculated with SPSS v15.0 software. Allele 
frequencies were calculated using Pedstats software. Haplotypes were obtained when 
appropriate using Haploview 4.0 software (173). Extremely rare variants (N=1 or 2) were 
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compared manually. Initial ANOVAs comparing allele frequencies were using SPSS v15.0. 
Discrete association analysis was calculated with the algorithm present at Haploview 
software (174) and LAMP v0.0.9 software (175). Graphics were performed using SPSS 
v15.0 software. 
 
To take some account of the risk of false-positive findings because of multiple 
comparisons, the results were interpreted based on the false discovery rate (176). The 
program QVALUE was used running on top of the statistical package R to determine q 
values (177). An arbitrary false discovery rate threshold of 0.05 was adopted. 
 
2.4. ROCK1 duplication analysis 
2.4.1. Bioinformatics analysis 
 
Due to higher than expected heterozygosity rates in the SNPs at Exon 31 of ROCK1, a 
bioinformatics analysis was undertaken to explore the reasons for this.  
 
The SNP rs35881519 mapped to two regions when Ensembl web page was consulted at 
the time. A search of duplicated regions was performed for ROCK1 at the Human Genome 
Segmental Duplication database (178).  The original overlapping clones for ROCK1: 
AC021727, AC036178, AC131287, AC135340, AC139704 and the clone for the potential 
duplication: AP001005 were downloaded from the Entrez Nucleotide database at the NCBI 
web page (179). Sequences were stored as Microsoft Office Word 2003 files. 
 
Dot plots (180) were constructed using the web based resource DNA dot (181) to compare 
each one of the sequence to the duplicated one. The dot plot is a graphical representation 
of a matrix comparison of two sequences. A user defined “window” spanning a number of 
bases is compared with the entire length of the subject sequence. If identity is found a dot 
is placed in the corresponding X-Y coordinate. 
 
Using dot plots the sequence spanning the duplication was identified.  The sequences 
were copied into Microsoft Wordpad software files. The files were aligned using the Clustal 
function present at the MEGA 4 software (182, 183). The graphic interface was used to 
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identify regions with differences within the duplication. A search using sequences 
characteristic to each one of the clones was performed at nucleotide BLAST against the 
expressed sequence tags EST database (184). Results of the BLAST search were 
manually analysed to determine if the duplication was previously identified as an EST.  
 
2.5. MINIGENES 
 
2.5.1. PCR and E. coli transformation 
 
The method used for the minigene experiments has been described before in the literature 
(185). Exon 8 of ROCK1 and exon 1 of WNT11 including 300 nucleotides of intronic 
flanking region were amplified using the phusion PCR kit (NewEngland Biolabs ®) from 
DNA samples of heterozygote subjects for the ROCK1 uncommon variant 807 C>T and 
the WNT11 207 +47 G>T uncommon variant. Primers designed using the web based 
software Primer 3 were modified to include an ECORI site and a Poli-A tail. HPLC purified 
primers were purchased from Metabion®. See Table 22.  
 
PCR reactions were performed following manufacturer guidelines.  A mixture of 100uM of 
dNTPs, 0.5uM of each primer, 1,5 ul of DNA template (20mg/ul) and 0.5ul of polymerase 
were cycled 35 times under the conditions specified in Table 23. PCR reactions were 
performed on a DNA engine Tetrad2 thermal cycler. The concentration of PCR product 
was measured using a Nanodrop® spectrophotometer.  
 
 
Table 22. Minigene primers 
 
 
Table 23. Phusion PCR cycling conditions 
Variant Forward Primer Reverse Primer Product lenght
ROCK1 807 C>T AAAAAAAAAGAATTCTTGCACTGGCCTGTGTACTT AAAAAAAAAGAATTCTCAGTTTCAAAGGAAGAGTCAAA 823
WNT11 207 +47 G>T AAAAAAAAAGAATTCCCTGGACTCCTGATTCCTCA AAAAAAAAAGAATTCAGGTCCTTTCAGGAGCCTCT 1126
N of cycles Temperature and time
1 98°C for 1 minute
98°C for 20 seconds
34 62°C for 10 seconds
72°C for 30 seconds
1 72°C for 10 seconds
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The PCR products were cleaved with ECORI (New England Biolabs ®), and purified using 
the Qiaquick PCR purification kit from Qiagen®. 1ug of PCR was mixed with 5ul of 10X 
buffer, 1 U of ECORI and 44 ul of H2O and incubated at 37°C for 4 hours.  Qiagen® 
instructions for PCR purifications were followed (186): 250ul of buffer PB were added to 
50ul of reaction; the mixture was transferred to a Qiaquick spin column and centrifuged at 
13000 rpm for 30 seconds in a tabletop microcentrifuge; flow through was discarded and 
the column washed with 0.75 ml of buffer PE; the column was centrifuged twice at 13000 
rpm for 30 seconds in a tabletop microcentrifuge, flow through was discarded; DNA was 
eluted applying 30 ul of buffer EB to the column and centrifuging at the same conditions for 
1 minute.  The concentration of product was measured using a Nanodrop® 
spectrophotometer. 
 
The purified fragments were inserted into the MfeI cloning site of the non commercial 
vector Pxj41 (187) kindly gifted by Prof David Elliot. Briefly, digestion of the circular vector 
was performed adding 1ug of it to 5ul of 10X buffer, 1 U of MfeI enzyme, and 44 ul of H2O 
and incubated at 37°C for 4 hours.  MfeI enzyme was purchased from New England 
Biolabs.  
 
After digestion the vector was purified using the Qiagen PCR purification kit following the 
procedure explained before. Both digestion fragments, the PCR products and the digested 
vector, were ligated using T4 DNA ligase from New England Biolabs. 1ul of vector, 8ul of 
PCR product, 2 ul of DNA ligase, 2 ul of T4 DNA ligase buffer 10X and 7 ul of water were 
incubated at room temperature for 6 h.   The cloning site in the Pxj41 vector is located 
midway in the Intron between the constitutively expressed mouse B-globin exons 2 and 3 
(185). See Figure 16.     
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Figure 16. Pxj41 globin exons and their relation with the inserted exon. 
 
The ligated fragments were cloned transforming competent E Coli cells JM109 from 
Promega ®. Briefly, 5ul of ligation were mixed with 50ul of competent cells and incubated 
on ice for 30 minutes. Subsequently cells were heat shocked at 42°C for 90 seconds and 
incubated again on ice for 5 minutes. After a recovery incubation time at 37°C cells were 
spreaded on agar-LB media plates (See Table 24 for preparation instructions) with 
Ampicilin at a concentration of 100 mg/ml to select transformed cells. Plates were 
incubated at 37°C overnight. 
 
 
Table 24. Preparation of LB media agar plates 
 
Colonies were picked after 12 h of incubation and DNA was extracted using a simple 
heating procedure: each colony was manually picked with a pipette tip and loaded into 50 
ul of water. The mixture was incubated at 100°C for 5 min. 
 
PCR amplification of the B-globin and inserted exon was performed on each colony using 
the vector specific flanking primers PXJRTF and PXJB1. The PCR was performed using 
the Hotstar Taq polymerase kit from Qiagen. Reaction mixtures had the same 
Ingredient Quantity
Tryptone 10 g
Yeast 5 g
NaCl 5 g
1M NaOH 1 ml
Agar 15 g
Water 1 L
B-Globin 2,3 
Inserted Exon 
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concentrations as described in the section 2.2.1.1 and were cycled at the conditions 
described in Table 19.  PCR product length was checked on a 2% agarose gel 
electrophoresis. See Figure 17 
 
 
Figure 17. Agarose gel electrophoresis of Pxj41 transformed colonies 
 
Colonies with the expected length were subsequently tested for insert orientation, using a 
PCR with a combination of primers from the insert and vector. For example, forward 
PXJRTF and reverse ROCK1 exon 8. PCR was performed using the Hotstar Taq 
polymerase kit from Qiagen. Reaction mixtures had the same concentrations as described 
in the section 2.2.1.1 and were cycled at the conditions described in Table 19. 
 
Colonies with the insert in the correct orientation were seeded and cultured on 50 ml of 
LB-ampicilin media for 12 hours in a shaker at 37°C. DNA from the culture was extracted 
using the Miniprep kit from Qiagen® : cultures were spinned at 3000 rpm for 5 minutes; 
pelleted bacterial cells were resuspended in 250ul of P1 buffer and transferred into an 1,5 
ml microcentrifuge tube; 250 ul of buffer P2 were added; 350 ul of Buffer N3 were added; 
samples were spinned at 13000 rpm on a tabletop microcentrifuge for 10 min.; the 
supernatant was applied to a Qiaprep column and centrifuged for 30 sec at 13000 rpm on 
a tabletop microcentrifuge; flow-through was discarded, the column was washed with 0,5 
ml of PB buffer and spinned at the same conditions; flow through was discarded and the 
column was also washed with 0,75 ml of PE buffer and spinned again at the same 
conditions; after another 1 min spinning cycle, DNA was eluted adding 50 ul of EB buffer to 
the membrane and centrifuged at 13000 rpm for 1 min at a table-top microcentrifuge. The 
concentration of product was measured using a Nanodrop® spectrophotometer. 
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The DNA obtained was sequenced outside the Institute by Eurofins MWG Operon. 
Sequences were manually analyzed to identify colonies carrying the wild type and the 
mutated allele.  
 
2.5.2. HEK 293 transfection and splicing analysis 
 
2.5.2.1. HEK 293 culture and DNA Transfection 
All cell culture procedures were performed under clean conditions on an isolated room and 
cell manipulation was always performed at a laminar flow hood.  Human Embryonic kidney 
cells 293 (HEK293) were used for this set of experiments. The cell line was generated by 
the transformation of normal embryonic kidney cells with Adenovirus 5 DNA (188). 
  
HEK293 cells were cultured under standard conditions: DMEM media + 10% fetal calf 
serum at 37°C. DMEM media was purchased from GIBCO and Fetal calf serum from 
Sigma. Approximately 2.5 X 105 cells were seeded at each well on 6 well (10 cm2) plates 
and incubated at 37°C overnight to allow 70-80% confluency. HEK 293 cells were kindly 
gifted by Caroline Dalgliesh from Prof David Elliot’s group  
 
Transfection with the Pxj41+ ROCK1 (Exon 8)/WNT11 (Exon 1) DNA was made using 
standard procedures. Briefly, 97 ul of DMEM media without serum was mixed with 3ul of 
the Transfection reagent Gene Jammer from Stratagene ® and incubated at room 
temperature for 5 minutes. Around 500 ng of DNA was added to the mixture and incubated 
for 10 minutes at room temperature. The mixture was added to each well and incubated 
for 24h at 37°C. 
 
After the incubation, cells from each well were washed with 1 ml of PBS and trypsinised: 3 
drops of GIBCO® Trypsin-EDTA (0.25% Trypsin; 1mM EDTA) were added to each well 
and plates were incubated at 37°C for 5 min. The reaction was stopped adding 1 ml of 
DMEM containing 10% fetal calf serum. The content of each well was transferred to an 
eppendorf tube and spinned on a bench centrifuge at 6000 rpm for 2 minutes. Supernatant 
was discarded and pellets properly labeled and stored at -20°C until RNA extraction. 
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2.5.2.2. RNA extraction and qualitative analysis 
RNA from the samples was extracted using the Trizol® reagent from Invitrogen:   samples 
were vortexed and 20ul of chloroform was added to each one. The mixture was vortexed 
again and incubated for 2 minutes at room temperature. Afterwards, the samples were 
spun on a bench centrifuge for 15 min at 15000 rpm at 4°C. The aqueous layer obtained 
was mixed with isopropanol and incubated at room temperature for 10 minutes. After of a 
new spin of 10 min under the same conditions, supernatant was discarded. The pellet was 
resuspended on 70% ethanol. The samples were spun for 8 min and ethanol removed by 
pipette. The pellet air dried and resuspended on RNAse free water. RNA concentration 
was measured using a Nanodrop® spectrophotometer. 
 
Splicing of the exon inserted was analyzed using RT-PCR. The one step RT-PCR Qiagen 
kit was used to perform the reaction with the PXJRTF and PXJB1 primers. Manufacturer 
instructions were followed: 1ul of 5X Qiagen buffer, 400 uM of each dNTP, 1 ul of Qiagen 
Q solution, 0.2 ul of the enzyme mixture, primers at a concentration of 0.6 uM and 100 ug 
of the extracted RNA were mixed and cycled following the program specified at Table 25. 
 
 
 Table 25. Cycling conditions for One Step RT-PCR 
 
Qualitative comparisons in splicing between the wild type containing exon and the mutated 
one were performed using agarose electrophoresis. Confirmation of RNAm sequence was 
obtained by sequencing. RT-PCR products were sent to Eurofins MWG operon to be 
sequenced. The files received were manually reviewed using the Staden package 
software. 
 
N of cycles Temperature and time
1 30°C for 30 minutes
1 95°C for 15 minutes
97°C for 30 seconds
34 55°C for 30 seconds
72°C for 1 minute
1 72°C for 10 minutes
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2.6. ROCK1 tag SNP genotyping 
2.6.1. Marker selection and assay design 
 
A search for ROCK1 was performed on the Hapmap database (157). Allele frequencies for 
the SNPs in the 28 first ROCK1 exons and a region of 15 Kb upstream were dumped from 
the database (Chromosome 18: 16792848..16960818) for the Utah residents with 
Northern and Western European Ancestry (CEU) population. The file comprising 167 Kb 
and 109 SNPs was analysed using Haploview 4.0 software. SNPs with a mAF of less than 
0.05 were excluded from the analysis. See Figure 18 
 
Tagging strategy was set for an r2 threshold of 0.8. A total of 34 SNPs were included and, 
according to the tagging analysis, captured using 12 SNPs. The software was forced to 
include the non synonymous SNPs rs2292296 (Leu1097Phe), rs2271255 (Lys222Glu) and 
rs45449301 (Ile432Val).  
 
The sequence for each one of the variants and 200bp upstream and downstream was 
obtained from the NCBI web page (39). Sequences were uploaded to the Real SNP web 
based resource in order to design the assays (165). Assays were designed as described in 
section 2.3.2. See Table 26 for primer sequences and mass. 
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Figure 18. LD plot showing all 34 SNPs included on the tagging analysis of ROCK1. Gray 
scales denotes R
2
 between markers. 
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Table 26. PCR primer extension primer and mass for the ROCK1 tagged SNPs Sequenom assay. 
SNP Forward primer Reverse primer EP Mass Extension primer Allele1 Allele1 Mass Allele 2 Allele2 mass
rs2292296 ACGTTGGATGTCAGCACTAGGAAAACTAGC ACGTTGGATGTGAGCAATTGCGTGCTAAAC 5507,6 CACTTGTAGAATCCGAGA A 5778,8 G 5794,8
rs17202375 ACGTTGGATGCATTATGTCCTTTAGAGCTT ACGTTGGATGCTGTCTCTATTTAAAAAAAAAA 5817,8 TCCTTTAGAGCTTGAAGTA G 6065 A 6144,9
rs1481280 ACGTTGGATGATCTGAGGTCCTTTGGGATA ACGTTGGATGCCAATCTCTCTGTTAAACCC 6174 CATGAATAACTAGATGGCAG C 6421,2 A 6445,3
rs398528 ACGTTGGATGCAGTTCGGTGTTACTGAACAT ACGTTGGATGCAATGGAGCCAGACCCTGT 6355,2 CATTTTCAAGGCCTTCTTAAA T 6626,4 A 6682,3
rs8085504 ACGTTGGATGAGGAGGAGGAGAGATTGGTC ACGTTGGATGCCCCTTCCATCTCTTTTACC 6531,3 AGGAGAGATTGGTCTTTGTAT G 6778,4 A 6858,4
rs7237677 ACGTTGGATGGGCTGAAATTTGCCTTTATGG ACGTTGGATGGTCAGTTTAATGAATCTCTG 6726,4 AGTGCTATAAATCAACACTGTA G 6973,6 C 7013,6
rs288979 ACGTTGGATGACAAAGCATGTAAAGAAGC ACGTTGGATGCACGCCTGGTGGTTTCTAAC 7155,7 AAAGCATGTAAAGAAGCAAGAAA A 7426,9 G 7442,9
rs7227454 ACGTTGGATGTTCACCTGTCCTAGAATTTC ACGTTGGATGGCTGAGTGAAAGAAACCACG 7237,7 CCTGTCCTAGAATTTCATCTACAT T 7508,9 C 7524,9
rs288989 ACGTTGGATGTCTTTAGGAATTTGCAGTGG ACGTTGGATGCATCTCTAGAGTAGTATTCC 7323,8 AGTGGTGATCATCTATTTTTATCC A 7595 T 7650,9
rs2271255 ACGTTGGATGGTTAGCAGATTTTGGTACT ACGTTGGATGCCTTGAATTAGCAAAAACT 7733 GTTAGCAGATTTTGGTACTTGTATG T 8004,2 C 8020,2
rs17202368 ACGTTGGATGGCAGCAATACCAGATGCTAC ACGTTGGATGGATTATAAATTGGAAGTTCA 7950,2 GCAGCAATACCAGATGCTACCAAAAA C 8197,4 A 8221,4
rs45449301 ACGTTGGATGATTAAAGCAGGAAAGTTTG ACGTTGGATGGCATTTCATTATGCAGCTGT 8053,3 TAAAGCAGGAAAGTTTGCAAAAAACA T 8324,5 C 8340,5
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2.6.2 iPLEX genotyping 
 
All 13 variants were genotyped, using the iPLEX® platform, in 465 CHA probands, 744 CHA 
parents and 1428 HTO controls. Multiplex PCRs were performed following the standardized 
process for iPLEX® experiments as described in section 2.3.2.  PCR products were cleaned using 
ExoSAP and extension reactions were performed as described in section 2.3.2. 
 
Reactions were cleaned with a spectroCLEAN enzyme. A Samsung TM nanodispenser was used 
to transfer 15 nl of sample to an SpectroChip (166). The SpectroChip was introduced and analysed 
into a Bruker Autoflex MALDI TOF spectrometer, producing the spectra and reporting the alleles 
for each sample and SNP. 
 
2.6.3. Statistical analysis 
 
Genotypes and pedigrees were stored as Microsoft Office Excel 2003 files. The files containing 
family-proband data and files containing genotypes were merged together using Microsoft Office 
Access 2003. The genotypes were checked for Mendelian errors using Pedstats ® (171), the 
resulting errors were reviewed and deleted when necessary. Additional checks based on unlikely 
recombination patterns within families were carried out using the error-checking option in MERLIN 
version 1.1.1 (172). Errors were corrected when possible by reference to the raw genotyping data, 
and when this was not possible, genotypes were excluded from analysis. The degree of fitness 
with Hardy Weinberg equilibrium was measured for each marker using the Pedstats ® software. 
 
Population variable frequencies were calculated with SPSS v15.0 software. Allele frequencies 
were calculated using Pedstats software. Haplotypes were obtained when appropriate using 
Haploview 4.0 software (173). Extremely rare variants (N=1 or 2) were compared manually. Initial 
ANOVAs comparing allele frequencies were using SPSS v15.0. Discrete association analysis was 
calculated with the algorithm present at Haploview software (174) and LAMP v0.0.9 software 
(175). Graphics were performed using SPSS v15.0 software. 
 
To take some account of the risk of false-positive findings because of multiple comparisons, the 
results were interpreted based on the false discovery rate (176). The program QVALUE was used 
running on top of the statistical package R to determine q values (177). An arbitrary false discovery 
rate threshold of 0.05 was adopted. 
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3. ROCK1 RESULTS 
3.1. CHANGE POPULATION DESCRIPTION 
 
A total of 565 TOF probands recruited to the CHANGE study were available for genetic analysis. 
For 39 of these probands it was impossible to recruit either parent. For 526 at least one of the 
parents was available and was recruited, 329 were trios. Two hundred and ninety six probands 
(52%) were males and 269 (48%) were females. Mean age for the 565 probands was 20 years 
with an interquartile range (IQR) of 16.71 years. Mean age of mothers was 46.9 years (IQR: 
14.41).  Mean age of mothers when the proband child was born was 28.6 years (IQR: 8).  
 
Data about personal and family history was obtained through interviews with a genetics trained 
nurse. In these interviews a total of 94 (16.6%) of the probands reported at least one second 
degree family member affected by any kind of congenital heart disease. One hundred of the total 
of TOF probands (17%) showed at least one other congenital abnormality, including 
developmental and blood disorders. Twenty six of the total 100 (26%) showing other congenital 
abnormalities, presented 2 or more of them. Classifying the total of 126 other malformations in 13 
anatomical-physiological groups, including one for cleft lip and palate: Twenty three (18.25%) 
corresponded to genitourinary malformations; fifteen (11.9%) to malformations that could be 
classified as skeletal, including craniosynostosis; fifteen (11.9%) to gastrointestinal malformations; 
fourteen (11.11%) were soft tissue malformations, including hernias;  thirteen (10.3%) to 
malformations in lungs or airways; eleven (8.73%) corresponded to other cardiovascular 
malformations additional to TOF; nine (7.14%)  were abnormalities in the sense organs; nine 
(7.14%) corresponded to CNS and developmental abnormalities; eight (6.35%) were 
malformations in vessels from second degree branching; four were cleft lip or palate (3.17%) 
cases; three (2.38%) were glandular abnormalities; and two suffered congenital blood 
abnormalities. See Table 27. 
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Table 27. Type of malformations and number of affected individuals at the TOF population. N: 
Number of affected individuals. Percentage refers to the percentage of the total malformations 
represented by each group 
 
 Nine out of 707 TOF probands’ siblings were also affected with TOF (1.2%), giving a λS (Sibling 
relative risk) of 40. One of 62 (1.62%) TOF probands offspring was also affected with TOF, giving 
a λ relative risk of 54. Calculations were made taking into account the UK population TOF 
incidence (0.301/1000 live borns). 
 
In terms of maternal conditions, 36 (6.8%) of mothers (526 available) of the probands suffered of 
pregnancy induced hypertension and 37 (6.8%) suffered any degree of vaginal bleeding during 
pregnancy, with two of these suffering both conditions. Ten (1.8%) of the mothers were diabetic 
prior to pregnancy and seven (1.3%) developed gestational diabetes. Of these 17 mothers 
suffering diabetes 7 were controlled with diet, 9 were receiving insulin and 1 was receiving oral 
hypoglycemic agents. Diagnosis criteria for diabetes could not be verified in this retrospective 
study, and the quality of metabolic control during pregnancy is also unknown. Thirteen (2.4%) 
mothers suffered epilepsy during pregnancy with 11 of them being diagnosed before pregnancy. 
Five (38%) of the epileptic mothers were receiving medication for the condition. 
 
3.2. Previously undescribed uncommon variants  
 
Sequences of 32 exons in 93 patients were obtained for Rock1. A total of 4065 bp in each 
individual were screened using methods described in section 2.2.1. The genetic duplication in 
ROCK1 which I discovered during the course of the work, described in the methods section, 
prevented the correct identification of genetic variation from exon 27 to 32. Three previously 
undescribed uncommon variants were encountered at ROCK1. See Table 28 
Group N Percentage 
Genito- urinary 23 18.25
Skeletal 15 11.90
GI 15 11.90
Muscular- soft tissue 14 11.11
Pulmonary- airways 13 10.32
Other CCM 11 8.73
Senses 9 7.14
CNS- developmental 9 7.14
Other circulatory 8 6.35
Cleft lip and palate 4 3.17
Glands 3 2.38
Blood 2 1.59
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Table 28. Previously undescribed uncommon variants. N: Number of carriers; AA: Aminoacid; S: 
Synonymous; NS: No synonymous; L: Leucine; S: Serine; T: Threonine. 
 
3.2.1.  ROCK 1 807 C>T 
The first uncommon variant is a synonymous change (C/T) in exon 7, mRNA position 807. The 
change was encountered in 1 patient in heterozygous state at the first mutational screening and is 
located in a codon translated into Leucine. See Figure 19. 
 
Despite the single base change not being in the consensus splice sequence, computational 
analysis of the variant in exon 7 showed interesting results. The mutation decreases the strength 
of the acceptor site at the end of the exon and produces disappearance of a SrP40 binding site 
located at its position. Additionally, 807C>T is located within the kinase motif of the protein, which 
increases the probability of functional alterations if this mutation causes splicing defects. 
 
The variant was inherited, in the first proband detected to be carrying this variant, from the mother 
who does not show an abnormal cardiac phenotype.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. ROCK1 807C>T variant trace display. Upper and medium panel show patient sequence, 
bottom shows a normal trace. 
 
Exon Variant Alleles Function AA
7 807 C>T C/T S L
16 1785 T>G T/G S S
20 Thr773Ser C/G NS T/S
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3.2.2. ROCK 1 807 C>T is associated with TOF 
 
A total of 1908 genotypes for ROCK1 807 C>T were obtained from controls (ECACC, HTO and 
CHANGE parents) following methods described in section 2.3.2. One thousand and seventy three 
genotypes (CHANGE, CONCOR, Oxford and Nottingham) were obtained from TOF probands, 
comprising cases from the CHANGE, Oxford, Nottingham and CONCOR cohorts. Power was 
calculated as 75% for a general case-control analysis, hypothesising a relative risk of 2 for the 
heterozygotes and alpha error of 0.05. Genotyping was successful for 98% of the samples. The 
estimated genotype miscall rate was <1% for the SNP. ROCK1 807 C>T was in Hardy-Weinberg 
equilibrium at the 5% significance level for the global population and for each of the 
subpopulations. 
 
Table 29 shows allele counts and frequencies for the ROCK1 807 C>T variant. The variant was 
present in our population and there are no previously described frequencies in the databases. 
Thirty three heterozygotes were encountered among probands, whereas only 12 in controls. Four 
of the probands carrying the variant were males and 9 were females; sex was unknown in 20 of 
the probands due that they were identified in cohorts which I did not have that information at the 
time of analysis. Only 2 out of the 13 families, where demographic data were available, showed 
family history of CHD: one of the probands has a cousin with an unspecific CHD and the sister of 
another proband is affected with dextrocardia. Two out of the 13 probands carrying the 807C>T 
variant, where other medical data were available, showed other congenital abnormalities: one of 
them was born with a hypoplastic left lung and another has eye coloboma. 
 
Using data from 1073 TOF cases and 1908 controls, an association was found between TOF and 
genotypes at the uncommon variant ROCK1 807 C>T (p=0.000019, LOD: 3.15). Thirty three 
heterozygotes were found among TOF cases, whereas only 12 were encountered at the control 
population. Heterozygotes for ROCK1 807 C>T carry a calculated OR for TOF of 4.89 (95% CI: 
2.51-9.50). This association was still significant after correction with Qvalue for multiple testing (15 
SNPs), using a 5% false discovery rate level. Figure 30 shows a graphical comparison of the 
proportion of the genotypes in each subpopulation.  
 
 
Table 29. ROCK1 807 C>T allele counts and frequencies for probands and controls  
  
C/C C/T T/T MAF mAF
Probands 1073 33 0 98.5% 1.5%
Controls 1908 12 0 99.7% 0.3%
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3.2.3. ROCK1 807 C>T does not affect splicing in a Minigene model 
 
A minigene including ROCK1 exon 8 was constructed following the methods described in section 
2.5.1. The minigene was expressed in HEK 293 cells following the methods described in section 
2.5.2.  Qualitative analysis on agarose gels of RT-PCR products, from total mRNA, using specific 
primers for the minigene showed no difference in splicing (transcript length and number) when 
mutant allele constructs were compared to wild type. See  
 
Figure 20. The bands correspond to the mature mRNA transcribed from the Pxj41+ ROCK1 (Exon 
8) wild type and Pxj41+ROCK1 (Exon 8 (807C>T)) carrying the variant.  In Figure 21 a scheme is 
shown explaining the possible results of the Minigene experiment. 
 
Sequencing of the RT-PCR product of both minigenes (807 C>T and wild type) showed 100% 
identity, showing not only an equal product size but also the same RNA nucleotide sequence after 
transcription for both 807 C>T and wild type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Agarose gel showing the RT-PCR product for minigenes carrying (M=mutant) and not 
carrying (WT=wild type) the ROCK1 807 C>T variant.  
  
100 bp
300 bp
500 bp
M WT
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Figure 21. Representation of Minigene product qualitative analysis. The plasmid is represented at the 
top left corner. In yellow, rabbit β globin exon 1 and in red β globin exon 2. Between β globin exons, 
in blue, ROCK1 exon 8 with the flanking intron regions in green.  At the bottom right a representation 
of the possible results for the agarose gel. If the exon inserted is skipped, a lighter band 
proportionally to the exon skipped length is expected. If an exonic cryptic donor splicing site a 
shorter product will also be expected. In the case of the inclusion of an intronic pseudoexon a larger 
product would be expected 
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3.2.4. ROCK1 1785 T>G 
 
The second uncommon variant is a synonymous change (T/G), in exon 16, mRNA position 1785. 
The variant was identified in 1 patient in the heterozygous state in the initial mutational screening. 
The codon translates into Serine (535). Serine number 535 is located in the coiled coil region of 
the protein, and does not belong to recognized conserved domains. The variant is not located in 
consensus splicing sequences and it does not disrupt known splicing cis regulatory sequences. In 
silico analysis showed no splicing changes associated.  
 
Samples for both parents were available for the first proband detected to be carrying ROCK1 1785 
T>G. Sequences were obtained. The variant was inherited from the mother who does not have an 
abnormal cardiac phenotype. See Figure 23 for the ABI sequencing traces of the parents of the 
first proband detected to be carrying the variant.   
 
 
 
Figure 22. ROCK1 1785 T>G variant. Trace display. Upper and medium panel show patient sequence. 
Bottom panel shows a normal trace. 
 
 
 
Figure 23. ABI sequencer traces for the parents of the carrier of ROCK1 807C>T. Upper panel shows 
mother’s sequence. Bottom panel shows father’s sequence. 
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3.2.5. ROCK1 1785 T>G is present in controls 
 
One thousand three hundred nineteen HTO controls, 457 probands and 169 CHA parents were 
genotyped using a Sequenom assay following methods described in section 2.3.2 to assess the 
presence of 1785 T>G. Ten heterozygotes and no homozygotes were found among controls.  
 
Five heterozygotes and no homozygotes were found among the CHA probands. Three of the 
probands carrying the mutation were females and 2 males. Only one out of these 5 probands had 
a family history of CHD with the father and brother being affected by unspecified congenital 
defects. Both populations are in Hardy Weinberg equilibrium.  There are no significant differences 
when allele frequencies are compared between probands and controls (p=0.499). See Table 30.  
. 
 
 
Table 30. ROCK1 1785 T>G allele frequencies and p value calculated for the genotype difference. 
 
3.2.6. ROCK1 Thr773Ser 
 
The third uncommon variant encountered is non synonymous (C/G), and is located in exon 20. The 
variant causes a translational substitution from Threonine to Serine in residue number 773, and 
was found in 1 patient in the heterozygous state.  
 
Residue number 773 is located at the Tropomyosin recognizing motif of the protein (124). Samples 
from both parents of the proband carrying the variant were available. The variant was paternally 
inherited. See Figure 25 for ABI sequencing traces from the parents of the first detected carrier. 
Abnormal cardiac phenotype was not observed within the family. 
 
To determine the theoretical degree of structural and functional impact of  the variant, the 
Polyphen prediction web based resource was used (158). The variant in aminoacid number 773 
appeared benign using this approach. 
  
Variant n MAF mAF n MAF mAF p value
1785 T>G 457 0.99453 0.00547 1319 0.99621 0.00379 0.499
CHA probands HTO controls
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Figure 24. ROCK1 Thr773Ser variant trace display. Upper and medium panel show patient sequence. 
Bottom panel shows a normal trace. 
 
 
 
Figure 25. ABI sequencer traces for the parents of the carrier of ROCK1 Thr773Ser. Upper panel 
shows father’s sequence. Bottom panel shows mother’s sequence. 
 
3.2.7. ROCK1 Thr773Ser is present in controls 
 
One thousand three hundred and thirty one HTO controls, 458 probands and 169 CHA parents 
were genotyped using a Sequenom platform and following methods described in section 2.3.2. 
Forty six heterozygotes and no homozygotes were found among controls.  
 
Seventeen heterozygotes and no homozygotes were found among the CHA probands. Both 
populations are in Hardy Weinberg equilibrium.  Ten of the probands carrying the mutation were 
females and 7 males. Five out of 17 probands carrying the Thr773Ser variant show other 
congenital abnormalities: one pulmonary atresia, 2 laryngomalasia, 1 plagiocephaly and 1 present 
major aorto pulmonary collateral arteries. Six out of the 17 families carrying the variant had a 
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history of CHD: one of the probands has a cousin and an uncle affected by TOF, 2 probands have 
cousins with unspecified CHD, 1 proband has a brother with patent truncus arteriosus (PTA), 1 
proband has an aunt presenting complete situs inversus and the father of one of the probands has 
an unspecified CHD.  
 
There are no significant differences when allele frequencies are compared between probands and 
controls (p=0.77). See Table 31 for allele frequency of the variant in probands and controls and the 
p value calculated for the difference between them. 
 
 
Table 31. ROCK1 Thr773Ser allele frequencies and p value calculated for the genotype difference. 
 
3.3. Three exons of ROCK1 are duplicated on chromosome 18 and are 
possibly expressed 
 
Due to 100% heterozygosity of all SNPs located in exons 30-32 a search of the human segmental 
duplication database was performed identifying a duplication on chromosome 18. The probable 
source was located at 16774338..16793806 (ROCK1) and the target located at 102547..121692. 
The human genome clones in ROCK1 (AC021727, AC036178, AC131287, AC135340, AC139704) 
and the duplicated region (AP001005) were downloaded. The pseudogene was named as 
Q49AA3 in Ensembl release number 38. The resource DNA dot was used to identify the region 
overlapping between clones (181). See Figure 26. 
 
The regions identified as duplicated between clones were annealed using the mega 4 software 
(183) to define the limits of the duplications and differences between clones. The duplicated region 
comprises a total of 19413 bp. However, the region is not completely identical: a first stretch of 
sequence of 603 bp located at ROCK1 intron 29, with 97% identity, and 6 gaps is separated by a 
AT rich region from a second stretch of duplication of 18565 bp, 98% identical and with 87 gaps. 
The duplicated region ends 9391 bp downstream from the end of Rock1 exon 33. The pseudogene 
shows a calculated pairwise distance of 0.01 with ROCK1. 
 
 
Variant n MAF mAF n MAF mAF p value
Thr773Ser 458 0.98144 0.01856 1331 0.98272 0.01728 0.77
CHA probands HTO controls
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Figure 26. Dot plot for AC021727 and AP001005.  Each axis represents a DNA sequence. A dot is 
placed for each 3 base pair window of identity. Red arrow identifies the duplicated region. 
 
 
 
 
Figure 27. Schematic view of the relationship between ROCK1 and the duplication and their relative 
position in chromosome 18. In the upper part of the graph Exon 29-31 of ROCK1 are represented as 
yellow boxes. The blue box corresponds to an intronic region separated by an AT rich region, 
represented as a red box, from the stretch of exon 30-32 and a portion corresponding to the 5’end of 
the gene. Rock1 is orientated on the minus strand. 
  
AT rich region
Duplication
Chromosome 18
Exon 29 Exon 30 Exon 31 Exon 32
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Exonic regions were identified within the pseudogene (Q49AA3). Differences in exonic regions 
between ROCK1 and the duplication were identified. A region in exon 30 with 2 differences 
separated by 4bp was used to perform a BLAST search at the human genome EST database for 
the sequence corresponding to ROCK1 and Q49AA3. The difference in this region allowed 
differentiation between the products of the pseudogene and ROCK1.  Seven BLAST hits showed 
transcripts with sequences specific to the Q49AA3 pseudogene. The majority of RNA libraries 
where the transcript was identified were obtained from testis samples. Protein expression has not 
been documented.  
 
One variant initially thought to be a SNP, 3649 G>C, located in a codon translated into Serine in 
ROCK 1 exon 31, was detected to be a difference between ROCK1 and the pseudogene. The 
variant showed 100% heterozygotes in 93 TOF probands. To determine if the duplication was also 
present in all controls exon 31 was sequenced in 93 HTO controls. Heterozygosity was also 100% 
in this sample subset for 3649 G>C. 
 
3.4. Tagging SNP genotyping in ROCK1. Common genetic variation in 
ROCK1 is associated with TOF 
 
ROCK 1 common genetic variation was genotyped using the tagging strategy described in section 
2.6.1. Thirty seven SNPs located in the first 28 ROCK1 exons and 15Kb upstream (See Table 32) 
were captured genotyping 12 SNPs. As described in section 2.6.1, the Haploview 4.0 software was 
forced to include the previously described non synonymous SNPs rs2292296 (Leu1097Phe), 
rs2271255 (Lys222Glu) and rs45449301 (Ile432Val). Figure 28 shows a Haploview plot 
representing all SNPs in ROCK1 and their LD relationships.  
 
Genotyping was successful for at least 98% of the samples for all of the SNPs. The estimated 
genotype miscall rate was 1% for all of the SNPs. All 13 of the markers were in Hardy-Weinberg 
equilibrium at the 5% significance level. Table 33 shows genotype frequencies and counts for the 
population. The minor allele frequencies ranged from 0% to 46.0%, yielding marker 
heterozygosities from 0% to 46.8%. Allele frequencies were highly similar to previously published 
Hapmap data for CEU population, see Table 33. 
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Table 32. ROCK1 SNPs captured with the tagging strategy. mAF: minor allele frequency. 
 
SNP mAF
rs7234943 0.05
rs8089184 0.05
rs7244299 0.052
rs7237677 0.417
rs7227454 0.045
rs8085654 0.405
rs288989 0.442
rs394715 0.061
rs11877273 0.06
rs17202347 0.058
rs288980 0.442
rs7239317 0.058
rs288979 0.059
rs17202361 0.076
rs17202368 0.025
rs17202375 0.076
rs7238386 0.06
rs4800367 0.058
rs720109 0.058
rs4800118 0.05
rs4800119 0.05
rs9948357 0.056
rs10775457 0.058
rs2127958 0.433
rs1481280 0.375
rs12957846 0.058
rs10084016 0.058
rs7242932 0.058
rs7237099 0.058
rs1552110 0.058
rs8085504 0.058
rs11876799 0.058
rs1006881 0.058
rs11874761 0.05
rs398528 0.027
rs1275227 0.05
rs10083915 0.05
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Figure 28. LD plot showing all 34 SNPs included on the tagging analysis of ROCK1. Gray scales 
denotes R
2
 between markers. 
 
 
 
Table 33. Counts and allele frequencies for our population and Hapmap CEU data. Hom WT: 
Homozygotes wild type; Hom NWT: Homozygotes not wild type; mAF: minor allele frequencies; MAF: 
major allele frequencies; Het: Heterozygotes. 
  
SNP Genotypes Hom WT Heterozygotes Hom NWT mAF MAF Het mAF MAF
rs2292296 2238 2238 0 0 0.000 1.000 0.000 0.000 1.000
rs7237677 2220 819 1040 361 0.397 0.603 46.800 0.417 0.580
rs7227454 2208 1790 401 17 0.099 0.901 18.200 0.052 0.948
rs288989 2192 698 973 521 0.460 0.540 44.400 0.167 0.833
ROCK1 807 C>T 3026 2981 45 0 0.007 0.993 1.500 * *
rs45449301 2227 2226 1 0 0.000 1.000 0.000 0.025 0.975
rs288979 2225 2045 167 13 0.043 0.957 7.500 0.059 0.941
rs17202368 2074 1993 79 2 0.020 0.980 3.800 0.025 0.975
rs17202375 2099 1809 278 12 0.072 0.928 13.200 0.076 0.924
rs2271255 2223 2222 1 0 0.000 1.000 0.000 0.000 1.000
rs1481280 2220 901 988 331 0.372 0.628 44.500 0.364 0.636
rs8085504 2228 2061 161 6 0.039 0.961 7.200 0.058 0.942
rs398528 2243 2137 105 1 0.024 0.976 4.700 0.973 0.027
Experimental population Hapmap CEU
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The three non-synonymous SNPs included in the genotyping showed very low frequencies at our 
population, similar to previous Hapmap CEU data. Rs2292296 was not found in the population. 
Rs45449301 and rs2271255 were found only in one heterozygote control.  
 
Correlation between our SNPs was, as expected, modest. Figure 29 shows linkage disequilibrium 
relationships between the typed SNPs. Seven haplotype blocks containing all SNPs in ROCK1, 
defined using the four gamete rule (189), with frequencies of more than 1%, account for more than 
95% of genetic variation within the population. Haplotype blocks included 9 SNPs:  rs7227454, 807 
C>T, rs288979, rs288989 rs17202368, rs17202375, rs1481280, rs8085504 and rs398528. 
Common haplotype composition and frequencies were in close agreement to those described in 
previous published Hapmap CEU data. Haplotype composition and frequencies are detailed in 
Table 35. 
 
There was no evidence of strong linkage disequilibrium between any of the tagged SNPs and 807 
C>T. Table 34 show LD values between 807 C>T and the tagged SNPs. Tests using LAMP 
software showed no evidence for linked variants explaining the association found between 807 
C>T and TOF. 
 
 
Figure 29. SNPs genotyped (mAF>0.001) and relationships between them. The linkage disequilibrium 
relationships between SNPs are represented by Haploview triangle plots; darker small squares 
denote higher linkage disequilibrium (represented by r2), and the numbers in the small squares show 
the significant pairwise D_ values derived from the present study. Haplotype block is delimited by a 
line, and designed as Block 1. 
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Table 34. Quantified linkage disequilibrium for our population between the tagged SNPs (mAF<0.001 
not included) and 807 C>T. LD is expressed as R-square 
 
 
Figure 30. Comparison of the proportion of genotypes, for ROCK1 807 C>T between TOF patients 
and controls. Allele frequencies show a significant difference (p=0.000019) between probands and 
controls. 
 
 
 
 
SNP r-square
rs7237677 0,012
rs7227454 0,001
rs288989 0.001
rs288979 0,000
rs17202368 0,002
rs17202375 0,001
rs1481280 0,008
rs8085504 0,000
rs398528 0,000
N= 1908
N= 12
N= 1073
N= 33
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Table 35. Common Haplotypes (Frequency >1%) for ROCK1 within our research population. 
Genotypes are specified for the following SNPs: rs7227454, 807 C>T, rs288989, rs288979, 
rs17202368, rs17202375, rs1481280, rs8085504 and rs398528. 
 
 
Table 36. Chi square p values for association between common haplotypes and TOF. 
 
Association analysis, using Chi square tests, for the common Haplotypes found in the population 
showed no association between blocks and TOF.  Table 36 shows common Haplotypes and 
calculated p values. 
 
In the allele frequencies analysis with LAMP software, an association between rs288979 and 
Tetralogy of Fallot (p=0.000015) was found. Rs288979 is an intronic uncommon SNP (mAF= 
0.043) located in ROCK1 intron 9, at 8189 bp from exon8/Intron boundary. Case/control ratios 
encountered were: AA: 1666/395 AC: 121/40 CC: 3/3. See Figure 31 for a graphical comparison of 
genotype frequencies. The minor allele (C) confers a protective effect with a calculated OR of 
0.6127 (95% CI: 0.434-0.866) for TOF. In silico analysis of the variant showed no evidence of 
splicing changes associated with it. This association was still significant after correction with 
Qvalue for multiple testing (12 SNPs), using a 5% false discovery rate level.  
 
There was no evidence for linkage between rs288979 and the other tagged SNPs and tests using 
LAMP software showed no evidence for linked variants explaining the association found. 
Rs288979 is not in linkage disequilibrium with ROCK1 807 C>T. Only one proband carrying 
ROCK1 807C>T also carries the allele C of rs288979 in the heterozygote state. No other 
significant association was found between any of the variants and TOF. Table 37 shows the p 
value calculated using LAMP for the differences between cases and controls in allele frequencies 
for each SNP genotyped. 
 
Haplotype Frequency
GAGAGAGCA 0.468
GTGAGAACA 0.180
GTGAGAGCA 0.128
TTGAGAACA 0.098
GTGAGCACA 0.074
GTGCGAGAT 0.019
GTGCAAGAA 0.019
Haplotype p value
GAGAGAGCA 0.3925
GTGAGAACA 0.2666
GTGAGAGCA 0.6174
TTGAGAACA 0.037
GTGAGCACA 0.4239
GTGCGAGAT 0.2762
GTGCAAGAA 0.272
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Table 37. Calculated p value for a model comparing the null hypothesis of no association with 
association models for the tagged genotyped SNPs. 
 
 
Figure 31. Bar plot comparing genotype frequencies for rs288979. Yellow bars represent control 
subjects and blue bars TOF subjects.  
 
  
SNP p value
rs7237677 0,690000
rs7227454 0,230000
rs288989 0,151600
rs288979 0,000015
rs17202368 0,390000
rs17202375 0,530000
rs1481280 0,119000
rs8085504 0,116000
rs398528 0,240000
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3.5. DISCUSSION 
 
To our knowledge this is the first study to examine common and uncommon genetic variation at 
ROCK1 and TOF. Also, our sample is the largest reported and the only thus far with sufficient 
power to explore genetic variation and its relationship with non-syndromic TOF. 
 
It would be expected that the loss or decrease of function in ROCK1 would be associated with 
cardiac malformations, as illustrated by previous experimental data showing expression of the 
protein during cardiogenesis (121, 126) and regulatory functions of the protein in convergent 
extension movements in Xenopus, Drosophila and C. Elegans (128, 129). In 2002 Zhao and cols 
published a paper showing that inhibition of Rho kinases with Y27632 on cultured murine embryos 
causes failure in chamber septation, heart looping and cardiac cushion proliferation (131). His 
group also showed that Rho kinases are expressed throughout cardiogenesis, data in accordance 
to the work published by Wei and cols (126). However, ROCK1 knockout mice do not show cardiac 
phenotype (133), showing perhaps the functional overlapping between ROCK1 and 2. 
 
Three previously undescribed variants were found at ROCK1. The first one 807 C>T is a 
synonymous variant located at exon 7, at a codon translating into Leucine. Despite the variant not 
being located at consensus splice sites, automated splice analysis showed that the minor allele 
may decrease the splicing acceptor site strength and causes disappearance of a Srp40 binding 
site. The variant is uncommon, with a minor allele frequency of 0.7% in the population (n= 3026, 
cases frequency: 1.5%; controls frequency: 0.3%). Allele frequencies are significantly different 
between cases and controls (p=0.000019), and the minor allele confers an OR of 4.89 for >TOF. 
Qualitative analysis of families carrying the variant showed no evidence of higher incidence of 
cardiac or other congenital defects compared to other proband families not carrying the variant. 
Also, genotyped parents carrying the variant did not show abnormal cardiac phenotype. 
 
However, in our splicing experimental model the variant does not cause aberrations, leading to the 
possibility of 807 C>T being linked to a different and unknown causal variant or causing its effects 
via different mechanism like quantitative changes in expression levels. At the initial mutational 
screening (n=93), I did not encounter any other uncommon variant in ROCK1 or in any other of the 
screened genes, to be linked to 807 C>T. Nevertheless, the mutational screening sample size 
would be insufficient to detect variants with allele frequencies of roughly less than 1/186. 
 
To explore the hypothesis that the association between 807C>T is due to a linked variant, a 
tagging strategy (190) was designed to capture genetic variation within the gene and linkage 
disequilibrium relationships between markers. Previously described missense SNPs were forced to 
be included. Previously described missense SNPs were practically absent in our sample.  
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No evidence of LD was found between 807 C>T and the other markers, no haplotype was 
associated with TOF and remarkably another intronic common variant (mAF: 0.051) showed 
association with TOF. Rs288979 is significantly associated with TOF (p=0.000015) and its minor 
allele confers a protective effect with an OR of 0.61. In silico analysis of 807 C>T did not showed a 
functional splicing explanation for the association. Again, as in the association for 807 C>T, there 
is neither a linked variant to explain an indirect association and further work is necessary to 
elucidate the mechanism underlying the association found. 
 
The two relatively uncommon variants are associated with TOF may be considered “low frequency 
intermediate penetrance” variants. However it would be also expected that these variants would be 
subjected to purifying selection in the population depending on their risk association (11, 22). In 
this respect the two variants differ in a way: whereas rs288979 confers a near to “expected” 
modest protective effect (OR= 0.61), the variant 807 C>T confers a high risk to suffer TOF (OR= 
4.89). This high risk associated with the variant would make the purifying selection, that the SNP is 
subjected to, greater than mild and its frequency would accordingly be (without an extraordinary 
mutation rate) very low as we found (191). 
 
Purifying selection in non-syndromic TOF sufferers has been greatly influenced by modern surgical 
therapy. About 86% of TOF affected individuals  survive beyond 30 years (59). Supposing a 
hypothetical model where TOF predisposing variants would only be deleterious due to the 
increased probability of cardiac malformation, natural selection over the variants would be greatly 
decreased by successful cardiac surgery and even highly deleterious variants might reach 
detectable levels at the population. Nevertheless, the number of generations after the development 
of successful surgical techniques is low and even if the fitness of TOF patients is close to 1, not 
taking into account an improbable selective advantage, the only quantifiable effect may be the 
maintenance of the allele frequencies dependent on the mutation rates. In a sort of mixture 
between common and uncommon variant theory, decrease of natural selection forces could make 
the TOF population a group of individuals where common and uncommon predisposing variants 
coexist.   
 
The effect size for rare variants is predicted by theory to be larger than that for commoner variants. 
If mAF frequencies are examined, 807 C>T is almost sevenfold less common than rs288979, 
frequencies are inversely related to the effect conferred by each one of them (807 C>T= 4.89; 
rs288979= 0.61). 
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Functional mechanisms were explored for 807C>T with the hypothesis that (due the findings of the 
in silico analysis and being a variant predicted to be synonymous) the most likely functional 
explanation for the association was a splicing change. However, the minigene did not show 
splicing changes associated with the variant. A functional explanation for the association with 
rs288979 is also yet to be found, the most likely mechanism, due to its intronic location, also an 
influence over splicing. A negative minigene experiment, however, does not discard the hypothesis 
of the variant exerting its influence through splicing changes.  
 
With the premise that the rs288979 also influences splicing, a minigene model for the variant as a 
starting point is needed. However, to confirm or discard this idea with  807C>T either a direct RT 
PCR amplification of RNA from a subject carrying the variant, sample type that was not available, 
or the expression of a bigger construct, perhaps the complete gene, in a mammalian cell line with 
quantitative and qualitative analysis of RNA would be required to give the definite answer. 
Additionally, the variants might also influence the rate of expression of ROCK1. The previously 
described experiments with abundance quantification of ROCK1 RNA might clarify that hypothesis.   
 
In the case of indirect association being the cause of the associations found, future work should 
explore both common and uncommon genetic variation to discover causative alleles. First, 
mutational screening of the pathway, involving multiple genes or even complete genomes/exomes 
in bigger samples using next generation sequencing platforms could unravel uncommon genetic 
variants associated and not detected in our mutational screening.  
 
Even if a functional explanation for the associations found is discovered, they would only account 
for a small fraction of the heritability of the trait.  Systematic approaches that are recently feasible 
utilising the increased understanding of human genetic variation anticipated to come from the 1000 
genomes project, the increasing capacity of genotyping chips to incorporate intermediate-
frequency (0.5% to 5%) variants, and next-generation resequencing studies for rarer variants, will 
be required to identify the remaining heritability of the trait. 
 
3.6. CONCLUSIONS 
 
I found that common and uncommon genetic variation at ROCK1 is associated with TOF in 
Caucasian subjects.  Three previously undescribed uncommon variants were encountered in the 
sample. One of the newly described uncommon variants, 807 C>T, a synonymous SNP, is 
significantly associated with TOF. 807 C>T confers an OR of 4.5 for TOF. Splicing functional data 
did not give an explanation for the association found. A tagging strategy was adopted to explore 
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the possibility of 807C>T being linked to another variant. No variant was found to be linked to 
807C>T.  
 
Another association was encountered between rs288979, an intronic SNP, and TOF. In silico 
analysis of the variant did not show splicing aberrations associated with the variant. Rs288979 
confers an OR of 0.61 for TOF. Despite the low likelihood of a protective effect being exerted by a 
relatively uncommon variant, this is not the only explanation possible for the OR found. Natural 
selection or indirect associations can explain the decreased number of TOF probands carrying the 
variant.  
 
In conclusion one uncommon synonymous SNP and a relatively uncommon intronic SNP located 
at ROCK1 are associated with TOF. No functional explanation was found for direct or indirect 
association with the variants. It remains a question if whether the associations found cause splicing 
changes not detected by the experimental means used or are explained by linkage disequilibrium 
with undetected uncommon variants. The fact that two variants are significantly associated with 
TOF, neither of which were in significant LD with each other, independently confirm that there is an 
association of ROCK1 with TOF.   Due that the strongest a animal model, the ROCK1 KO mouse, 
does not show a cardiac phenotype is unlikely that isolated genetic variation at ROCK1 can be 
responsible for the predisposition to TOF 
 
This study represents the first large sample to explore genetic variation at ROCK1 in association 
with TOF. Further work is needed to elucidate the functional implications of the associations found. 
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4. ANKRD6 AND WNT11 
 
4.1 ANKRD6 
 
4.1.1. Previously undescribed uncommon variants 
 
Sequences of 16 exons, including the 5’ UTR region, were obtained for ANKRD6 in 93 CHANGE 
probands. A total of 2490 bp were screened using methods described in section 2.2.  Two 
previously undescribed uncommon variants were encountered at ANKRD6. See Table 38. 
 
 
Table 38. ANKRD6 Previously undescribed uncommon variants. AA: Aminoacid; NS: Non 
synonymous; L: Leucine; F: Phenylalanine; N: Asparagine; T: Threonine. 
 
4.1.1.1. ANKRD6 1-304 G>A 
The first novel variant found was a single base substitution (A/G) in the ANKRD6 5’ UTR region, 
position 1 -304. The variant was found in a single CHANGE proband at the initial mutational 
screening. See Figure 32 for the ABI sequencer traces from the carrier and a proband not carrying 
the variant. 
 
In silico analysis of the variant using the web resource NSITE (192) to identify regulatory motifs in 
the sequence revealed that despite being located at the 5’ UTR the variant is not located at any 
known regulatory motif. It was not possible to determine if the variant was inherited or de novo, as 
we had no DNA sample from either mother or father. Neither of the parents presented an abnormal 
cardiac phenotype.  
 
 
Exon Variant Alleles Function AA
1 1 -304 A>G A/G UTR (-304)
7 Leu192Phe C/T NS L/F
7 Thr176Asp C>A NS T/N
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Figure 32. ANKRD6 1-304 G>A variant trace display. Upper and medium panel show patient 
sequence, bottom shows a normal trace. 
 
4.1.1.2 ANKRD6 1-304 G>A is present in controls 
A total of 1744 genotypes were obtained from cases and controls using the Sequenom platform 
and the methods described at 2.3.2. . The estimated genotype miscall rate was less than 1% for 
the SNP. 1- 304 G>A was in Hardy-Weinberg equilibrium at the 5% significance level for the global 
population and for each of the subpopulations. Genotyping was successful for 98% of the samples. 
 
Five heterozygotes were found in both populations: probands and controls. I did not find a 
significant difference at genotype or allele frequencies between cases and controls for ANKRD6 1- 
304 G>A (Chi-squared [1df] = 0.052; p= 0.061). For allele counts and genotype frequencies see 
Table 39.  
 
  
Table 39. Genotype counts and allele frequencies for ANKRD6 1-304 G>A. MAF: Major allele 
frequency, mAF: minor allele frequency 
 
 
  
G/G G/A A/A MAF mAF
Probands 411 5 0 0.9940 0.0060
Controls 1323 5 0 0.9981 0.0019
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4.1.1.3. ANKRD6 Leu192Phe 
The second novel variant found was a single base substitution (C/T) in ANKRD6 exon 7, producing 
a change from Leucine to Phenylalanine at codon number 192.  This change from a non-polar 
aminoacid to a similar non-polar one is located at the end of the ankirin repeats domain, which is 
the described functional domain of the protein. In silico analysis of the variant using the web based 
resource Polyphen did not indicate that it is structurally damaging. The variant was originally 
encountered in a single CHANGE proband in the heterozygous state. Figure 33. shows ABI 
sequencer traces for the wild type allele and the variant 
 
It was not possible to determine if Leu192Phe was inherited or de novo, as we had no DNA 
sample from either mother or father. Apparently neither of the parents presented an abnormal 
cardiac phenotype.  
 
 
Figure 33. ABI sequencer traces for Leu192Phe. Upper panel shows the variant carrier and the 
bottom one am homozygous wild type subject. 
 
4.1.1.4. ANKRD6 Leu192Phe is present in controls 
A total of 2779 genotypes, in 1062 TOF probands (CHANGE, Oxford, Nottingham and CONCOR) 
and 1718 controls (ECACC and HTO), were obtained using the Sequenom platform and the 
methods described at 2.3.2. Genotyping was successful for 98% of the samples. The estimated 
genotype miscall rate was less than 1% for the SNP. Leu192Phe was in Hardy-Weinberg 
equilibrium at the 5% significance level for the global population and for each of the 
subpopulations. 
 
A total of 2 heterozygotes were found in the population, with one heterozygote found in both 
populations: probands and controls. I did not find a significant difference in genotype or allele 
frequencies between cases and controls for ANKRD6 Leu192Phe (Chi square: 1.737, p value: 
0.41). For allele counts and genotype frequencies see Table 40. No sample was available from 
parents of the control subject carrying the variant. 
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Table 40. Genotype counts and allele frequencies for ANKRD6 Leu192Phe. MAF: Major allele 
frequency, mAF: minor allele frequency 
 
4.3.1.5. ANKRD6 Thr176Asp 
The third uncommon variant found was a single base substitution (C>A) in ANKRD6 exon 7, 
producing a change from Threonine to Asparagine at codon number 176.  The change from a polar 
aminoacid to a similar polar one is located in the ankirin repeats domain, which is the described 
functional domain of the protein. In silico analysis of the variant using the web based resource 
Polyphen indicated that the variant might be structurally damaging. The variant was originally 
encountered in a single CHANGE proband in the heterozygous state. Figure 34 shows ABI 
sequencer traces for the wild type allele and the variant. 
 
Sequences of exon 7 on the parents of the proband carrying the variant revealed that it was 
maternally inherited. The mother carrying the variant does not have an abnormal cardiac 
phenotype. Figure 34 below shows the sequencer traces for the parents. There was no family 
history of CCM among the family of the carrier. 
 
 
Figure 34. ABI sequencer traces for ANKRD6 Thr176Asp. Upper and medium panels show the variant 
carrier and the bottom one a homozygous wild type subject. 
 
C/C C/T T/T MAF mAF
Probands 1060 1 1 0.9995 0.0005
Controls 1717 1 0 0.9997 0.0003
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Figure 35. ABI sequencer traces for ANKRD6 Thr176Asp in the parents of the carrier. Upper panel 
shows mother’s sequence. Bottom panel shows father’s sequence. 
 
4.3.1.6. ANKRD6 Thr176Asp is present in controls 
One thousand six hundred and fifty two genotypes were obtained from CHANGE TOF probands 
(N=459) and HTO controls (N=1193) using the Sequenom platform and the methods described at 
2.3.2. Genotyping was successful for more than 95% of the samples. The estimated genotype 
miscall rate was less than 1% for the SNP. Thr176Asp was in Hardy-Weinberg equilibrium at the 
5% significance level for the global population and for each of the subpopulations. 
 
Three heterozygotes were found at the population, with one heterozygote found among the TOF 
probands and 2 among the controls. I did not find a significant difference at genotype or allele 
frequencies between cases and controls for ANKRD6 Thr176Asp (Fisher exact test p value: 
0.624). Allele counts and genotype frequencies are shown at Table 41.  
 
 
Table 41. Genotype counts and allele frequencies for ANKRD6 Thr176Asp. MAF: Major allele 
frequency, mAF: minor allele frequency. 
 
4.1.2. Previously unreported common variants 
 
One previously undescribed common variant was encountered in the mutational screening of the 
first 93 CHANGE probands. 
C/C C/T T/T MAF mAF
Probands 458 1 0 0.9989 0.0011
Controls 1191 2 0 0.9992 0.0008
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4.1.2.1. ANKRD6 Phe636Leu 
The common variant found was a single base substitution (C/T) in ANKRD6 exon 16.  The variant 
produces a change from phenylalanine to leucine at residue 636. The change from a non-polar 
aminoacid to a similar non-polar one is not located in conserved domains on the protein sequence. 
However, in silico analysis of the variant using the web based resource Polyphen indicated that the 
variant is probably structurally damaging. Additional in silico analysis showed that it probably does 
not produce splicing changes. The residue has not been reported as functionally essential. 
 
The variant was originally encountered in 21 heterozygotes and 1 homozygote of the CHANGE 
proband population (N=93). Figure 36 shows ABI sequencer traces for the wild type allele and the 
variant. 
 
 
Figure 36. ABI sequencer traces for ANKRD6 Phe636Leu. Upper and medium panels show the variant 
and the bottom one a homozygous wild type subject. 
 
4.1.2.2. ANKRD6 Phe636Leu is present in controls 
One thousand seven hundred and fifty eight genotypes were obtained from CHANGE TOF 
probands (N=442) and HTO controls (N=1316) using the Sequenom platform and the methods 
described at 2.3.2. Given the number of cases and controls and minor genotype number, power 
was calculated as 100% for a general case-control analysis, to detect a relative risk of 2 for 
heterozygotes and supposing an alpha error of 0.05. Genotyping was successful for more than 
98% of the samples. The estimated genotype miscall rate was less than 1% for the SNP. 
Phe636Leu was in Hardy-Weinberg equilibrium at the 5% significance level for the global 
population and for each of the subpopulations. 
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Three hundred and eighty three heterozygotes were found in the population. A significant 
difference was found in genotype frequencies between cases and controls for ANKRD6 
Phe636Leu (Chi square: 8.51, p value: 0.014). However, after correcting using q value for multiple 
testing the result was not significant at a 0.05 cutoff (q value: 0.11). Allele frequencies and 
genotype counts are shown at Table 42.  
 
Increasing the sample, including Oxford, Nottingham and CONCOR probands, and ECACC 
controls, to 1686 controls and 1041 cases showed no association between Phe636Leu and TOF 
(Chi square: 5.41, P value: 0.067). For allele frequencies and genotype counts see table 6. 
  
 
Table 42. Genotype counts and allele frequencies for ANKRD6 Phe636Leu. MAF: Major allele 
frequency, mAF: minor allele frequency. 
 
 
Tabla 43. Genotype counts and allele frequencies for ANKRD6 Phe636Leu including CHA, Oxford, 
Nottingham and CONCOR probands, and ECACC and HTO controls. MAF: Major allele frequency, 
mAF: minor allele frequency. 
 
4.1.3. Common previously described variants 
 
A total of nine previously described SNPs were encountered in the mutational screening on 93 
TOF CHANGE probands. Most of them were in Hardy Weinberg equilibrium and showed no 
significant differences in allele frequencies when compared to previously reported data on 
Caucasian populations (CEU population at Hapmap). For a table showing all SNPs, their minor 
and major allele frequencies, and their p values for fit to the Hardy Weinberg equilibrium, and for 
comparisons to the published CEU Hapmap data (N=90) see Table 44. 
 
Three common previously described variants at ANKRD6 were genotyped in the control population 
and the total of available CHANGE samples due to their lack of Hardy Weinberg equilibrium and 
also the lack of previous published allele frequencies data: rs2273238, rs9344950 and rs9353687.  
 
One thousand seven hundred and ninety eight genotypes were obtained from CHANGE TOF 
probands (N=453) and HTO controls (N=1345) for rs2273238; 1769 for rs9344950 (Probands: 455, 
controls: 1314) and 1772 (Probands: 449, controls: 1323) for rs935368, using the Sequenom 
C/C C/T T/T MAF mAF
Probands 315 118 9 0.8462 0.1538
Controls 1026 265 25 0.8803 0.1197
C/C C/T T/T MAF mAF
Probands 766 258 17 0.8598 0.1402
Controls 1686 354 32 0.8991 0.1009
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platform and the methods described at 2.3.2. Power was calculated as 100% for all 3 SNPs, using 
a general case-control analysis, to detect a relative risk of 2 for heterozygotes and supposing an 
alpha error of 0.05. Genotyping was successful for more than 98% of the samples. The estimated 
genotype miscall rate was less than 1% for the SNP. Rs2273238, rs9344950 and rs9353687 were 
in Hardy-Weinberg equilibrium at the 5% significance level for the global population and for each of 
the subpopulations. 
 
 
Table 44. Previously described SNPs in ANKRD6, Allele frequencies (N=93) and p values for Hardy 
Weinberg equilibrium and for comparisons with previous published data for Caucasian population 
when available. AA: Amino acid; mAF: minor allele frequency; MAF: major allele frequency; HW: 
Hardy Weinberg; p value comp: Chi square p value when compared with previous data; Int: Intronic; 
NS: Non synonymous; S: Synonymous;  NT3’: Non translated 3’. 
 
For the SNPs rs2273238 and rs9344950 no significant allele frequency differences were 
encountered in our sample. In the case of rs9353687 a significant difference was found between 
cases and controls (Chi square: 6.48, p value: 0.039). However, after correcting for multiple testing 
the result was not significant at a 0.05 cutoff (q value: 0.182). Allele counts and genotype 
frequencies are shown in Table 45. 
 
Increasing the number of genotyped samples for rs9353687 to 2740 including Oxford, Nottingham 
and CONCOR cases, and ECACC controls (Probands: 1016, controls: 1694), completely 
abolished the association (Chi square: 1.13, p value: 0.56). For genotype counts and allele 
frequencies see Table 46. 
 
 
Table 45. Common ANKRD6 SNPs genotyped at a control population. Hom WT: Homozygotes wild 
type; Het: Heterozygotes; Hom N WT: Homozygotes non wild type. 
 
 
SNP Function AA mAF MAF HW p value P value comp
rs10944453 Int 0.2000 0.8000 0.9800 0.6800
rs16881983 NS 122(Q/E) 0.0100 0.9900 0.9900 0.6800
rs3748085 NS 128(I/V) 0.1400 0.8600 0.8100 0.8100
rs1179906 Int 0.1400 0.8600 0.9700 0.0680
rs2273238 NS 233(T/M) 0.0400 0.9600 0.0510 NI
rs17292811 S 0.2200 0.7800 0.9600 0.9400
rs9344950 NT 3' 0.0400 0.9600 0.0000 NI
rs9353687 S C 0.1279 0.8721 0.0432 NI
rs3210511 S S 0.4505 0.5495 0.9754 0.4832
Hom WT Het Hom N WT Hom WT Het Hom N WT Chi square p value
rs2273238 1245 99 1 423 29 1 1.15 0.573
rs9344950 916 363 35 337 105 13 3.59 0.16
rs9353687 914 373 36 337 99 13 6.48 0.039
Probands Controls
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Table 46. Genotype counts and allele frequencies for rs9353687. CHANGE, Oxford, Nottingham and 
CONCOR cases included. HTO and ECACC controls included. MAF: Major allele frequency, mAF: 
minor allele frequency. 
 
Rs9353687 is a single base change (C>T) located at exon 11 of ANKRD6. The SNP is 
synonymous and is located at a residue coding for cysteine (Residue number 506) in the 
conserved ankirin repeat domain. In silico analysis of the SNP sequence showed that it probably 
does not produce splicing changes. 
 
 
 
 
  
C/C C/T T/T MAF mAF
Probands 740 276 30 0.8394 0.1606
Controls 1171 478 45 0.8323 0.1677
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4.2. WNT11 
 
4.2.1. Previously unreported uncommon variants 
 
Sequences of 4 exons, including the 5’ UTR region, were obtained for WNT11 in 93 CHANGE 
probands. Eight hundred and eighty five bp were screened using methods described in section 2.2.  
Two previously undescribed uncommon variants were discovered. See Table 47 
 
 
Table 47. WNT11 Previously undescribed uncommon variants. Both variants were intronic and 
located in the flanking regions included in the mutational screening. 
 
 
Figure 37. Schematic view of the location of the novel uncommon variants in Wnt11. Transcribed 
exons are depicted in yellow. Red boxes represent untranslated regions. Both variants are marked in 
blue. 
 
4.2.1.1. WNT 11 207 +47 G>T 
The first uncommon variant found was a single base substitution (G/T) at WNT11 intron 1, position 
207 +47. The variant was found in a single CHANGE proband in heterozygote state at the initial 
mutational screening. See Figure 38 for the ABI sequencer traces from the carrier and a proband 
not carrying the variant. 
 
This single base change is not in the consensus splice sequence, however computational analysis 
of the variant with spliceview suggested that the variant decreases the strength of the donor site at 
the end of exon 1 and produces disappearance of two splicing modulator binding sites located at 
its position: SC35 and SF2. 207 +47 G>T is located at an Intron within the WNT11 superfamily 
conserved domain of the protein, which increases the probability of functional alterations if this 
mutation causes splicing defects. 
Variant Alleles Function
207+ 47 G>T G/T INT
720 +6 C>T C/T INT
Exon 3Exon 2 Exon 4Exon 1 Exon 5
207 +47 G>T 720 +6 C>T
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Sequenom genotyping of parents of the proband carrying the variant showed that it was paternally 
inherited (For methods see section 2.3.2). The father carrying the variant does not show an 
abnormal cardiac phenotype. There was no history of CCM in the family carrying the variant.  
 
 
Figure 38. ABI sequencer traces for WNT11 207 +47 G>T. Upper and medium panels show the variant 
and the bottom one a homozygous wild type subject. 
 
4.2.1.2. WNT 11 207 +47 G>T is not present in controls 
A total of 1674 control genotypes from HTO and ECACC samples and 931 TOF proband 
genotypes (CHANGE, CONCOR, Oxford and Nottingham) were obtained for WNT 11 207 +47 
G>T using a Mass extend Sequenom experiment (For methods see section 2.3.2), to check for the 
presence of the variant in controls. Genotyping was successful for 98% of the samples. The 
estimated genotype miscall rate was 1% for the SNP.  
 
Nine TOF probands among CHANGE, Oxford, Nottingham and CONCOR populations were found 
to be carrying the 207 +47 G>T variant, none of the HTO or ECACC controls. The frequency 
difference between cases and controls reached significant levels (Fisher p value: 0.00009) 
 
 4.2.1.3. WNT 11 207 +47 G>T does not cause splicing changes 
Despite the intronic location of the 207 +47 G>T mutation, the positive results from in silico splicing 
analysis and the significant difference in allele frequency between cases and the control population 
prompted me to carry on further functional investigation of this variant.  
 
A minigene including WNT11 exon 1 and Intron 1 was constructed following the methods 
described in section 2.5.1. The minigene was expressed in HEK 293 cells following the methods 
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described in section 2.5.2.  Qualitative analysis on agarose gels of RT-PCR products, from total 
mRNA, using specific primers for the minigene showed no difference in splicing (transcript length 
and number) when mutant allele constructs were compared to wild type. See Figure 39. The bands 
correspond to the mature mRNA transcribed from the Pxj41+ WNT11 (Exon 1+Intron 1 207 +47 
G>T) wild type and Pxj41+Wnt11 (Exon 1+Intron 1) carrying the variant. See Figure 21 for a 
graphical explanation of the minigene experiment. 
 
Sequencing of RT-PCR product for both minigenes, wild type and WNT11 207 +47 G>T variant 
showed complete identity, with splicing taking place at the same donor and acceptor sites. 
 
 
Figure 39. Agarose gel showing the RT-PCR product for minigenes carrying (M=mutant) and not 
carrying (WT=wild type) the WNT11 207 +47 G>T variant. Both lines show the expected length of 
mRNA including rabbit beta globin exons 2 and 3, and human Wnt11 exon 1 (467bp) 
 
4.2.1.4. WNT 11 720 +6 C>T 
The second uncommon variant encountered was a single base substitution (C/T) at WNT11 intron 
3, position 720 +6. The variant was found in a single CHANGE proband in homozygote state at the 
initial mutational screening. See Figure 40 for the ABI sequencer traces from the carrier and a 
proband not carrying the variant. 
 
This single base variant is not located at known consensus splice sequences. In silico analysis of 
the variant using ESEfinder and SpliceView showed that the variant does not decrease the 
strength of acceptor and donor splicing sites and is not located at known modulator sequence 
motifs.  WNT 11 720 +6 C>T is not located at known conserved domains within the protein. 
  
500 bp
300 bp
100 bp
M WT
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Genotyping of parents of the proband carrying the variant was performed using a Sequenom 
experiment (For methods see section 2.3.2) Despite the proband carrying the variant being a 
homozygote, only the mother was detected to be carrying the variant, with the father showing an 
homozygous wild type genotype. Due to the results obtained on the control genotyping, which 
showed the variant to be present in the control population, no further investigation was made for 
this SNP. The finding was interpreted as a possible case of non-paternity although a deletion in the 
father could not be ruled out. The proband carrying the variant did not show other associated 
conditions and there was no family history of CCM or other inherited conditions. 
 
 
Figure 40. ABI sequencer traces for WNT11 720 +6 C>T. Upper panel show the variant (homozygote) 
and the bottom one a homozygous wild type subject. 
 
4.2.1.5. WNT 11 720 +6 C>T is present in controls 
A total of 1339 control genotypes from HTO samples and 458 CHANGE TOF proband genotypes 
were obtained for WNT 11 720 +6 C>T using a Mass extend Sequenom experiment (For methods 
see section 2.3.2).  
 
Genotyping was successful for more than 98% of the samples. The estimated genotype miscall 
rate was less than 1% for the SNP. Hardy-Weinberg analysis at the total population and each of 
the subgroups showed that 720 +6 C>T was in equilibrium at the 5% significance level for both the 
total and the subgroups. 
 
Twelve heterozygotes were found in the population. Strikingly, the only homozygote encountered 
was the initial proband detected to be carrying the variant. I did not find a significant difference in 
genotype or allele frequencies between cases and controls for WNT 11 720 +6 C>T (Chi square: 
0.392; p value: 0.531). Although the intention of control genotyping was to test for the presence of 
the variant in controls power was calculated as 25% for a general case-control analysis, to detect a 
relative risk of 2 for heterozygotes and supposing an alpha error of 0.05. Approximately 2200 TOF 
cases would be needed to obtain 80% power. Allele counts and genotype frequencies are shown 
in Table 48. 
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Table 48. Genotype counts and allele frequencies for WNT 11 720 +6 C>T. MAF: Major allele 
frequency, mAF: minor allele frequency. 
 
4.3. DISCUSSION 
 
4.3.1. Summary of ANKRD6 variants 
 
Three previously undescribed uncommon variants were found at ANKRD6 in the screening of 93 
CHANGE TOF probands. The first uncommon variant found, 1-304 G>A, was a single base 
substitution (A/G) at ANKRD6 5’ UTR region. It was impossible to determine if the variant was de 
novo. The variant was not located at known cis regulatory motifs. There was no allele frequency 
differences between TOF cases and controls for ANKRD6 1-304 G>A. 
 
The second uncommon variant found at ANKRD6 was a single base substitution (C/T) at ANKRD6 
exon 7, producing a change from Leucine to Phenylalanine at codon number 192. It was 
impossible to determine if the variant was de novo. Phe192Leu is located at the Ankirin repeats 
domain of the protein. In silico analysis of the variant did not indicate that it is structurally 
damaging. There was no allele frequency difference between TOF cases and controls at 
Leu192Phe. 
 
The third uncommon variant found was a single base substitution (C>A) at ANKRD6 exon 7, 
producing a change from Threonine to Asparagine at codon number 176. Thr176Asp in silico 
analysis showed that the variant might be structurally damaging. The variant was maternally 
inherited.  I did not detect allele or genotype frequencies differences between TOF cases and 
controls. Since all these three variants could be demonstrated to be present in controls, they were 
given a low priority for functional investigation. 
 
One previously undescribed common variant was encountered at ANKRD6. The variant is a single 
base substitution (C/T) at ANKRD6 exon 16 producing a change from phenylalanine to leucine at 
residue 636. Phe636Leu in silico analysis showed that the variant might be structurally damaging 
and probably does not cause splicing changes. Although a nominally significant difference was 
demonstrated in genotype frequencies between cases and controls for ANKRD6 Phe636Leu (Chi 
C/C C/T T/T MAF mAF
Probands 454 4 1 0.9935 0.0065
Controls 1331 8 0 0.9970 0.0030
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square: 8.51, p value: 0.014) q value correction for multiple tests deemed the association not 
significant and increasing the sample to 1686 probands and 1041 controls did not confirm the 
association. 
 
Three previously described common variants (rs2273238, rs9344950 and rs9353687) were 
genotyped in the total of available CHANGE TOF samples and HTO control samples. For the 
SNPs rs2273238 and rs9344950 no significant allele frequency differences between cases and 
controls were encountered. Significant genotype frequencies differences were encountered for 
rs9353687 (Chi square: 6.48, p value: 0.039). However, after correcting for multiple testing the 
result was not significant at a 0.05 cutoff (q value: 0.182). Moreover, increasing the number of 
genotypes to 1694 controls and 1046 probands did not confirm the association (Chi square: 1.13, p 
value: 0.56).  
 
4.3.2. ANKRD6 results in context of previous studies 
 
To our knowledge this research work is the first to explore the relationship between human genetic 
variation at ANKRD6 and TOF. Several pieces of previous work support the hypothesis that protein 
function variation at ANKRD6 might be related to cardiac malformations on humans. 
 
Previous studies indicate that loss or decrease of function of ANKRD6 could cause defects in 
cardiogenesis due to its known involvement at the PCP pathway. ANKRD6 is a human ortholog for 
the protein Diversin in vertebrates (136).  Diversin is in turn a protein related to Diego in 
Drosophila, which has a recognized role in the non canonical Wnt signaling (116, 137). Diego, like 
frizzled, is a non canonical Wnt agonist preventing Prickle from binding to dishvelled (193). 
 
No ANKRD6 knockout mouse has yet been described in the literature. However, most of the work 
and animal models on Diversin and Diego supports the idea that ANKRD6 suppression is likely to 
produce a cardiac phenotype. In 2002 the group of Moeller et al. reported that injection of ANKRD6 
mRNA lacking the ankirin repeats (Div-∆ANK) into early zebrafish embryos produces cardia bifida 
(116). Apparently the phenotype was caused by a dominant negative effect of this form of diversin. 
The phenotype was not reproduced by injecting morpholinos against diversin. It is also interesting 
that the cardiac phenotype in this model is rescued by the coinjection of an activated form of RhoA, 
indicating a downstream function of this small GTPase protein. The same group reported that 
injection of full size forms of mouse diversin or the ankirin repeats rescued the phenotype (cardia 
bifida) induced by Wnt5A-Wnt11 morpholinos, inferring that the action of the protein is located 
downstream in the pathway from the Wnt secreted proteins.  
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4.3.3. Summary of Wnt11 variants 
 
Two previously undescribed uncommon variants were found in the mutational screening. The first 
uncommon variant found was a single base substitution (G/T) at WNT11 intron 1, position 207 +47. 
The variant is located at the Wnt11 conserved domain. In silico analysis of the variant showed that 
it can cause decrease of strength of the acceptor site at the end of the exon and also 
disappearance of SC35 and SF2 binding sites. 207 +47 G>T was paternally inherited at the 
proband found to be carrying it.  The variant was a found in nine probands and none of the 
controls. A minigene experiment showed no difference in splicing (transcript length and number) 
between the variant and wild type alleles. 
 
The second uncommon variant encountered was a single base substitution, on homozygous state, 
(C/T) at WNT11 intron 3, position 720 +6. WNT 11 720 +6 C>T is not located at known conserved 
domains within the protein and does not cause splicing changes at in silico analysis. I did not 
detect allele or genotype frequencies differences between TOF cases and controls for WNT 11 
720 +6 C>T. 
 
4.3.4. Wnt11 in context of previous work 
 
To our knowledge this work is the first to explore the relationship between genetic variation at 
WNT11 and TOF. Several pieces of previous work support the hypothesis that protein function 
variation at WNT11 might be related to cardiac malformations in humans. 
 
Wnt 11 and its homologues have been shown to be consistently expressed in the heart forming 
fields in quail chicken mouse and xenopus (85, 194), and in the mature heart in humans. Its 
expression in the primary heart tube has been also demonstrated in mouse, chicken and xenopus 
embryos. Wnt11 has been shown to induce cardiogenesis in Xenopus and Zebrafish (103, 107). In 
quail embryo mesodermal explants, Wnt11 expression or addition produces cardiomyocyte 
differentiation (104).  
 
In an exquisite set of experiments Pandur et al. in 2002 showed that the addition of dominant 
negative Wnt11 constructs to Xenopus embryos decreased the expression of cardiac markers like 
Nkx2.5 (107). Injection of Wnt11 inhibiting morpholinos exerted the same effect. 
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4.3.5. A functional explanation for 207 +47 G>T 
WNT 11 207 +47 G>T is a synonymous variant detected in 9 probands.  Taking into account the 
proportion of strongly and mildly deleterious missense uncommon variants we might also think that 
this is probably a medically deleterious variant.   According to my findings it is likely that the variant 
does not affect splicing. If the variant is truly pathogenic, it is unlikely that is a marker of a second 
linked pathogenic variant due to its low mAF. Wnt11 +47 G>T influence in protein function can be 
exerted in two ways: the first is a splicing effect not detected in the minigene experiment. A 
minigene is a simplification of a complex network of factors interacting to define exon and intron 
boundaries. This type of experiment does not take into account the genomic environment of the 
exon, the usual gene promoter and regulating factors located farther than a couple hundred of 
base pairs, the splicing change could be not detected with a minigene. 
 
4.4. Conclusions 
 
The major finding of this part of my research was the discovery of an intronic uncommon variant in 
9 TOF probands that was not found in controls. Despite being an intronic variant, functional 
analysis for WNT11 207 +47 G>T failed to show a splicing effect of the variant. Also a common 
variant (Phe636Leu) in ANKRD6 was initially found to be associated with TOF but p values were 
not significant after multiple test correction. Increasing the sample ruled out the association. 
 
Despite that theoretical research have shown a high probability of uncommon missense variants in 
ANKRD6 and Wnt11 of being medically detrimental and previous animals models have shown the 
implications of both genes in cardiogenesis, my research have found several genetic variants 
without finding significant associations with TOF. However, the results are not conclusively 
negative. For most of the uncommon variants the sample needed for detecting a difference 
between cases and controls, if the risk associated is low, would be difficult to collect. Increasing 
the sample for variants like WNT11 720 +6 C>T, ANKRD6 1-304 G>A, Leu192Phe or Thr176Asp 
can confirm differences between cases and controls. 
 
An alternative approach to the functional implication of WNT11 207 +47G>T like quantitative RT 
PCR or reverse transcriptase amplification of total RNA from a carrier of the variant can give 
definite answers to the question of whether or not this variant influence protein expression and 
splicing. Due to the important role of these two genes (ANKRD6 and Wnt11) in cardiogenesis, and 
the finding of uncommon and common novel variants, potentially associated to TOF, it is worth to 
undertake bigger sequencing experiments in bigger samples, not only to describe the remaining 
uncommon genetic variation yet to be discovered but also to confirm or rule out the associations 
between the already discovered variants. 
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5. ROCK 2, DVL1L1, DVL2, AND DVL3 
 
5.1. DVL1L1 
 
Sequence of the only DVL1L1 exon was obtained in 93 CHANGE probands. A total of 350 bp were 
screened using methods described in section 2.2.  I did not find any previously unreported variants 
either common or uncommon. Two previously reported SNPs were found at the exon: rs807429, a 
SNP located at the 3’ end of the pseudogene; and rs812088, an exonic apparently synonymous 
SNP. Both SNPs were in Hardy-Weinberg equilibrium at the 5% significance level. The SNPs were 
not typed in control populations because there were not significant differences with previously 
reported allele frequencies in Caucasian populations. For allele counts and frequencies see Table 
49. 
 
 
Table 49. Genotype counts and allele frequencies for rs807429 and rs812088. mAF: Minor allele 
frequencies; MAF major allele frequencies 
 
5.2. ROCK2 
 
5.2.1. Previously undescribed common variants 
 
Sequences of 32 exons, not including the UTR, were obtained for ROCK2 in 93 CHANGE 
probands. A total of 4283 bp were screened using methods described in section 2.2. I did not find 
any novel rare variants among the 93 TOF probands screened. 
 
5.2.1.1. ROCK2 145 -25 A>T 
The only previously undescribed common variant found was a single base substitution (A>T) in 
ROCK2 intron 1. The variant was found in eight CHANGE probands in heterozygote state on the 
fist mutational screening. 
  
HWT Het HNWT MAF mAF
rs807429 69 20 1 0.8700 0.1300
rs812088 80 11 0 0.8800 0.1200
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Intron 1 is not a conserved region. The variant is not located at consensus donor or acceptor 
splicing sites. In silico analysis of the variant using ESE finder showed that the variant does not 
alter the strength of theoretical splicing regulator sites around the region.  Analysis using 
spliceview showed no differences in the strength of donor and acceptor splicing sequences 
between wild type and mutant alleles.  
 
 
Figure 41. ABI sequencer trace displays for ROCK2 145 -25 A>T variant.  Upper and medium panel 
show heterozygote sequences, bottom shows a normal trace. 
 
A total of 1772 genotypes were obtained from cases and controls using the Sequenom platform 
and the methods described at section 2.3.2. . Due to its allele frequency and given the number of 
cases and controls, power was calculated as 100% for a general case-control analysis, to detect a 
relative risk of 2 for heterozygotes and supposing an alpha error of 0.1. Genotyping was successful 
for more than 98% of the samples used. The estimated genotype miscall rate was less than 1% for 
the SNP. 145 -25 A>T was in Hardy-Weinberg equilibrium at the 5% significance level for the 
global population and for each of the subpopulations. 
 
An almost equal percentage of heterozygotes were found in both populations: probands and 
controls. I did not find a significant difference in genotype or allele frequencies between cases and 
controls for 145 -25 A>T (X2= 0.22; p= 0.89). Allele counts and genotype frequencies are shown in 
Table 50. 
 
  
Table 50. Genotype counts and allele frequencies for ROCK2 145 -25 A>T. MAF: Major allele 
frequency, mAF: minor allele frequency. 
 
A/A A/T T/T MAF mAF
Probands 410 45 1 0.9485 0.0515
Controls 1193 120 3 0.9521 0.0479
149 
 
5.2.2. Previously described common variants 
 
Four previously described SNPs were encountered at ROCK2 mutational screening on 93 TOF 
CHANGE probands. All but one of them were in Hardy Weinberg equilibrium and showed no 
significant differences when compared to previously Hapmap data on Caucasian population (CEU 
population). ROCK2 SNPs found at the initial mutational screening, their allele frequencies, 
measurements for fitness to the Hardy Weinberg equilibrium and comparisons for allele 
frequencies with the published CEU data see Table 51. 
 
 
Table 51. Previously described SNPs on ROCK2, allele frequencies and p values for Hardy Weinberg 
equilibrium and for comparisons with previous published data with Caucasian population when 
available. AA: Amino acid; mAF: minor allele frequency; MAF: major allele frequency; HW: Hardy 
Weinberg; p value comp: Chi square p value when compared with previous data; Int: Intronic; NS: 
Non synonymous; S: Synonymous;  NT3’: Non translated 3’. 
 
One common previously described SNP (rs2271621) at ROCK2 was genotyped in the control 
population and the total of available CHANGE samples due to its significant allele frequency 
difference with previously published data (p value: 0.00005).  
 
One thousand six hundred and fifty four genotypes were obtained from CHANGE TOF probands 
and HTO controls for rs2271621, using a mass Extend experiment (methods described at section 
2.3.2). Power was calculated in 100% for a case control allele frequency comparison for the SNP 
to detect a relative risk of 2 for heterozygotes and supposing an alpha error of 0.01. Genotyping 
was successful for more than 98% of the samples. The estimated genotype miscall rate was less 
than 1% for the SNP. Rs2271621 was in Hardy-Weinberg equilibrium at the 5% significance level 
for the global population and for each of the subpopulations. However, I did not find significant 
differences in genotype or allele frequencies between cases and controls (X2 square: 0.024; p 
value: 0.988). 
 
 
Table 52. Genotype counts and allele frequencies for rs2271621. MAF: Major allele frequency, mAF: 
minor allele frequency 
 
SNP Function AA mAF MAF HW p value P value comp
rs41264193 S 114(S) 0.0417 0.9583 0.9237 NI
rs9808232 NS 431(T/N) 0.4000 0.6000 0.8186 0.7093
rs41264191 Int 0.0444 0.9556 0.9072 NI
rs2271621 Int 0.3708 0.6292 0.5969 0.0000
A/A A/T T/T MAF mAF
Probands 241 188 29 0.7314 0.2686
Controls 630 488 78 0.7308 0.2692
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5.3. DVL3 
 
5.3.1. Previously undescribed uncommon variants 
 
Sequences for the 15 DVL3 exons, including the 5’ UTR region, were obtained in 93 CHANGE 
probands at the initial mutational screening. Two thousand two hundred and seventy five bp were 
screened in each proband using methods described in section 2.2.  Two previously undescribed 
uncommon variants were encountered at DVL3. See Table 53. 
  
 
Table 53. Not previously described uncommon variants encountered at DVL3. AA: Aminoacid; S: 
Synonymous; INT: Intronic; P: Phenylalanine.  
 
5.3.1.1. DVL3 446 T>A  
The first uncommon variant found was a single base substitution (T>A) located at DVL3 exon 3, 
mRNA position 446. The SNP is located within a codon that translates a phenylalanine and does 
not produce changes at the protein sequence level. The variant was found in a single CHANGE 
proband in heterozygous state at the initial mutational screening. See Figure 41 for the ABI 
sequencer traces from the carrier and a proband not carrying the variant. 
 
 
Figure 42. ABI sequencer trace displays for DVL3 446 T>A variant.  Upper and medium panel show 
heterozygote sequences, bottom shows a normal trace. 
 
Exon Variant Alleles Function AA
3 446 T>A T/A S P
11 1339 +17 A>G G/A INT
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The variant is not located at conserved domains of the protein, and does not disrupt known splicing 
donor or acceptor sites. In silico analysis of the variant showed that the variant does not change 
the relative strength of splicing donor and acceptor sites and also does not influence any 
theoretical binding sites for known splicing regulators.  
 
The variant was inherited, in the first proband detected to be carrying it, from the father who does 
not show an abnormal cardiac phenotype. The carrier did not show evidence of other inherited 
conditions. There is no history of CCM within the family.  
 
5.3.1.1. DVL3 446 T>A is present in controls 
A total of 1538 genotypes were obtained from cases and controls through a Sequenom assay 
following methods described at 2.3.2.  According to the number of probands and controls power 
was calculated in 81% for a general case-control analysis, to detect a relative risk of 2 for 
heterozygotes and supposing an alpha error of 0.1. Genotyping was successful for >98% of the 
samples. The estimated genotype miscall rate was less than 1% for the SNP. 446 T>A was in 
Hardy-Weinberg equilibrium at the 5% significance level for the global population and for each of 
the subpopulations. 
 
Forty four heterozygotes were found in total at both populations: probands and controls. No 
homozygotes for the variant were found. Minor allele frequency for the entire population was 1.4%.  
I did not find significant differences at genotype or allele frequencies level between cases and 
controls for DVL3 446 T>A (X2= 0.128; p= 0.864). For allele counts and genotype frequencies see 
Table 54. 
 
 
Table 54. Genotype counts and allele frequencies for DVL3 446 T>A. MAF: Major allele frequency, 
mAF: minor allele frequency. 
 
5.3.1.3. 1339 +17 A>G 
The second uncommon variant found was a single base substitution (A>G) located at DVL3 intron 
11, seventeen bp from the 3’ end of the exon. The SNP is not located at consensus splicing donor 
or acceptor sites and the intron does not belong to known conserved domains. The variant was 
found on a single CHANGE proband in heterozygous state at the initial mutational screening. See 
Figure 43 for the ABI sequencer traces from the carrier and a proband not carrying the variant. 
 
A/A A/T T/T MAF mAF
Probands 410 11 0 0.9869 0.0131
Controls 1084 33 0 0.9852 0.0148
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Figure 43. ABI sequencer trace displays for 1339 +17 A>G variant.  Upper panel shows a 
heterozygote for the variant, bottom shows a homozygote wild type. 
 
In silico analysis of the variant showed that the variant does not change the relative strength of 
splicing donor and acceptor sites and is not located within any theoretical binding site for known 
splicing regulators. 
 
In the first proband carrying the variant was impossible to determine if the variant was inherited. 
The mother of the carrier does not carry the variant and we do not have sample from the father.  In 
the controls, the three heterozygotes are members of the same family and the original carrier is the 
father.  
 
5.3.1.4. 1339 +17 A>G is present in controls 
One thousand seven hundred and seventy five genotypes were obtained for DVL3 1339 +17 A>G 
including 455 TOF probands and 1320 controls. Genotypes were obtained using a mass Extend 
assay on the Sequenom platform following methods described in section 2.3.2. Power calculation 
according to the number of cases and controls included, showed a power of 22% to detect a 
difference between cases and control in a general case and control analysis hypothesizing a 
relative risk of 2 for heterozygotes and taking into account an alpha error of 0.1. Nevertheless, as 
mentioned previously, control genotyping was performed to check the presence of the uncommon 
variants in the control population, as to design a case and control study on variants as uncommon 
as 1339 +17 A>G would require an unfeasible number of cases: approximately 3663 for 80% 
power. 
 
Five heterozygotes were found among both, cases and controls: two among the probands and 
three among the controls. No homozygotes for the variant were found. Minor allele frequency for 
the entire population was 0.14%.  No statistically significant difference was found between cases 
and controls in allele frequency at 1339 +17 A>G (Fisher exact test p value: 0.608). For allele 
counts and genotype frequencies see Table 55. 
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Table 55. Genotype counts and allele frequencies for DVL3 1339 +17 A>G. MAF: Major allele 
frequency, mAF: minor allele frequency. 
 
5.4. DVL2 
 
Mutational screening for two exons (11 and 15) was performed for this gene during the 
experimental work of this thesis. The remaining 13 were screened during previous work at our 
laboratory. A total of 1102 bp were screened. I did not find new or previously described common 
variants during the mutational screening. 
 
5.4.1. Control genotyping for not previously reported uncommon variants 
 
5.4.1.1. DVL2 Thr536Ile 
A non synonymous (Thr536Ile) maternally inherited single nucleotide variant (C/T) was found in 
heterozygote state in one TOF proband in a previous mutational screening performed for Dvl2 at 
our laboratory. Arg163Trp was genotyped in 1244 controls and 142 CHANGE TOF probands using 
an RFLP following methods detailed in section 2.3.3. The variant is not located at conserved 
domains within the protein. In silico analysis of the variant showed that it is unlikely to be 
structurally damaging and it does not alter cis splicing regulatory elements. 
 
Power calculation according to the number of genotypes included showed a power of 80% to 
detect a difference in a general case and control analysis hypothesizing a relative risk of 2 for 
heterozygotes and taking into account an alpha error of 0.1. Genotyping was successful for >98% 
of the samples. The estimated genotype miscall rate was less than 1% for the SNP. Thr536Ile was 
in Hardy-Weinberg equilibrium at the 5% significance level for the global population and for each of 
the subpopulations. 
 
Seventy three heterozygotes were found in total, cases and controls: sixty three among the 
probands and ten among controls. One homozygote was found in each one of the populations. 
The variant was found in 3% of the alleles of the global population. An association was found 
between the variant and TOF (p value: 0.0006). Correction with Qvalue for multiple testing, using a 
A/A A/G G/G MAF mAF
Probands 453 2 0 0.9978 0.0022
Controls 1317 3 0 0.9989 0.0011
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5% false discovery rate level, yielded the association not significant. For allele counts and 
genotype frequencies see Table 56. 
 
 
Table 56. Genotype counts and allele frequencies for DVL2 Thr536Ile. MAF: Major allele frequency, 
mAF: minor allele frequency. 
 
 
5.4.2. Control genotyping for previously reported common variants 
 
5.4.2.1. rs2074216 
A synonymous SNP located at codon 135 of Dvl2 protein was decided to be genotyped on a 
control population due to its differences in allele frequencies at a previous mutational screening 
when compared to previously published data on Caucasian populations and allele frequency 
failure at Hardy Weinberg equilibrium tests. The SNP is located in exon 3 of the protein and does 
not belong to known conserved domains within the protein. The variant does not disrupt consensus 
splicing sequences and in silico analysis does not show disruption of cis splicing regulatory 
sequences with the variant. 
 
Rs2074216 was genotyped in 1236 HTO controls and 175 CHANGE TOF probands using a 
Taqman platform experiment and following methods detailed in section 2.3.4. Minor allele 
frequency in the total population was 0.37. Power calculation according to the number of cases 
and controls included showed a power of 100% to detect a difference in a general case and control 
analysis hypothesizing a relative risk of 2 for heterozygotes and taking into account an alpha error 
of 0.05. Genotyping was successful for >98% of the samples. The estimated genotype miscall rate 
was less than 1% for the SNP. Rs2074216 was in Hardy-Weinberg equilibrium at the 5% 
significance level for the global population and for each of the subpopulations. There was no 
difference between TOF cases and controls at the allele frequencies level (p value: 0.14). For 
genotype and allele frequencies at TOF probands and controls see Table 57. 
 
 
Table 57. Genotype counts and allele frequencies for rs207416. MAF: Major allele frequency, mAF: 
minor allele frequency.  
C/C C/T T/T MAF mAF
Probands 131 10 1 0.9845 0.0155
Controls 1180 63 1 0.9824 0.0176
C/C C/T T/T MAF mAF
Probands 71 75 29 0.6200 0.3800
Controls 490 589 157 0.6347 0.3653
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5.5. DISCUSSION 
 
5.5.1. Summary of ROCK2 findings 
 
I did not find uncommon variants in ROCK2. One previously undescribed common variant was 
found in the mutational screening. ROCK2 145 -25 A>T is an intronic single nucleotide variant 
located at intron 1 of the protein. In silico analysis of the variant showed that does not cause 
splicing changes. ROCK2 145 -25 A>T is not located at conserved domains within the protein. The 
minor allele frequency of the variant was 0.048 and there was no allele frequency difference 
between probands and controls.  
 
One previously described common variant in ROCK2 (rs271621) was genotyped in a control 
population due to allele frequency differences with previously published data in the first mutational 
screening. Rs2271621 is an intronic variant not located at consensus splicing sequences and not 
previously described as of clinical relevance. Minor allele frequency at the total population is 0.26 
without significant differences between probands and controls. The initial differences encountered 
between CHA cases and previous data were probably due to sample size.  
 
5.5.2. ROCK2 findings in context of previous studies 
 
Previous studies indicate that Rho kinases in general and ROCK2 function in particular are crucial 
for cardiogenesis. To our knowledge this is the first study to examine common and uncommon 
human genetic variation at ROCK2 and its relationship with TOF. 
 
ROCK2 or ROCKα is one of the Rho GTPases effectors, with multiple functions at development 
and that exerts its function through phosphorylation of multiple proteins like myosin light chain 
kinase, myosin light chain phosphatase, LIM kinases and Adducin (195)  Previous animal and 
molecular experiments have consistently linked ROCK2 with PCP and cardiogenesis (127, 130). 
The results of those studies indicate that a function disarrangement of the protein is highly likely to 
produce cardiac malformations. ROCK2 expression has been reported in murine and chick 
embryos at stage E7.5-9.0 (126). Zhao et al. also reported expression of the protein in murine 
myocardium and trabeculae in tissue sections at E9.5-E12 (121).  
 
Zhao et al. showed that inhibition of Rho kinases using Y27632 (an unspecific Rho associated 
kinases inhibitor) in cultured mouse embryos prevented heart looping, septation and atria 
formation. Embryos treated with Y27632 showed at E9.5 a bulbous like primitive structure with a 
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conotruncus like structure anterior and posterior to it. Primitive atria and AV canal did not form in 
these embryos (121). Also when Y27632 was added to embryos at later stages of development 
cardiogenesis seemed to be further arrested showing smaller hearts and dilated pericardium. 
Examination of tissue sections of these hearts showed a condensed myocardium mass without 
development of the trabeculae and failure to develop the compact myocardium of the ventricular 
wall. Part of the development failure was apparently due to inhibition of cardiomyocyte proliferation 
as measured on the inhibition treated embryos. 
 
Wei et al. also researched on the effect of Rho kinases inhibition using Y27632 in chick embryos. 
Their experiments showed that inhibition of Rho kinases produced a failure to fuse in the midline 
with severity that depended on the stage at which the inhibitor was added. The conclusion was that 
Rho kinases regulated the process controlling cell migration (126). Zhao’s group also showed that 
Rocks are expressed in mouse endocardial cushions. At the same experiment this group tested 
the effect of Y27632 on monolayer and 3D collagen cultures of endocardial cushion explants(131). 
Again, inhibition of ROCKs produced decrease in endocardial cell migration, a finding that was 
partly explained by the inhibition of the transformation of endocardial cells into a mesenchymal 
phenotype (131). Sakabe et al. reported a similar finding using chick embryos (132). 
 
It is however striking that ROCK2 KO mouse does not show cardiac phenotype. Its phenotype is 
rather characterized by intrauterine growth retardation and lethality associated with abnormalities 
and thrombus formation at the labyrinth layer of the placenta. The placental abnormalities occur 
mainly at the maturation and adaptation stage taking place at E12-E16 and are related to 
regulation of protein expression, in particular of prolactin like GTPase 1 or PAI I (120). A possible 
explanation that is given by Thumkeo et al. for the absence of other phenotypes is the functional 
overlapping of the two ROCK isoforms. However, compensating overexpression of ROCK1 was 
not detected in the ROCK2 KO mouse. 
 
Despite ROCK2 being a good candidate gene to cause a portion of TOF in human population, and 
findings in this research linking a portion of TOF inheritance to common and uncommon variation 
at the other Rho kinase isoform ROCK1, only one novel common variant was discovered in the 
mutational screening in ROCK2. It is however likely that due to the low allele frequencies of the 
variants associated with cardiac phenotypes in humans, this mutational screening was 
underpowered to detect such variants in our population. Screening of 186 chromosomes only give 
us a power of around 80% to detect variants present in 2.5% of the probands, not taking into 
account random effects. To definitively rule out the hypothesis of uncommon genetic variation at 
ROCk2 being linked to TOF, a bigger sample should be sequenced. Given the next generation 
sequencing platforms now available, the possibility of sequencing not only this gene but a number 
of them in bigger samples is not only possible but the logical next step.    
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5.5.3. Summary of Dvl findings 
 
Two previously undescribed uncommon variants were encountered at DVL3. The first uncommon 
variant found was a synonymous single base substitution located at mRNA position 446, DVL3 446 
T>A. The variant is not located at consensus splicing sequences and in silico analysis does not 
show that it disrupts cis splicing modulators. DVL3 446 T>A is present in controls without 
significant differences in allele frequency.  
 
The second uncommon variant found was a single base substitution (A>G) located at DVL3 intron 
11, 1339 +17 A>G. The SNP is not located at consensus splicing donor or acceptor sites and 
according to in silico analysis does not disrupt splicing modulators. Allele frequency of the variant 
did not show statistical significant differences when compared to controls.  
 
One novel uncommon and one novel common variant described in a previous mutational 
screening on Dvl2, performed in our laboratory, were genotyped in a control cohort. The 
uncommon variant is a non synonymous maternally inherited SNP, Thr536Ile. The variant is not 
located at consensus splicing sequences. In silico analysis of the variant showed that is unlikely to 
be structurally damaging. Thr536Ile was found in controls at an apparently significantly different 
frequency when compared to probands. Nevertheless when corrected for multiples tests the 
difference was not significant. 
 
Also a Dvl2 synonymous SNP, rs2074216, was genotyped in a control population. The SNP is 
located at exon 3 of the protein and does not belong to known conserved domains. The variant 
does not disrupt consensus splicing sequences and in silico analysis does not show disruption of 
cis splicing regulatory sequences with the variant. I did not find significant differences between 
cases and controls at the allele frequency of this SNP. 
 
5.5.4. Dvl findings in context of previous studies 
 
This is the first study to explore genetic variation in Dvls and its relationship with TOF. In the light 
of previous findings, it would be expected that a loss or decrease of function at the Dvl proteins 
causes developmental abnormalities, in particular in cardiogenesis. It is also expected that the 
genetic influence of a variant in a single gene of these group of paralogs will produce an 
identifiable phenotype independent of the functional overlapping between members of the protein 
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family. This fact is illustrated by findings of Hamblet et al., a group that described the phenotype of 
Dvl1 and Dvl2 KO mouse showing that penetrance of cardiac defects was similar between single 
and double knockout mice (113).  
 
Hamblet et al. published a paper in 2002 describing the phenotype of Dvl1-2 KO mouse. Dvl2 
mouse showed 50% perinatal lethality. The surviving KO mice were almost invariably females and 
developed normally to adulthood. Lethality was explained by a 50% penetrance of cardiac defects, 
with the majority exhibiting DORV and VSD, 12.5% TGA and 25% PTA. Cardiac conotruncal 
septation defects were explained according to the authors by neural crest cell migration defects. 
Whole mount probe hybridization showed that Dvl2 embryos did not show Pitx expression, a 
neural crest cell marker, at the 4th branchial arch, neural crest cells or the developing outflow tract 
(113). Interestingly Dvl1 -/- mice do not show cardiac abnormalities. The Dvl1 -/- phenotype is 
characterized by poor social interaction and gating defects (148). 
 
Dvl isoforms’ involvement in convergent extension movements at embryogenesis and its regulatory 
role in wnt pathways, including canonical, non canonical and calcium controlled, has been largely 
recognized (141). See Figure 44 for a graphical illustration of Dvl involvement in the Wnt pathways. 
Itoh showed that explants of Xenopus caps not only elongated in a Xdsh (Xenopus paralog of Dvl) 
dose dependent manner but also developed different types of tissue depending on the amount of 
the mRNA added. (145). In 2004, Ewald and coworkers demonstrated that Dvl inhibition in 
Xenopus embryos cause gastrulation defects(146). Cell studies trying to elucidate this fact have 
shown that disruption of disheveled genes block the formation of lamellipodia in migrating cells  
(147). 
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Figure 44. Dishvelled involvement in the Wnt signalling pathways. A. Activation of the canonical 
pathway depends on the FZ (Frizzled) receptor and the LRP co receptor, activation of Dvl produces 
disassembly of the complex of Axin, adenomatous polyposis coli (APC) and Glycogen synthase 
kinase 3 (GSK3) blocking β catenin phosphorylation and therefore decreasing is degradation. B. A 
signal is transduced by a FZ receptor activating Dvl that in turns activates the small GTPases Rho 
and Rac that exerts their function trough their respective kinases. C. WNT signalling through the FZ 
receptors and Dishevelled and G-proteins produces the release of intracellular calcium and 
activation of Phospholipase C, CamK2 and PKC. Graph reproduced with permission from 
Wallingford, J.B. and R. Habas, The developmental biology of Dishevelled: an enigmatic protein 
governing cell fate and cell polarity. Development, 2005. 132(20): p. 4421-36. 
 
The previous literature evidence suggests that a Dvl loss of function would likely cause 
incompletely penetrant defects in cardiac outflow tract and may cause other congenital defects 
consequence of abnormal convergent extension movements. However, only one partially positive 
result was found. A non synonymous SNP, DVL2 Thr536Ile, apparently a structurally benign 
variant, showed significant differences in allele frequency between cases and controls. The 
difference was not significant when corrected for multiple testing. Failing multiple test corrections is 
a fact that could be derived from the risk associated with the variant and sample size. Thr536Ile 
was present in 3% of chromosomes and therefore a low OR is expected to be associated with the 
variant, given the risks associated to variants of similar frequency reported in the literature for other 
complex diseases. This is explained by the evolutionary pressures that a variant is subjected to 
depending on their fitness impact. Without random genetic drift or reproductive advantages of 
heterozygotes, the frequency of a variant with influence on fitness is proportional to the amount of 
this so called influence. The risk associated with Th536Ile might be as expected modest and 
perhaps a bigger sample is needed to confirm or rule out the possible implication of uncommon 
genetic variation at Dvl2 in the pathogenesis of TOF. 
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However, it is interesting that Thr536Ile was present in a higher frequency in controls, giving a 
calculated OR of 0.7. In other words the variant seems to be protective and decrease the risk of 
suffering TOF. The mechanisms explaining the possible protective effect of the variant are 
complicated. Dvl protein function or expression variation, due to its extensive implications in 
multiple embryogenetic processes might have profound effects on development. This fact leaves 
three possible explanations for a protective effect given by a non synonymous variant in a key 
protein such as Dvl: the protective effect is the result of a gene to gene interaction; the protective 
effect manifests itself due to gene-environment interactions; or the protective effect is not exerted 
by Dvl2 but the marker is in LD with the locus-loci responsible for the protection. 
 
5.6. CONCLUSIONS 
 
One novel common variant was found in the mutational screening at ROCK2. 145 -25 A>T is an 
intronic variant found in 0.048% of chromosomes that seems to be benign according to in silico 
analysis. Comparison of allele frequency between TOF cases and controls did not show significant 
differences. 
 
Two uncommon variants were found at DVL3 during the mutational screening:  446 T>A, a 
synonymous variant, and 1338 +17 A>G, an intronic variant. Both of Dvl3 uncommon variants did 
not show positive results at in silico analysis and were found in controls at similar frequencies 
when compared to cases. 
 
Two Dvl2 variants, a novel uncommon non synonymous (Thr536Ile) and a previously described 
common (rs2074216) were genotyped in the HTO controls. There was not significant allele 
frequency difference between TOF probands and controls for rs2074216. However, for Thr536Ile 
an apparently benign change an association was found but p values were not significant after 
multiple test correction. Due to the crucial involvement of Dvl2 in embryogenesis and taking into 
account that this is the first study to explore human genetic variation at Dvls in relationship with 
TOF the next logical step is to increase the sample to confirm or rule the possible protective 
association between Thr536Ile and TOF. The mechanistic and functional implications of the variant 
are more complicated and should be explored if the association is confirmed 
 
It is likely due to the functional overlapping of Dvls that a single uncommon variant can solely 
explain a cardiogenesis disarrangement as complex as TOF, excepting in the case of dominant 
negative forms of the proteins. It is also likely that the truly deleterious variants in ubiquitous 
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proteins as Dvls are subjected to such a negative evolutionary pressure that they are difficult to 
reach detectable levels even if they cause any form of TOF. 
 
In the case of ROCK2 it seems to be not associated with TOF. As it was mentioned, previous 
knockout mouse models have shown no evidence of a cardiac phenotype, and all previous works 
reporting cardiac malformations associated with the inhibition of ROCKs have unespecifically 
inhibited both forms of Rho kinases in the experiments. 
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6. WNT5A 
 
6.1. Previously unreported uncommon variants 
 
Sequences of 5 exons in 93 patients were obtained for WNT5A. Two previously undescribed 
uncommon variants were encountered at WNT5A. See Table 28. 
 
 
Table 58. Previously undescribed uncommon variants. N: Number of carriers; AA: Aminoacid; UTR: 
untranslated region; NS: No synonymous; D: Aspartic acid; S: Serine; T: Threonine. 
 
6.1.1. Asp119Ser 
 
The first uncommon variant found was a non synonymous change in exon 2 detected in 1 patient 
in heterozygous state. The A/G mutation produces a change in residue number 119 from Aspartate 
to Serine. The residue is located within the Wnt conserved domain. The residue has not been 
reported as functionally essential. In silico analysis of the mutation indicate that it is not structurally 
damaging and does not produce splicing changes. Figure 45 shows the ABI sequencer traces for 
the wild type allele and the variant. Analysis of the residue shows that it is conserved among chick, 
mouse and human. 
 
It was not possible to determine if the variant was inherited or de novo, as we had no DNA sample 
from either mother or father. Apparently neither of the parents presented an abnormal cardiac 
phenotype.  
 
Exon Variant Function AA Residue N
2 Asp119Ser NS D/S 212 1
Non translated 3' 1461 +38 C>T UTR 3
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Figure 45. WNT5a mutation 363A>G trace display. Upper and medium panel show patient sequences. 
Bottom panel shows a normal trace. 
 
6.1.2. Wnt5A Asp119Ser is not present in controls 
 
A total of 1336 control genotypes from HTO samples and 457 CHANGE TOF probands genotypes 
were obtained for 363 A>G using a Sequenom platform experiment and following the methods 
specified in section 2.3.2. Allele frequencies for probands and controls are shown in Table 59. 
 
Despite that control genotyping was performed in our sample to check for the presence of the 
variant, power was calculated as 20% to detect genotype frequencies differences for Asp119Ser 
between cases and controls, hypothesising a relative risk of 2 for the heterozygotes and alpha 
error of 0.05. Genotyping was successful for 98% of the samples. The estimated genotype miscall 
rate was 1% for the SNP.  
 
Only the initial individual identified on the mutational screening was found to be carrying the Wnt5A 
363 A>G variant, none of the other cases or the controls was found to be carrying it.  
 
6.1.3. Wnt5A 1461 +38 C>T 
 
The second uncommon variant was found at the 3´ untranslated region of the gene: 1461 +38 
C>T. The C/T change was encountered in 3 patients in the heterozygous state. The mutation is not 
located within known cis regulatory sequences and according to in silico analysis is unlikely to 
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cause splicing changes. Figure 46 shows the ABI sequencer traces for the wild type allele and the 
variant. 
 
Obtaining sequences of the region on the parents of the probands carrying the variant revealed 
that it was paternally inherited in two of them and maternally inherited in one. The parents carrying 
the variant do not show an abnormal cardiac phenotype Figure 47 shows the sequencer traces for 
the parents. Only one of the families has family history of CCM with one uncle having a nonspecific  
history of a “hole in the heart”, that could not be further investigated in the context of this study. 
 
 
 
Figure 46. WNT5a mutation 1461 +38 C>T trace display. Upper panel shows variant trace. Medium 
and bottom panel shows wild type traces. 
 
 
 
Figure 47. WNT5a mutation 1461 +38 C>T parents trace display. Upper panel shows father’s trace. 
Bottom panel shows mother’s trace. 
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Table 59. Allele frequencies for Wnt5A Asp119Ser and 1461 +38 C>T. mAF: Minor allele frequency; 
MAF: Major allele frequency 
 
6.1.4. Wnt5A 1461 +38 C>T is present in controls 
 
Three hundred and ninety five CHANGE TOF proband genotypes and 1293 HTO control 
genotypes were obtained for   1461 +38 C>T using a Sequenom experiment and following 
methods detailed in section 2.3.2.  
 
For 1461 +38 C>T power was calculated in 90% for a general case-control analysis, hypothesising 
a relative risk of 2 for the heterozygotes and alpha error of 0.05. Genotyping was successful for 
98% of the samples. The estimated genotype miscall rate was less than 1% for the SNP. 1461 +38 
C>T was in Hardy-Weinberg equilibrium at the 5% significance level for the global population and 
for each of the subpopulations. 
 
Fourteen heterozygotes and 1 homozygote for the 1461 +38 C>T allele were found among 
probands. Fifty heterozygotes for the T allele were identified within control samples. I did not find a 
significant difference at genotype or allele frequencies between cases and controls for Wnt5A 1461 
+38 C>T (χ2(2 df) = 0.21; p= 0.64) 
  
6.2. Discussion 
 
Wnt 5a has been detected in the primitive streak, precardiac mesoderm, outflow tract and primitive 
ventricle of chick and mice embryos (71). Also, as previously discussed in this thesis, both 
canonical and non-canonical Wnt signalling are critical for cardiogenesis and their disruption has 
been previously linked to cardiac malformations in animal models (90, 114).  
 
Two previously undescribed uncommon variants were found at our mutational screening on 
Wnt5A. The first uncommon variant found was a non synonymous A>G change that produces a 
change in residue number 119 from Aspartate to Serine at the Wnt conserved domain. In silico 
analysis of the mutation using the web based resource Polyphen indicates that it is benign. The 
mAF MAF mAF MAF
Asp119Ser 0.9989 0.0011 1.0000 0.0000
1461 +38 C>T 0.9988 0.0012 0.9805 0.0195
CHA HTO
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variant is uncommon.  Only the initial individual identified on the mutational screening was found to 
be carrying the variant, none of 1336 controls or any other of the probands (456) was found to be 
carrying it. It was impossible to determine if the variant was de novo due to that we had no DNA 
sample from the parents.  
 
The association between Wnt5a and TOF phenotype is complicated to elucidate.  However it is 
well known the involvement of the protein in convergent extension processes. The relevance of the 
non canonical Wnt pathway derives from the seminal research in zebrafish mutagenesis that 
resulted on the description of the mutant fish named siberblick (slb), pipetail (ppt), trilobite (tri), and 
knypek (kny) (196) . Similar evidence were subsequently gathered from works on xenopus (197, 
198). It is also widely known that Wnt5A (Drosophila ppt) in one of the principal activators of the 
Wnt PCP pathway (86).  
 
Sequencing studies of many hundreds if not thousands of cases and controls would be required to 
statistically compare the frequency of uncommon variants (less than 1% frequency) between cases 
and controls in any given gene.  While such studies are now entering the realms of technical 
feasibility, this was not the case during the conduct of my project.  Therefore, having discovered a 
rare variant absent in a large number of controls, the only way to proceed is to carry out functional 
investigation.  As outlined above, previously published animal model data strongly supports the 
idea that a loss of function at Wnt5A might be associated with OFT malformations. However, early 
attempts to test the functional implications of Wnt5a Asp119Ser were unsuccessful (data not 
shown). It is necessary, in the future, to design and perform a series of experiments to explore the 
functional implications of the variant at the developmental and cellular levels. To test the impact of 
Wnt5a Asp119Ser in cell migration using direct stimulation or knockdown experiments might be the 
objective of subsequent experiments.  
 
The second uncommon variant found at the initial mutational screening was a single nucleotide 
change at the 3’untranslated region (1461 +38 C>T). The mutation is not located within known cis 
regulatory sequences and according to in silico analysis is unlikely to cause splicing changes. No 
significant differences were found at allele frequencies between 395 CHANGE TOF probands and 
1293 HTO control genotypes. The variant was considered of minor pathological relevance. 
 
6.3. Conclusions 
 
I described two previously undescribed uncommon variants at Wnt5A. The first of them is a non 
synonymous A>G change that produces a change in residue number 119 from Aspartate to Serine 
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at the Wnt conserved domain. In silico analysis showed that the variant might be benign. This non 
synonymous variant was found as a “singleton”: only the initial individual identified on the 
mutational screening was found to be carrying the variant, none of 1336 controls or any other of 
the probands (456) was found to be carrying it. Due to the findings previously exposed, Asp119Ser 
is thought to be probably associated with TOF. Previous published works indicate that, due the 
frequency detected, the variant might be de novo, and at least mildly medically detrimental (191).  
 
Despite a variant found as a singleton (Asp119Ser) in Wnt5a and not found in controls, I did not 
find any other evidence of uncommon genetic variation within the gene being associated with TOF. 
Even if the functional implications of Asp119Ser are elucidated and it is in fact a functionally 
deleterious variant, the PAR explained by this extremely uncommon variant will be very low. It is 
unlikely that a significant portion of TOF heritability is explained by uncommon genetic variation in 
Wnt5a. 
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7. DISCUSSION 
7.1. Overview 
 
This chapter summarizes the findings of this thesis in the broader context of human and animal 
genetic studies of CCM. Detailed discussion for each of the genes has been provided within the 
body of the results chapter. Here I also discuss the results of my sequencing based studies in the 
context of approaches targeting common genetic polymorphisms and copy number variation that 
have emerged during the time this work has been undertaken.   
 
The principal positive result of my work was the detection of a novel LFIP variant in ROCK 1, 
807C>T, presence of which was significantly associated with the risk of TOF.  The variant 
conferred an OR of 4.89 (95% CI: 2.51-9.50), and the association was significant at p=2x10^-5; 
this association remained significant after correction for multiple testing using QVALUE with an 
FDR of 5%.  The variant appeared not to affect splicing in a functional assay; a possible effect on 
the regulation of ROCK1 expression during development remains to be confirmed.  An association 
between a previously described common variant in ROCK1 (rs288979) and TOF was also found. 
 
I found one non-synonymous variant in the genes I screened that was absent in 1000 
chromosomes from a population free of CVM; this was the Asp119Ser substitution in the Wnt5A 
gene.  Functional investigation of the effect of this Wnt5A variant on cell motility was undertaken, 
but this was hampered by the difficulties in the detection of the protein (Data not shown). I also 
found an intronic variant in WNt11, 107 +47 G>T, in 9 TOF subjects and none of more than 1000 
control chromosomes. The variant appeared not to affect splicing in a minigene experiment. 
 
7.2. Summary of uncommon variants found in Wnt pathway genes 
 
The first approach of this work was to explore uncommon genetic variation within the non-
canonical Wnt pathway by performing a mutational screening on the exons of seven key genes 
within the pathway. The rationale of doing this was derived from two key facts that have been 
previously mentioned but that will be discussed further in this chapter. First, the amount of 
evidence associating the PCP pathway with the process of cardiogenesis. Second, the results from 
previous research suggesting that a portion of genetic predisposition to non syndromic cardiac 
malformation may be related to uncommon genetic variants of intermediate penetrance. 
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Twelve uncommon variants were found at the 6 genes in the mutational screening using samples 
from 93 TOF probands. Four of them were non synonymous, 2 were located at untranslated 
regions, 3 were intronic and 3 synonymous. None of the 465 probands genotyped for all 
uncommon variants carried more than one of them. Findings of the screening are summarized at 
Table 60. 
 
None of the variants was proven to be de novo, but parent samples were missing for 4 of the 
probands, making it impossible to discard that hypothesis. Statistically significant differences in 
allele frequencies were found for two variants, ROCK1 C807T and WNT11 207 +47 G>T. 
Estimates derived from the 1000 genomes project are that the substitution probability in the human 
genome is 1.2X10-8 per base pair, per generation. Positive in silico assays for structure disruption 
or splicing changes were found in four cases: ANKRD6 Thr176Asp, WNT11 207 +47 G>T, ROCK1 
807 C>T and 1785 T>G. The decision of going further into functional analysis was made in three of 
the variants: ROCK1 807 C>T, a synonymous variant with significant allele frequency differences 
between cases and controls, showing a plausible influence on splicing; WNT5A Asp119Ser, a 
missense variant found as a singleton and not present in controls: and WNT11 207 +47 G>T, an 
intronic variant found in 9 probands and not present in controls with positive results on the in silico 
analysis for splicing disruption. Each case will be discussed in detail below. 
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Table 60.  Uncommon variants encountered at mutational screening on 6 genes at the Non-canonical Wnt pathway. First column lists the genes, with the 
variants in each one of them listed on the second one. Relevant data about the variants is specified in the table: the genetic functional implications of the 
variants, if they are de novo, the number of TOF probands carrying the variant, the minor allele frequency in probands, if they were found on controls 
and the minor allele frequency in that case on them, p value for allele frequency comparison between cases and on controls, results of in silico assays 
and finally if functional tests were performed on them. Number of cases and controls vary slightly for each variant, see each chapter. UTR: untranslated 
region; NS: Non synonymous; INT: Intronic; S: Synonymous; U: Unknown; M: Maternally inherited; P: Paternally inherited; Y: Yes; N: No; NA: Not 
applicable; Neg: Negative; Pos: Positive. 
Variant Function De novo? Number mAF Present in controls mAF in controls p value for controls In silico results Functional tests
ANKRD6 1 -304 A>G UTR (-304) U 5 0.0020 Y 0.0060 0.06100 Neg N
Leu192Phe NS U 1 0.0005 Y 0.0003 0.42000 Neg N
Thr176Asp NS M 1 0.0008 Y 0.0011 0.62400 Pos N
WNT 5A Asp119Ser NS U 1 0.0005 N 0.0000 NA Neg Y
1461 +38 C>T UTR   P 14 0.0170 Y 0.0195 0.64000 Neg N
WNT11 207 +47 G>T INT P 9 0.0048 N 0.0000 0.00009 Splicing,SC35 Y
720 +6 C>T INT M 9 0.0047 Y 0.0026 0.53000 Neg N
DVL3 446 T>A S P 11 0.0140 Y 0.0130 0.86000 Neg N
1339 +17 A>G INT U 2 0.0033 Y 0.0018 0.60800 Neg N
ROCK1 807 C>T S M 33 0.0150 Y 0.0030 0.00002 Splicing, SrP40 Y
1785 T>G S M 5 0.0024 Y 0.0029 0.49000 SC35 N
Thr773Ser NS P 33 0.0155 Y 0.0176 0.77000 Neg N
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7.3. Weaknesses of association studies 
 
It is expected that in complex systems, like the factors influencing the risk of suffering a 
common disease, the interactions between the elements (environment and genes) should 
be taken into account to design effective research strategies. However, genetic 
association studies are focus on the additive effects of genes simplifying the etiological 
models of common diseases.  Before the GWA era, one of the main problems of 
associations was the lack of reproducibility of results that can be explained by a series of 
problems inherent to association studies. Most of the results showed in previous pages 
correspond to a case control analysis and therefore might have some of the limitations of 
this type of research. 
 
One of the main problems explaining spurious positive results in association analysis is 
selection bias. Bias can occur when the population is composed by strata in terms of allele 
frequencies with probabilities of being selected as a case or control varying between 
strata. Population substructure is composed by a number of these strata with different 
risks of suffering the disease. Additionally, measurement of the exposure can be biased if 
genotyping is performed at different times with different genotyping errors or techniques. 
Bias can also occur in outcome measurement if genotypes are known before classification.  
 
In terms of my research there is the small possibility of population stratification in the 
selection of controls. The main control population used was the HTO, a population 
recruited based in one hypertensive patient. By definition, the HTOs correspond to a 
subpopulation and therefore it is possible, but unlikely, that they have different allele 
frequencies when compared to TOF subjects solely due to their selection. In that respect, 
a vast amount of genotyping have been performed (and published) in the HTO population 
showing that the group is not a strata (168, 199-201). However, it is important to not forget 
that my control population was selected due to one hypertensive proband, and even if 
most of the subjects were normotensive the ideal control population would have been a 
ramdomly selected sample from general population. 
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Other of the common problems encountered in the old case control studies was the lack of 
power. Sample size was oftenly calculated with an overestimation of the true genetic effect 
and recruitment of patients was a constraint in many diseases (like TOF) by low disease 
incidence. Additionally, as it was previously mentioned, effects of common variants in 
common diseases (when present) are associated with small effects, requiring enormous 
sample sizes to be detected. In this respect, power calculations were performed and 
described for each one of the variants tested in probands and controls. In summary, most 
of the common variants tested showed more than enough power to detect differences with 
controls using a sample size as the one available to us. However, when uncommon 
variants were tested the power attained was insufficient to confidently discard the 
hypothesis of association.  
 
For example power was calculated in 20%, 14% and 17% for ANKRD6 1-304 G>A, 
Leu192Phe and Thr176Asp respectively for a general case-control analysis, to detect a 
relative risk of 2 for heterozygotes and supposing an alpha error of 0.1. The variants 
showed mAFs of 0.004, 0.003 and 0.001. For the uncommon variants like Asp119Ser 
approximately 17000 TOF cases would be needed to assume with 80% power that the 
variant is absent on 51000 controls. Due to TOF prevalence it would be extremely difficult 
to collect that sample. For a prevalence of 0.31/1000 liveborns there would be 
approximately 18000 TOF cases in the UK, supposing a 100% survival rate and including 
syndromic cases. It is important to say that the control genotyping was performed to 
screen for the presence of the variants in controls and not to perform a statistical test of 
association. In general I believe that power was sufficient for the tests comparing genotype 
frequencies of common variants between cases and controls. However in the case of 
including a major number of SNPs or to perform a whole genome screening for uncommon 
variants, a bigger sample will be needed as it is mentioned in other sections of this 
chapter.  
 
Spurious results in association analysis can also arise solely by chance. If we take into 
account the number of tests performed in a trait, a proportion of positive results would be 
produced by random effects. In my research positive results were corrected taking into 
account the number of tests performed, using Q value, decreasing the possibilities of 
positive associations due to chance. 
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7.4. Mutational load and other strategies 
 
In 2004 Cohen and cols published a paper that is one of the seminal works of the analysis 
of mutational load in complex diseases. In that work the sequence of three candidate 
genes (ABCA1, APOA1, and LCAT) previously identified as associated with rare genetic 
forms of HDL deficiency, was obtained in 32 individuals from general population of 4 ethnic 
origins and each sex, representing the upper and lower 5% of the plasma HDL levels. The 
number of non-synonymous variants in the low HDL group was significantly higher when 
compared to the low HDL individuals and 16% of the subjects in the low-HDL group had 
variants not present in the high-HDL group. The findings were reproduced in a Canadian 
cohort (202).     
 
The strategy used in the Cohen and cols work is called mutational load and can be used to 
determine the contribution of rare genetic variants to common genetic traits, especially 
quantitative traits. The advantage of analyzing the mutational load in quantitative traits 
strives in the enrichment of uncommon highly penetrant variants in the extremes of the 
distribution. Tetralogy of Fallot constitutes an example of discrete trait with difficult 
quantization of severity due that up to date there is not an accepted form of classifying the 
condition.   
 
Different strategies and approaches to the question about the contribution of uncommon 
variants to the predisposition to TOF could have been used and might be the objective of 
future work. A mutational load in the non canonical Wnt signaling comparing TOF sufferers 
with general population can show significant differences in the number of uncommon 
variants reinforcing the idea that the variants found are indeed disease causing alleles.  
 
7.5. Uncommon variants previously associated with CCM 
 
If a search is performed at OVID Medline, from 1988 to 2004 including the terms Cardiac 
congenital malformation and limiting to the genetics subheading in humans, a total of 1201 
articles are cited. Much of the published literature corresponds to positive results on 
syndromic CCM. Findings in non syndromic CCM are illustrated by three seminal works: 
the association of NKX2.5 and ASD, TOF and JAG1, and CCM and GATA4.  
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Schott et al. published in 1998 in Science the results of a genetic linkage screen of 4 
families showing autosomal dominant transmission of CCM with the majority of affected 
individuals showing secundum ASDs and conduction defects. Results showed a linkage 
peak at 5p35, where NKX2.5 is located. Mutational screening of the gene showed that 
affected individuals in two of the families shared a missense variant (Thr178Met), and the 
other two of the families carried a nonsense variant (Gln170ter) (203). Subsequent work 
showed that mutations on the homeodomain were associated to CCM and often to AV 
block.  
 
Two works by the group of Goldmuntz reinforced the idea that uncommon variants at the 
homeo domain were responsible for a percentage of “sporadic” CCM with great phenotypic 
variability. In 2001 this group screened 114 TOF and 100 control patients describing 4 
uncommon variants on probands. Goldmuntz et al. found 3 novel (Glu21Gln, Arg216Cys, 
and Ala219Val) and 1 previously reported (Arg25Cys) uncommon variants in TOF 
probands. The three novel variants were not found in controls and the previously reported 
variant was found in black controls. According to the authors approximately 4% of TOF 
might be attributed to uncommon variants at NKX2.5 (204). However, Arg25Cys was found 
at similar frequency in controls and the number of controls genotyped for the novel ones 
might be insufficient to discard their presence in normal subjects given the frequency of 
the variants.  
 
In 2003 the same group published a screening on 608 patients including conotruncal 
anomalies, left sided lesions, ASDs and Ebstein’s anomaly. Twelve variants in Nkx2.5 
were identified in 18 patients (3%) (205).  Ten of the variants were non synonymous, one 
was an in frame deletion and one was synonymous. It is important to say that despite the 
number of patients screened, the number of probands in each subgroup is small. It is 
interesting that most of the variants found were missense rather than synonymous, a fact 
that is contradictory to evolutionary predictions and opposite to my findings. Recent work 
from the 1000 Genomes project showed significant evidence of selection pressure against 
potentially damaging non-synonymous SNPs, since these SNPs are found throughout the 
genome at lower allele frequencies than would be predicted from an evolutionary neutral 
model.  Finally, despite the undeniable value of the work of Goldmuntz and colleagues the 
number of controls (n= 50) is certainly too small to categorically deny the presence of the 
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variants in a normal population.  Such a number of controls would only have about 66% 
power to detect a variant of 1% population frequency, and far lower power to detect 
variants that would be classified as rare (ie less than 0.5% frequency).  Although the 
contribution of Nkx2.5 to CCM is definite from the Mendelian families described, and the 
studies of sporadic CCM patients are consistent in suggesting a role for LFIP variants, it 
seems likely that the contribution of this gene has been overestimated in the literature to 
date.    
 
In 2000 Eldadah et al published a paper with a genetic linkage search for the cause of non 
syndromic TOF in a large kindred segregating TOF as an autosomal dominant trait. Data 
was consistent with linkage at 20p12 on JAG1, a gene previously known to cause Alagille 
syndrome (See introduction). Analysis of the gene in the kindred revealed a missense 
mutation G274D being carried by 13 members of the family (206). The variant was not 
found in 100 unrelated control chromosomes. The interesting fact is that JAG1 
haploinsufficiency caused by nonsynonymous mutations seems to cause clinically milder 
forms of Alagille syndrome including TOF. The fact that disease genes implicated in the 
pathogenesis of syndromic CCM are involved in the non syndromic forms is important, but 
not directly explored in this work, since to date there is no syndromic form of human CCM 
reported to be caused by mutations of the non-canonical Wnt genes that I have studied. 
 
Vidu et al. reported in 2003 the results of linkage analysis in a large family with 16 
individuals affected by CCM. A linkage peak was discovered in 8p22-23 were GATA4 is 
located. Mutational screening of the gene showed a non synonymous variant (G296S) with 
complete penetrance being carried by all affected individuals. The variant was not found in 
non affected family members and 3000 unrelated healthy controls. NKX2.5 and TBX5 
were also screened without finding any variant, a finding that indicates the genetic 
heterogeneity of CCM, with different kindreds getting the predisposition from different 
genes-alleles (207). 
 
At our hypothesis based on findings at NKx2.5, GATA4 and JAG1, as main examples, 
susceptibility to non syndromic CCM and particularly TOF may be given by a number of 
uncommon variants not fully  penetrant, and subjected to selection pressure proportional 
to the risk conferred. Taken the evidence previously cited the first step was a mutational 
screening. 
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7.6. Splicing functional analysis 
 
After the mutational screening the next step was to test the most likely pathogenic variants 
in functional tests to link the statistical facts to pathophysiological explanations. Rock 
807C>T was the first variant to be tested: a relatively uncommon variant, that confers a 
high calculated OR, with statistically significant (multiple test corrections < 0.05) 
differences in genotype frequencies when compared to a large control sample and with 
results of in silico analysis which showed a high likelihood of causing splicing changes. 
Splicing was tested using a minigene approach, but the experiment comparing the mutant 
allele with the wild type failed to show splicing differences.  
 
Wnt11 207 +47 G>T was also functionally tested. This intronic uncommon variant was 
found in nine probands, 1 TOF in the CHANGE population, 7 TOFs in the Nottingham and 
Oxford population and another one on the CONCOR population. The variant was not 
found in controls (p= 0.00009, multiple test corrections < 0.05) and in silico analysis 
showed that is likely to produce splicing changes. Nevertheless, the minigene experiment 
testing splicing consequences of the variant was negative: no splicing difference was 
found between the mutant allele and the wild type. It is important to stress that a major 
limitation of my minigene experiments is that despite historical positive controls using the 
same vector and conditions were taken into account, no parallel positive control 
experiment was performed during the experimental stages of this thesis leaving the 
possibility of methodological factors preventing the recognition of splicing changes 
associated with the variants.  
 
The association found for both variants, ROCK1 807 C>T and Wnt11 207 +47 G>T might 
be explained by two additional reasons, obviating the necessity to explore further the 
splicing hypothesis (See below). The first explanation is an effect on transcriptional 
activity. It has been proposed that a big portion of phenotypic variability among humans is 
due to variation in RNA transcription and processing. Data in the literature supports the 
idea that synonymous variants influence the transcriptional activity of a gene resulting in a 
phenotype. In 2006 Wang et al. published a study showing the results of allelic expression 
imbalance (AEI) experiments in a few genes to correlate previous associations apparently 
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synonymous SNPs and their phenotypes (208). Wang et al. investigated the relevance of 
the synonymous SNP C3435T at ABCB1 in transcriptional activity. Recent works have 
shown that genetic variation in ABCB1 can be correlated to individual response to certain 
drugs. This group showed a two fold increase in transcriptional activity for the T allele. 
C3435T was not in linkage disequilibrium with any variant located in the promoter. A next 
step to take with the synonymous variants found to be significantly associated in our 
sample might be to analyze in heterozygotes the allelic expression imbalance to confirm or 
discard a possible influence exerted over transcriptional activity.  
 
The second possible explanation for an association is LD in the region. Exploring the 
region were ROCK1 is located the nearest gene is ESCO1 a gene that belongs to a 
conserved family of acetyltransferases involved in sister chromatid cohesion. ESCO1 has 
been associated with some cancers (209) but it has not previously been associated with 
CCM. Other genes in the region include SNRPD1 and ABHD3. The two nearest described 
genes to WNT11 are PRKRIR, a p58 inhibitor, and UVRAG. UVRAG is a gene associated 
with UV radiation resistance, vitiligo, tumorogenicity decrease in colon cancer and 
strikingly to left right malformations in a case report (210). Despite LD with a variant in the 
region can explain the associations found, the likelihood of the nearest genes being 
associated with TOF is lower than the non canonical wnt genes being responsible 
themselves for the associations found.  
 
 
7.7. How likely is it that uncommon variants are pathogenic? 
 
The negative functional results can be explained starting with the premise that these three 
variants have a high likelihood to be pathogenic. Not only does biologically sound literature 
link Rock1 and Wnt11 to cardiogenesis, but also previous theoretical approaches to the 
problem of rare missense mutations and human disease back up the idea that these 
uncommon genetic variants not found in controls could be pathogenic (191, 211). 
 
The variants discussed: ROCK1 807 C>T, Wnt5A Asp119Ser and Wnt11 207 +47 G>T are 
uncommon variants not found or found at significantly lower frequencies in controls. The 
question of the theoretical likelihood of an uncommon variant being deleterious can be 
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seen not only using the perspective of the known data about structure and function but 
also taking into account the so called “fitness distribution” of human genetic variation.   
 
Some previous research has investigated the distribution of fitness in humans. Eyre-
Walker et al. published a paper in 2006 where they tested a method to estimate the fitness 
distribution of alleles subjected to selective pressure. They tested the distributions 
produced by theoretical expressions predicting the number of polymorphisms segregating 
in any given sample, against sequencing results of 320 human genes to infer the fitness 
distribution associated with SNPs of different frequencies. However, their estimates are 
based on the assumption that intronic variants are evolutionary neutral, a fact that is not 
completely accurate if we take into account the possibility of either splicing changes or 
changes in gene expression levels that may be visible to natural selection. Both exonic 
and intronic variants in their sample were skewed towards the uncommon, a finding that 
they interpreted as due to selection in the exonic case and due to population growth and 
admixture in the intronic ones. Eyre et al. estimated that 19% of mutations are neutral and 
14% slightly deleterious (segregated but not fixed) (212). 
 
Kryukov and his team published a research paper in 2007 where they analyzed the 
theoretical probability of missense and nonsense variants being medically detrimental 
according to comparisons between data on human disease causing mutations, 
chimpanzee divergence and modern human genetic variation. They calculated that 
approximately 20% of de novo missense mutations are strongly detrimental. This finding is 
in accordance to the previously published data by Yampolsky (211). Following a similar 
approach, they estimated that 27% of missense mutations are effectively neutral and 53% 
are mildly deleterious. According to their calculations 50-70% of de novo variants showing 
a frequency <1% are at least mildly deleterious.  
 
Recently, in October 2010, a paper that undoubtedly will change the way we interpret 
association data in humans, specially for uncommon variants, was published in Nature by 
the 1000 genomes project (213). The work shows the summary of results coming from 
three projects: low coverage whole genome sequencing of 179 individuals from 4 
populations; high coverage sequencing of two mother-father-child trios; and exon targeted 
sequencing of 697 individuals. Variant discovery number depended on the sequencing 
strategy with 14.4 million SNPs, 1.3 million indels and 20000 large structural variants being 
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detected in the low coverage sequencing. Summarizing most of the common SNPs were 
previously described in public databases but evidently uncommon and structural variants 
were mostly novel, reflecting poor previous characterization.  In terms of functional 
implications of the variants, they quantified that an average human subject differs from the 
human genome reference sequence in 10000-12000 synonymous and 10000-12000 non 
synonymous SNPs. The number of strongly detrimental variants in an average human 
being is, however, much lower: 190–210 in-frame indels, 80–100 premature stop codons, 
40–50 splice-site-disrupting variants and 220–250 frame shift deletions. Also they 
quantified that a typical human subject is heterozygote for 50-100 variants previously 
classified as causing inherited disorders. 
 
Given the data published in the era preceding next-generation sequencing, it can be 
inferred that uncommon variants, like the ones found in the non-canonical Wnt pathway, 
are subjected to evolutionary pressures and therefore a proportion of them are likely to be 
pathogenic. However, new data coming from enormous sequencing projects like the 1000 
genomes project depict a more complex picture with hundreds and even thousands of 
these deleterious alleles being carrying by each individual. Gene-gene and gene-
environment interactions should now be researched to explain the individual contribution of 
complex disease pathogenesis in general and TOF in particular.  
 
 
7.8. Complexity of alternative splicing 
 
One of the difficulties of demonstrating the functional implications of the Wnt11 207 +47 
G>T and ROCK1 807 C>T variants is the complexity of alternative splicing in the human 
genome. Genomic variation leading to splicing changes represent almost 50% of the 
pathogenic variants among human diseases (214). It has been also demonstrated that the 
majority of multiexon genes are alternatively spliced making this process the greatest 
source of proteomic variation. A study published in 2004 researching on the exon-exon 
junctions in 10000 human genes in 52 tissues and cell lines, using microarrays, concluded 
than more than 74% of the genes were alternatively spliced (215).    
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Exon recognition by the splicing machinery on the primary transcripts where small exons 
should be picked among vast intronic sequences represents a delicate process with 
numerous factors implicated. The first recognizable factor would be the conserved 
sequences denoted exon- intron junctions or 5’-3’splicing sites. Recognition of these 
consensus sequences not only depends on them but also on cis acting sequences within 
introns and exons (214). These regulatory motifs have been called intronic and exonic 
enhancers and silencers. Enhancers and silencers influence exon definition trough the 
recruiting of splicing machinery and the interaction between them.  
 
Most of the reported splicing variants in databases such as the Human Gene Mutation 
Database correspond to mutations at the consensus splicing sequences causing “exon 
skipping”. For example, this is the operative mechanism in the case of the synonymous 
transversion described by Montera et al. in 2001 in a family presenting with familial 
adenomatous polyposis (FAP). This single nucleotide change in nucleotide position 1869 
of the APC gene, produces complete skipping of APC exon 14 that translates into FAP 
(216).  
 
However, less frequently a cryptic splicing site is created and other complex patterns of 
protein splicing can also be created due to the interactions of the different regulating 
factors (217). An example of this aberrant splicing pattern is the single nucleotide change 
in BRCA1 R71G described in several families presenting a familial form of breast cancer. 
cDNA analysis of the non synonymous (R71G) variant showed that it causes deletion of 
the last 22bp of BRCA1 exon 5 and the reading frame alteration produces a stop codon in 
the first nucleotides of exon 6 at codon position 64 (218).  
 
Although disruption of exon and intron junction is not the case for our suspicious variants, 
located at 47 bp from the 3’ junction (Wnt11 207 +47 G>T) and 13 bp from the 3’end of an 
exon (ROCK1 807 C>T), the theoretical disruption of cis regulatory elements and the 
repercussion of such changes on splicing caused by these variants was the reason for 
carrying forward functional investigation on them. 
 
It is worth mentioning that not only local factors are involved in the process of exon 
recognition. Elements of the wider context within which the exon is found, such as the 
splicing events taking place before the exon of interest, the type of promoter and the 
181 
 
presence of other regulatory elements throughout the gene (214) should be taken into 
account to interpret the results of a highly simplified model of splicing such as a minigene. 
A minigene only includes the variant within the exon or intron of interest and a shorter 
context within an artificial gene composed by non human exons with a different promoter. 
If the changes exerted by the variant do not grossly disrupt the splicing junction, a high 
likelihood of not being recognized might be expected in this type of experiments.  
 
There are multiple examples in the literature of pathogenic variants which could be 
misclassified as synonymous harmless SNPs, if enhancers, silencers, RNA secondary 
structure and the wider splicing context are not taken into account (217). Two works 
illustrate in a mechanistic way the pathogenic implications of this type of splicing variation: 
In 2000 Ars et al. published a paper exploring the RNA implications of published genomic 
variants in Neurofibromatosis type 1. They performed a mutational screening in the NF1 
gene in 80 NF1 patients identifying 44 previously undescribed variants. Out of the total, 14 
variants caused splicing changes with 1 frameshift, 2 nonsense and 2 missense also 
causing splicing variation.  Twelve variants were located at introns with only 6 of them 
disrupting splicing consensus sites (219). In 1999 a similar study was published by 
Teroaka et al. analyzing the possible splicing implications of mutations found in a 
screening of 49 ataxia telangiectasia disease patients. Sixty two variants were found 
during the screening. Ten of the variants were located at splicing consensus sequences 
causing mainly exon skipping. However, three of the variants were found out of splicing 
consensus sites and created cryptic splicing sites. Also, two nonsense variants produced 
splicing aberrations detected on RT PCR sequencing (220).  
 
It is evident in the previously exposed examples that misclassification of variants during 
mutational screening due to solely analysis of genomic sequence is possible. Not only is a 
high level of awareness of this fact required but it is also important to design optimal 
experiments to test the hypothesis at the splicing level. In my case testing the splicing 
consequences of these two highly likely pathogenic variants needed the construction of a 
model of splicing due to the lack of RNA samples from the probands carrying the 
mutations. As previously mentioned, the model is too simplistic to be taken as a definite 
confirmation of absence of splicing consequences being associated with the variants. 
Reverse transcriptase RNA amplification and direct sequencing of the RNA from patients, 
or from cell lines expressing the entire gene, carrying the variants might be the most direct 
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way to test the splicing implications of these two variants (Wnt11 207 +47 G>T and 
ROCK1 807C>T). However, obtaining RNA from patients requires to collect a new sample 
with the technical and ethical drawbacks associated. This strategy, however, does not 
explore the impact of alternative splicing and splicing changes taking place and being 
relevant only at certain stages of heart development. 
    
7.9. Common genetic variants and the risk of TOF 
 
Although my work principally focused on uncommon genetic variation, I also explored the 
impact of common variation at my candidate genes on the risk of TOF. Common genetic 
variants were genotyped in the complete CHA population and controls when they failed 
Hardy Weinberg equilibrium tests (since this might indicate the presence of a copy number 
variable region) or if they showed significant differences in allele frequency when 
compared to previous data. Four common variants - ROCK2 rs2271621, ANKRD6 
rs2273238, rs9344950 and rs9353687 - were genotyped. No significant differences in 
allele frequencies were found between cases and controls for any of the previously 
described common variants. 
 
Two previously undescribed common variants were found in the mutational screening. 
One of the common variants described is a single base substitution (A>T) at ROCK2 intron 
1 (ROCK2 145 -25 A>T). The variant is not located in a conserved domain and in silico 
analysis did not show changes at splicing cis regulatory sequences. Genotyping of 
controls for ROCK2 145 -25 A>T did not show significant differences with TOF cases 
(mAF in probands and controls 0.13). The second common variant found in our sample is 
a single base substitution (C/T) at ANKRD6 exon 16.  The variant produces a change from 
phenylalanine to leucine at residue 636. The variant is not located in a conserved domain 
within ANKRD6. In silico analysis of Phe636Leu using the web based resource Polyphen 
indicated that the variant might be structurally damaging. Genotyping of controls did not 
show significant allele frequencies differences between cases and controls (mAF: 
Probands: 0.14: Controls: 0.10).  
 
To elucidate a possible genomic explanation for the strong association found between 
ROCK1 807 C>T and TOF a tagging strategy (190) was designed to capture common 
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genetic variation within the gene and to explore linkage disequilibrium relationships 
between markers. Previously described missense SNPs in the gene were forced to be 
included. The hypothesis was that the variant was only indirectly associated with the 
condition and that was the explanation of the negative result at the splicing experiment.  
No evidence of LD was found between 807 C>T and the other markers, and no common 
haplotype was associated with TOF. Rs288979, an intronic common variant (mAF=0.051) 
was significantly associated with TOF (p=0.000015) with a protective effect and OR 
calculated for its minor allele of 0.7. In silico analysis of the variant did not show splicing 
changes associated with the SNP. None of the common genotyped variants was in 
disequilibrium with either rs288979 or ROCK1 807 C>T. Both the uncommon and the 
common variants could represent independent associations or be linked by a third causal 
variant. Sequencing of bigger samples using new platforms might confirm their 
independent associations or find other causal variants not detected up to this moment.  
 
To my knowledge this is the first study to examine human common and uncommon 
genetic variation at the Wnt pathway and TOF. Also, our sample is the largest reported 
and the thus far the only with sufficient power to explore genetic variation and its 
relationship with non-syndromic TOF. 
 
7.10. The genetic architecture of TOF 
 
It is reasonable to expect genetic architecture (number, type, frequency and effect size of 
susceptibility variants) to vary between traits. Research into the allelic spectrum of human 
disease has progressed enormously in the postgenomic era and some insights from 
previous research can give clues about the architecture of TOF. Susceptibility to some 
monogenic disorders like cystic fibrosis is associated to a relatively small number of alleles 
with high population attributable risk (PAR) within a frame of less common alleles with 
lower PARs. Some other monogenic disorders like β thalassemia have multiple associated 
alleles with some groups presenting a small number of them (221). 
 
In the case of common diseases a good example is Alzheimer disease. A metanalysis 
published in the pre-GWA era by Betram et al. illustrates the genetic architecture of the 
condition. Literature review covering 789 publications up to 2005 confirmed the association 
184 
 
with the well known high risk allele ApoE4 with ORs ranging from 2.7 to 5.2, and a 
population attributable risk of approximately 20%. However, 20 additional positively 
associated alleles in 16 non ApoE loci were also described with modest ORs associated 
with them (222). Three GWAs published from 2007 have confirmed this architecture, at 
least with respect to common alleles, with one allele conferring high OR and accounting for 
most of the heritability with multiple minor signals accounting for lower risks. In the first 
GWA published by Coon et al. in 2007 the association with rs4420638, a SNP located 
14Kb from ApoE, was the strongest signal detected (OR=4), confirming the previously 
described association (223). However, subsequent GWAs, one performed in 1411 
Alzheimer disease sufferers carrying ApoE4 found a significant association with rs2373155 
a SNP located in GAB2 (224), and one published recently showed a novel SNP associated 
located in MTHFD1L (225).  
 
Another example with a different character is the case of the variants associated with type 
2 Diabetes. Multiple GWA have identified numerous loci associated with type 2 diabetes 
confirming the hypothesis that genetic susceptibility for this condition is given by a 
heterogeneous group of variants associated with low risk. Up to date 22 GWAs have been 
published exploring genetic predisposition to type 2 diabetes, describing 101 significantly 
associated loci.  
 
Due to the findings of this thesis it might be concluded that CCM, and particularly TOF, is a 
group of diseases where common and uncommon variants coexist and are both 
responsible for genetic predisposition. Obviating the necessity of external reproduction of 
my findings, the allelic architecture of TOF in the Non-canonical Wnt pathway genes 
comprises a common variant in ROCK1 (rs288979) conferring a modest apparently 
protective OR (0.7), but due to its mAF, being associated with a PAR of 11%; and two 
uncommon variants at ROCK1 (807C>T) and Wnt5A (207 +47 G>T) apparently conferring 
high risk to suffer the disease but with low PARs associated. It is tempting to speculate on 
the consequences of surgical repair on the genetic architecture of CCM and particularly on 
TOF. It is however unlikely due to the number of generations since the introduction of 
surgery that a quantifiable effect on allele frequencies have been exerted by the late 
fitness increase of TOF sufferers. It is also to note that given the negative selective 
pressure associated with TOF susceptibility alleles, surgical repair could have, as the 
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most, increased the fitness to 1 and under normal conditions this would mean that allele 
frequencies will be maintained on the population. 
 
7.11. Genome wide association studies in complex diseases  
 
During the experimental work of this thesis the landscape in complex disease genetics 
entirely changed. Due to the modest results of the candidate gene approach in research of 
complex human traits, specific and powerful tools were needed to explore the contribution 
of common and uncommon genetic variants in large samples and with a “genomic” 
orientation. Development of human genetic variation databases and commercial 
highthrougput genotyping methods like the “SNP chips” allowed research efforts exploring 
hundreds of thousands of common genetic variants in samples of thousands of patients 
and controls. This type of research study is usually termed Genome wide association 
analysis (5, 8).  
 
The WTCCC study, published in Nature in 2007, was the first of its kind that show the 
potential of GWAs. The WTCCC was a joint GWA study made on a British population 
examining 7 diseases on 2000 probands and sharing 3000 controls, identifying 24 
independent association signals for rheumatoid arthritis, type 1 and 2 diabetes, bipolar 
disorder, Crohn’s disease and coronary artery disease (9). Up to date 674 published works 
describing the association with 3275 SNPs are listed on the GWAs catalogue (17). The 
results of GWAs represent a wealth of data with some optimistic views considering that in 
3 years most of the common genetic variation associated with human complex diseases 
will be identified. A review of the GWAs accomplishments is beyond the scope of this 
chapter but a good example are the advances in coronary artery disease (CAD) genetics. 
The first breakthrough in CAD was the publication in Science of two works reporting the 
first and most important locus associated with CAD: 9p21.3. In the work by McPherson 
and colleagues a GWA was performed in a 312 case cohort of Canadian subjects suffering 
early onset CAD. Significant results were tested in a second sample comprising 311 
additional cases. Fifty SNPs significantly associated in this second cohort were tested in a 
third sample comprising 1347 cases and 9054 controls. Two SNPs, located in 9p21 20Kb 
apart, were associated with CAD: rs10757274 and rs2383206. The association was 
validated in three additional cohorts (226).  
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A second work by Helgadottir et al. also reported an association between CAD and a LD 
block of 190 Kb located in 9p21 represented in their analysis by three SNPs:  rs1333040, 
rs2383207 and rs10116277. The work by the group of Helgadottir was performed in an 
Icelandic population comprising 1607 myocardial infarction sufferers and 6728 healthy 
controls without CAD history (227). It is interesting that, like many of the associated SNPs 
in GWAs, the variants in 9p21 associated with CAD are located in non coding regions. 
However, the variants seems to be involved in the production of a short form of a 
downstream gene (ANRIL) and probably influence the expression of cyclin dependent 
kinases (228). The region (9p21.3) has also been associated with aneurismal dilation of 
abdominal aorta and cerebral vessels, diabetes and numerous cancers opening the 
possibilities of multiple pathogenic implications. In a work from our laboratory, published in 
March 2009, Cunnington et al. tested the association between the SNPs located at the 
region and carotid intimal thickness and known cardiovascular risk factors without finding 
any significant association. Despite the robustness of the association between 9p21 and 
CAD, the functional implications of the variants and the clinical relevance for daily practice 
are still open questions. 
 
It is important to say that up to the moment of this thesis no GWA in CCM has been 
published. The finding in this work of a common variant in ROCK1 (Rs288979) significantly 
associated with TOF and previous findings in numerous complex traits support the idea 
that a least a portion of heritability-predisposition to CCM, and particularly to TOF, is due 
to common genetic variation. Despite the difficulties in recruiting a sample of any CCM big 
enough to attain acceptable power, is evident that one of the necessary steps to follow is 
to perform a GWA with TOF probands. The sample of the CHANGE population recruited 
by our laboratory can be the starting point for this work.  
 
GWAs were designed to capture most, if not all, common genetic variation on the genome, 
but it has become clear in the last three years that most of complex disease heritability is 
still not explained by the associated loci (8). A number of explanations have been 
suggested to explain this “missing heritability” from GWAs. Importantly, the possibility of 
larger numbers of variants of smaller effect not found yet; the effect of uncommon variants 
poorly detected by available genotyping arrays; structural variants not captured (like copy 
187 
 
number variants (CNVs)); low power in studies thus far to detect gene to gene interaction; 
and the still to be researched interaction between genetics and environment.   
 
Since the description of the first copy number variant (CNV), trisomy 21, fifty years ago, a 
vast amount of developments have changed our understanding of this type of genetic 
variation. Despite CNV corresponding to any variation of the dogma stating that genes 
come in pairs, from small indels to large chromosomal variants, traditionally the term CNVs 
have been used to describe DNA segments of 1Kb or more that show copy number 
variation when compared to reference sequence (229). In the last 5 years recognition of 
CNV prevalence in our genome have been catalogued and documented in databases as 
the Database of Genomic Variants (DGV) (230). The DGV lists 66741 CNVs in October 
2010 (http://projects.tcag.ca/variation/). In terms of abundance, it is still debated if whether 
or not CNVs are more abundant than SNPs in the human genome. Nevertheless, the 
amount of genetic variation due to CNVs is far greater than that due to SNPs, with a group 
quantifying that 1.28% of nucleotide differences between humans is due to CNVs (231).  In 
terms of phenotypic impact of CNVs, this depends on the variant size, with microscopically 
visible CNVs almost always being associated with a phenotype. Smaller CNVs can be 
clinically relevant, being influential to normal human phenotypic variation or being 
functionally silent (229).  
 
In 2008 Eichler et al. published the results of a screening for CNVs at the 1q21.1 region in 
5218 patients suffering unexplained mental retardation, autism or congenital anomalies. 
This group identified 25 unrelated probands carrying an overlapping deletion and 9 
additional probands carrying the reciprocal duplication in the region.  Analysis of the same 
region in 4737 controls showed no deletion and only two small duplications. The deletion 
seems to be associated not only to cognitive impairment but also to a number of 
phenotypes as cataracts, joint hipermobility, seizures or hypotonia. Interestingly 6 of the 25 
patients carrying the deletion showed CCM. As explanations for the phenotypic variability 
associated with the deletion Eichler et al hypothesized that factors as genetic imprinting, 
epigenetic influences, genetic background or recessive variants expressed in the case of 
deletions (232). This might be the case for the associated, not fully penetrant, relatively 
uncommon variants found, as ROCK1 807 C>T. Epigenetic, background or associated 
recessive uncommon variants can influence the development of the fully TOF phenotype. 
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This ground breaking paper opens the door to explore the possible pleiotropic effects in 
development of such key genes as the non canonical wnt pathway.   
 
In 2009 a paper published by Greenway et al. reported the results of a genome copy 
number variants (CNV) survey on 121 TOF trios (proband and two unaffected parents) 
using an Affimetrix 6.0 chip assay. A total of 17 rare CNVs not present in controls were 
identified. One percent of non syndromic TOF sufferers presented a CNV on 1q21.1; 
additional CNVs were identified at 3p25.1, 7p21.3 and 22q11.2; in a single individual 6 
CNVs were identified, two of them on genes previously reported to be associated with 
TOF. These results illustrate the relevance of the previously mentioned structural variants 
not captured in most GWAs, a field needing to be explored at common disease genetics. 
One of the next steps needed to be taken to unravel all components of heritability of TOF, 
especially at the non canonical Wnt pathway is to explore CNVs in our population. 
 
7.12. Environmental factors in complex diseases 
 
In 2006 Hemminki et al. published a paper exploring the implications of environment in 
complex disease susceptibility (233). Epidemiological research has shown that 
environmental population attributable risk in complex diseases, like cancer is 90%, and 
coronary artery disease is over 70% (234). If we take into account that environmental risk 
factors’ effect is not additive and that the individual response to an exposure also depends 
on the genetic makeup, research into these environmental factors is complex. A good 
example is the mental retardation associated to phenylketonuria, depending on the point of 
view the disease can be seen as 100% environmental (dietary) or genetic. Additionally, 
there are problems determining the environmental components of heritability. A non 
quantifiable portion of family clustering in common diseases is given by shared 
environmental exposures. It is worth asking how much of the heritability in CCM is due to 
shared environment and establish not only a strategy to include environmental factors into 
genetic research but also the maximum possible of the heritability expected to be linked 
solely to genetic variants. Lately the National Institutes of Health announced a gene- 
environment initiative to boost the inclusion of environmental exposures in genetic 
research.  
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Due to the difficulties in obtaining accurate environmental information, and due to that the 
design of sample recruitment was not made to specifically test gene-environment 
interactions, the amount of information in this thesis about environmental influences is 
scarce. However, some facts are interesting, in our sample pregestational diabetes 
prevalence is 1.2%, higher than the 0.4% previously reported for UK population (235). At 
the same time the prevalence of gestational diabetes in CHANGE mothers is lower than 
the reported for general population. The etiological implications of these facts are 
unknown, and they can be purely unrelated facts. Designing a strategy of data mining in 
our TOF CHANGE sample to obtain sufficient and reliable environmental data is key to 
quantify the effect of such factors, and to identify the ones likely to interact with genotypes 
to increase the risk of suffering TOF. 
 
7.13. Next generation sequencing  
 
As previously discussed, GWAs are designed to capture common genetic variation 
(mAF>5%) and its relationship to human complex diseases. Despite encouraging results, 
the majority of trait heritability is not explained by the associated SNPs found in GWAs. An 
example of this fact is the case of Diabetes type 2. A metanalysis of the available GWAs in 
diabetes mellitus type 2 was published in 2008 comprising the data from a total of 4549 
cases and 5579 controls (236). Despite the finding of 18 significantly associated SNPs, 
only 6% of heritability has been explained. Another interesting fact derived from the results 
of GWAs is that despite multiple variants being significantly associated with a myriad of 
traits, only rarely have the functional implications/causal variants been identified, and in 
many cases uncommon variants found in the associated blocks have been overlooked due 
to the presumption of a common variant being the causal one (237).  It is expected that 
after the description and classification in databases of variants with frequencies between 
1-5%, as a result of projects like the 1000 genomes, these variants are going to be 
included in GWAs and another portion of heritability will be explained. 
 
Three of our positively associated variants are uncommon, and they explain only a small 
fraction of heritability in TOF. There is a strong possibility of numerous uncommon variants 
across the genome contributing to the risk of suffering TOF, and this hypothesis should be 
190 
 
explored. Discovery of variants with mAF<1% can only be achieved by sequencing 
complete genomes-exomes in large samples, and that task was until recently regarded as 
impossible. 
 
During the period of my work, a number of new technologies called “high throughput 
sequencing” or “next generation sequencing” were made available. These technologies 
outperform the traditional Sanger technology by a factor of 100-1000 with a cost that is 
0.1-4% of the old Sanger sequencing cost. Four types of these next generation 
sequencing are now on the market: pyrosequencing on the Roche/454 GS FLX Titanium 
sequencer, the first of these platforms, allowing sequencing of 750Mb a day at a cost of 
about U$20 per Mb; the Illumina Genome Analyzer with a capacity of approximately 
5000Mb per day at a cost of U$0.5 per Mb; the Applied Biosystems SOLiD with a capacity 
and price similar to the Illumina platform; and Helicos HeliScope, the only platform able to 
sequence complete molecules, with a performance of approximately 4250 Mb a day at a 
cost of U$ 0.33 per Mb but, at present, very poor accuracy (238). All of these platforms 
have the capacity of deep resequencing of large samples at achievable costs and in 
reasonable time spans.  
 
The idea of studies that involve whole genome/exome sequencing of all subjects is now 
possible, and is reasonable to expect that they will performed as the GWAs. In fact various 
examples have shown that is possible to identify rare disease causing variants using this 
type of approach. Two studies by Ng et al. have demonstrated reported the identification of 
the causal variants of two mendelian conditions, the Freeman Sheldon syndrome and the 
Miller syndrome, using whole exome sequencing (239, 240).  
 
However, although the strategy of whole genome sequencing seems straightforward, 
saving technical issues, it remains the question on how to approach the research, meaning 
who should be sequenced and how to confront the daunting task of analyzing the amount 
of data produced by this type of study. One of the proposed answers is to sequence 
multiple affected individuals in families looking for co-segregation. Nevertheless, the 
amount of co segregating variants, even if only the functionally relevant ones are taken, 
would be high making it necessary to narrow down depending on gene functions or 
previous linkage/association studies results (237). Another possible strategy is to 
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sequence the extremes of the phenotype distribution, knowing that in such extremes rare 
causative variants are enriched. 
 
The possibility of correctly identifying uncommon genetic variants associated with common 
diseases is now feasible with the use of next generation sequencing. The discovery of 
variants with large effects on gene function and influence in disease risk not only will allow 
the calculation of risk, but more importantly might give therapeutic targets for intervention 
in common diseases The idea of resequencing complete exomes or at least all genes at 
the Non-canonical Wnt pathway, in large samples will complete the puzzle of the 
involvement of uncommon genetic variation in TOF. 
 
7.14. Clinical perspectives 
 
As it is apparent from the results of this thesis not only multiple processes but, among a 
single pathway, numerous genetic variants, common and uncommon, might be involved in 
the pathogenesis of CCM and particularly of TOF. The implications of such variants are 
still under research and other relevant variants should be discovered in the future using 
new strategies designed to detect common and uncommon genetic variants. 
 
There are three main fields where the complete description of the genetic variants 
responsible for non syndromic TOF development is relevant in day to day clinical practice 
and patient care. It is important to note that a long way is still needed to be walked and the 
results of this thesis only represent one of the first steps towards a clinical application of 
basic research in the etiology of TOF. Firstly, it might be possible that with the 
identification of the complete genetic architecture of TOF, genetic risk could be calculated. 
It is however impossible to say if an accurate risk calculation would be attainable in the 
near future. Risk calculation depends largely in PAR attributable to genetics, environment 
and all possible relationships between them. According to the results of this thesis, risk of 
suffering TOF is given by a combination of common and uncommon variants with low 
PARs, the nature and number of the variants yet undiscovered is still unknown. The 
completion of the picture with whole genome sequencing and GWA studies will unravel if 
genetic risk calculation is possible or if in the other hand risk is heavily dependent on 
numerous uncommon variants making calculations for specific cases difficult. 
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Identification of genetic variants associated with non syndromic TOF might also be 
important in determining prognosis. However, phenotype-genotype relationships have not 
yet been established. It is important to say that due that our sample was not recruited with 
that objective in mind, and given the frequency of the variants associated, no genotype-
phenotype correlation could be inferred.  
 
Finally and perhaps the last clinical goal of genetic research in common diseases is 
making possible therapeutic interventions to prevent in high risk groups the incidence of 
CCM. Or in a more broad sense to provide therapeutic targets to either truncate the 
anomalous embryogenetic process or to specifically treat the complications.  It is 
impossible to say at this moment if such interventions are possible. Only the completion of 
the genetic research in TOF and the discovery of the majority of implicated genetic 
variants can give us targets to begin working.    
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